<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-12-15 09:24:37 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>91</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>134</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, , Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f99bb18019cd4b39bd05d6d11bec440e5d21593" target='_blank'>
              B cell transcriptomics reveals lasting dysregulation and rapid decline of protective immune memory after chronic hepatitis C cure
              </a>
            </td>
          <td>
            Fang Chen, E. Giang, Padmaja Natarajan, Tony S. Mondala, Steven R. Head, Sing Chau Lau, Aishwarya Sundaresan, Liudmila Kulakova, Xiaohe Lin, Jasneet Aneja, R. Andrabi, Yun Zhang, Richard H. Scheuermann, Eric A. Toth, Thomas R. Fuerst, Lia Lewis-Ximenez, Arthur Y Kim, Paul Pockros, Georg M Lauer, M. Law
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49cdf4d2b06dc0c77173ce97caf0d6a3fa0e9a28" target='_blank'>
              Single-Cell Immune Profiling Reveals Non-classical Monocyte-Driven Immunodepression in Tuberculosis Treatment Non-Responders
              </a>
            </td>
          <td>
            Yang Che, Yiqun Xiong, Dongliang Zhang, Yahong Qu, Hao Shen, Weixin Wang, Junshun Gao, ZhenBo Wang, Yi Chen, Zhihong Shen
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract Objectives Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant, yet their functions remain incompletely understood. This study aimed to comprehensively analyze the role of G-MDSCs in MM patients undergoing CAR-T therapy. Methods Single-cell transcriptomic data from seven MM patients before and after CAR-T therapy were analyzed to characterize G-MDSCs. Functional enrichment and gene set enrichment analysis (GSEA) were performed to identify signaling pathways. A risk prediction model was constructed using RNA-seq and survival data from 713 MM patients, and validated by Kaplan–Meier analysis. In vitro experiments were conducted to assess the immunosuppressive functions of G-MDSCs. Results The findings, though exploratory due to limited sample size and inter-patient heterogeneity, suggested pathological activation and immunosuppressive roles of G-MDSCs potentially linked to patient prognosis. G-MDSCs were identified as key modulators of immune responses within the TME, with GSEA indicating regulation via IFN-α/γ signaling. They may facilitate immune evasion of MM cells by promoting proliferation through the IGF1–IGF1R axis and inhibiting T cells and other immune cells via the SIRPA–CD47 pathway. The risk prediction model based on G-MDSC gene signatures demonstrated high prognostic accuracy (AUC = 0.94). PTGS1 was identified as a key marker associated with high-risk groups, and functional assays confirmed its role in mediating G-MDSC immunosuppressive activity. Conclusions This study provides preliminary insights into the functional role of G-MDSCs in the MM TME and highlights their impact on CAR-T therapy outcomes. The findings suggest potential therapeutic strategies, including targeting PTGS1, to enhance CAR-T efficacy. Larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-02</td>
          <td>Immunopharmacology and Immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background COVID-19, including its post-acute sequelae (Long COVID), is increasingly recognized as involving persistent immune dysregulation and chronic inflammation. Severe and prolonged disease states are often accompanied by sustained cytokine release, immune cell exhaustion, and ongoing cell-cell communication that shapes the inflammatory milieu. Among immune subsets, CD8+ T cells play a central role in antiviral defense, yet the molecular mechanisms linking their dysfunction to prolonged inflammation remain incompletely understood. Methods We analyzed 73,110 peripheral blood mononuclear cells (PBMCs) from individuals across four disease states (Healthy, Exposed, Infected, and Hospitalized) using single-cell RNA sequencing. Immune cell subsets were annotated, and T cell heterogeneity was profiled. Cytokine and inflammatory scores were calculated to assess immune activation. Differentially expressed genes (DEGs) underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Cell-cell communication was evaluated to map ligand-receptor networks. Additionally, nine machine learning models were trained on a bulk RNA-seq cohort, and the SHapley Additive exPlanations (SHAP) framework was applied to interpret key predictive genes. Results Progressive disease severity was associated with a decline in T cell proportions, enrichment of pro-inflammatory myeloid cells, and elevated cytokine expression, particularly IL-32. Memory CD8+ T cells showed increased exhaustion and inflammatory scores while maintaining a central position in MHC-I-mediated communication networks. Persistent activation of immune and metabolic pathways, including antigen presentation and oxidative phosphorylation, was observed in prolonged disease states. Seven genes (RPS26, RPS29, RPL36, RPL39, RPS28, RPS21, and CD3E) were identified as strong predictors of chronic immune dysregulation, with the XGBoost model achieving the highest AUC. SHAP analysis confirmed their contributions to disease classification. Conclusion This study maps the immune landscape of COVID-19 and Long COVID at single-cell resolution, revealing that persistent immune cell communication, particularly involving memory CD8+ T cells, may sustain chronic inflammation beyond the acute phase. The identified molecular signatures offer potential biomarkers and therapeutic targets for mitigating post-viral inflammatory syndromes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/536000d345ef1e6f7663efc28145b0e979e70e7b" target='_blank'>
              Immune cell communication networks and memory CD8+ T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID
              </a>
            </td>
          <td>
            Hengrui Liu, Zewen Xu, Ilayda Karsidag, Panpan Wang, Jieling Weng
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Abstract Despite advances in targeted therapies, treatment of chronic lymphocytic leukemia (CLL) remains challenging, highlighting the urgent need for effective new therapeutic strategies. Although chimeric antigen receptor (CAR) T‐cell therapy dramatically improved outcomes in acute lymphoblastic leukemia (ALL), its efficacy in CLL is limited. We hypothesize that this disparity results from pronounced CAR T‐cell exhaustion and the immunosuppressive tumor microenvironment (TME) in CLL. We utilized an autologous 3D TME co‐culture model to investigate the functionality of CAR T cells derived from CLL and ALL patients within physiologically relevant conditions. Our results revealed increased exhaustion levels and diminished cytotoxicity of CAR T cells from CLL patients compared to those from ALL patients. Importantly, combining CAR T‐cell treatment with interleukin‐10 (IL‐10) or CXCR4 blockade effectively improved cytotoxicity against CLL cells, even in stromal‐protected regions within the 3D model. These findings offer insights into CAR T‐cell dysfunction in CLL and support novel TME‐targeted combination strategies to improve clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1aec597c65d49a8cbf32e49d8a9716856ac9762a" target='_blank'>
              Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets
              </a>
            </td>
          <td>
            J. Dingfelder, M. Aigner, Jana Lindacher, Pascal Lukas, C. Flamann, Gina Nusser, Katharina Zimmermann, Axel Schambach, Frederik Graw, Simon Völkl, Heiko Bruns, Manuela Krumbholz, Martina Haibach, Jochen Wilke, Andreas Mackensen, G. Lutzny-Geier
          </td>
          <td>2025-12-01</td>
          <td>HemaSphere</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="High-affinity antibody production depends on CD4+ T-follicular helper (Tfh) cells. In humans, peripheral blood Tfh cells are heterogenous, as evidenced by differential expression of the chemokine receptors, CXCR3 and CCR6, which to date have served to classify three subsets, pTfh1, pTfh2 and pTfh17. Although pTfh1 responses dominate during blood-stage Plasmodium infections, a clear association with protective antibody responses remains to be described. We hypothesise that pTfh cells exhibit greater phenotypic and functional heterogeneity than that described by CXCR3/CCR6 alone, and that these more nuanced pTfh subsets play distinct roles during Plasmodium infection. We map pTfh cell heterogeneity in healthy individuals prior to and during controlled human malaria infection (CHMI) using parallel scRNA-seq and VDJ-seq. We uncover two pTfh1 subsets or differential phenotypic states, distinguishable by CCR7 expression. Prior to infection, Tfh1-CCR7neg cells exhibit higher baseline expression of inflammatory cytokines and genes associated with cytotoxicity. While Tfh1-CCR7pos cells have higher GC signatures. Indeed, during CHMI, Tfh1-CCR7pos, Tfh1-CCR7neg, and Tfh2 cells, all clonally expand and become activated. However, only Tfh1-CCR7pos and Tfh2 cells positively associate with protective antibody production. Hence, our data reveal further complexity amongst human Tfh cells, and highlight two distinct subsets associated with antibody-mediated immunity to malaria.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f9ba27b94246a8527ab6dda80d9a9001eb58f947" target='_blank'>
              Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria.
              </a>
            </td>
          <td>
            Megan S. F. Soon, D. Oyong, Nicholas L. Dooley, Reena Mukhiya, Zuleima Pava, D. Andrew, Jessica R. Loughland, James S. McCarthy, Jo-Anne Chan, James G. Beeson, C. Engwerda, A. Haque, Michelle J. Boyle
          </td>
          <td>2025-10-21</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/938f1648314d21b17f5602b7a84c055f9ef0d7b2" target='_blank'>
              Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays§
              </a>
            </td>
          <td>
            Miriam Kelm, Nourhan Nasr, S. Bendig, Dieter Kabelitz, M. Lustig, H. Trautmann, A. Laqua, Christian Peters, D. Wesch, Heiner Oberg, Ottmar Janssen, T. Valerius, C. Baldus, A. Scheffold, M. Brüggemann, G. Chitadze
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 antibodies are used to induce an immune response against many types of tumors. However, ICIs often also induce autoimmune responses, referred to as immune-related adverse events (irAEs), which occur unpredictably and at varying levels of severity in ICI-treated patients. The immunologic factors that predispose patients to the development of severe irAE are largely unclear. Here, we utilized high dimensional mass cytometry immunophenotyping of longitudinal blood samples from patients with metastatic melanoma treated with combination anti-PD-1/CTLA4 ICI therapy in the context of a clinical trial to characterize alterations in immune profiles induced by combination ICI therapy and to identify immune features associated with development of severe irAEs. Deep T cell profiling highlighted that ICI therapy induces prominent expansions of activated, CD38hi CD4+ and CD8+ T cells, which are frequently bound by the therapeutic anti-PD-1 antibody, as well as substantial changes in regulatory T cell phenotypes. However, neither the baseline frequency nor the extent of expansion of these cell populations was associated with development of severe irAEs. Rather, single cell-association testing revealed naïve CD4+ T cell abundance pre-treatment as significantly associated with the development of severe irAEs. Biaxial gating of naïve CD4+ T cells confirmed a significant positive association of naïve CD4+ T cell proportion and development of a severe irAE and with the number of irAEs developed in this cohort. Results from this broad profiling study indicate the abundance of naïve CD4+ T cells as a predictive feature for the development of severe irAEs following combination anti-PD-1/CTLA4 ICI therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b62cfec8fd4211059f5e6293956cd71228dc3135" target='_blank'>
              Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.
              </a>
            </td>
          <td>
            K. Marks, Alice Horisberger, M. Elahee, I. Adejoorin, Nilasha Ghosh, M. Postow, L. Donlin, Anne R Bass, Deepak A. Rao
          </td>
          <td>2025-11-25</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Abstract Introduction Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study was to describe systemic versus local inflammatory changes of NK cell subsets as well as their physical cell-cell interactions in arthritis patients. Methods Spectral flow cytometry was used to compare paired peripheral blood (PB) and synovial fluid (SF) immune cells from patients with active inflammatory arthritis and healthy controls. Physical cell-cell interactions within tissues were studied by applying a recently developed cellular interaction mapping framework. Results Our paired approach revealed significant local enrichment of immature and activated NK cells in SF, characterized by elevated markers of early differentiation, immune-checkpoint regulation, and tissue-residency, highlighting tightly controlled immune activation at inflamed sites. Single-cell analysis confirmed heterogeneity within SF-NK cells, suggesting multiple co-existing activation states and developmental stages. PB-NK cells from patients differed profoundly compared to healthy controls, showing less immature NK cell subsets and an enrichment of mature, pro-inflammatory subsets indicative of systemic immune activation. Cellular interaction mapping revealed mainly NK/neutrophil interactions of patients’ NK cells, while interactions with B-cells, T-cells, or monocytes were negligible. T-cells also displayed profound local and systemic alterations. Cellular interaction mapping revealed that next to NK/neutrophil interactions, interactions between B-cells with monocytes and T-cells with neutrophils characterize joint inflammation. Conclusion This paired high-dimensional analysis revealed systemic and local alterations in NK cell subsets shaped by co-existing developmental stages and immune regulatory mechanisms. Cellular interaction mapping indicated that neutrophils are a main interaction-partner of NK cells in inflamed joints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33e0fc210c968311a194a2ca7566f89ed217a080" target='_blank'>
              Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis
              </a>
            </td>
          <td>
            F. Deicher, T. Exner, Maren Claus, S. Yousefian, Lea Rodon, Sophie Elisabeth Leonhardt, J. H. Distler, Carsten Watzl, Hanns-Martin Lorenz, Simon Haas, Daniel Hübschmann, Wolfgang Merkt
          </td>
          <td>2025-10-31</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT Chronic antigen exposure drives CD4⁺ T cell senescence, yet how autoimmunity and persistent viral infections differentially shape T cell differentiation and function remains unclear. Using cytomegalovirus (CMV) and rheumatoid arthritis (RA) as models of chronic immune activation, we performed high‐dimensional mass cytometry and functional assays to define their impact on CD4⁺ T cells. In CMV‐seropositive individuals, CD27−CD28− CD4⁺ T cells were abundant and exhibited a predominantly cytotoxic, nonproliferative phenotype. Only a minor fraction was CMV‐reactive, suggesting that bystander‐driven differentiation contributes to this subset. In the absence of CMV, senescent CD4⁺ T cells were infrequent and phenotypically distinct, though they still exhibited low proliferative capacity. EBV and HSV did not independently increase CD27−CD28− CD4⁺ T cell frequency. Similarly, RA had little effect on their abundance but instead tuned the functional quality of senescent cells. In CMV‐seropositive RA patients, senescent CD4⁺ T cells produced less pro‐inflammatory cytokines and showed impaired cytotoxic degranulation. Central memory CD4⁺ and CD27−CD28− CD8⁺ T cell functions were preserved, with no evidence for CMV reactivation, suggesting maintained viral control by unaffected T cell responses. These findings highlight distinct, nonredundant effects of CMV and RA on CD4⁺ T cell senescence and reveal RA‐specific functional defects in senescent CD4⁺ T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3441dc9dbc45e96d9b0a98bad7c5d0ce97797b4d" target='_blank'>
              Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4+ T Cells
              </a>
            </td>
          <td>
            Lea Williams, Ali O Saber, Silina Awad, Xi Su, Asgar Ansari, Ruozhang Xu, Hannah Jung, Anupama Shahane, Joshua F. Baker, Laura F. Su
          </td>
          <td>2025-11-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Sepsis remains a leading global cause of death, with immune heterogeneity’s molecular mechanisms poorly understood. This study analyzed 1,862 human peripheral blood samples, constructing a molecular interaction disturbance network that first revealed the network biology underlying sepsis immune heterogeneity. We identified 3 sepsis subtypes with marked different prognostic characteristics, with the C1 subtype showing the worst prognosis characterized by severe CD4+ T cell exhaustion—validated across 10 independent cohorts. Integrating single-cell transcriptomics from over 450,000 cells, proteomics, and functional validation, we identified monocyte-derived matrix metalloproteinase-9 (MMP9) as a key regulator driving CD4+ T cell dysfunction. Mechanistically, MMP9 modulates T cell exhaustion through dual mechanisms: promoting leukocyte-associated immunoglobulin-like receptor-1 (Lair-1) aggregation on T cell membranes, directly inhibiting zeta chain of T cell receptor associated protein kinase 70 (ZAP70) phosphorylation in T cell receptor signaling, while impairing Ca2+-release-activated Ca2+ channel function and intracellular calcium clearance, causing calcium dysregulation that blocks nuclear factor of activated T cells (NFAT) activation and nuclear translocation. The selective MMP9 inhibitor MMP9-in-1 effectively reversed T cell dysfunction, restored calcium homeostasis and NFAT nuclear translocation, markedly enhanced CD4+ T cell interleukin-2 and interferon-γ production, and reduced programmed cell death protein 1 expression. This work establishes a comprehensive translational framework from molecular network disturbances to clinical phenotypes, advancing sepsis immunopathophysiology understanding and providing effective targets for the treatment of sepsis patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/669347da1bb81250d0a1cfa9e2302d53bc332296" target='_blank'>
              Targeting Matrix Metalloproteinase-9 to Alleviate T Cell Exhaustion and Improve Sepsis Prognosis
              </a>
            </td>
          <td>
            Xuan Wang, Jingyuan Ning, Liang Zhou, Hongrui Li, Jinlei Cui, Jiachao Wang, Xiangyang Liang, Jinquan Li, Miao Li, Xue Gao, Wen-jian Li, Xing Chen, Fei Yu, Lin Wei, Cuiqing Ma
          </td>
          <td>2025-11-02</td>
          <td>Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="


 Follicular lymphoma (FL) disease trajectory is characterized by a protracted preclinical stage, followed by iterative cycles of remission/relapse, suggesting that the elusive FL cancer precursor/persister cells (CPC) are not eradicated by current therapies and support early FL development and lymphoma recurrence. FL malignant B cells are dependent on a dynamic interplay with a heterogeneous tumor microenvironment (TME), dominated by amplified Treg, activated Tfh, and dysfunctional cytotoxic T cells. FL TME composition within invaded lymph nodes (LN) has been associated with clinical outcomes. However, neither CPC nor their specific supportive niches have been yet characterized, despite being the ultimate targets to cure FL. Compelling clinical evidence has identified the bone marrow (BM) as a permissive niche for FL CPC. Here, we analyze the BM T cell niche in low tumor burden FL patients treated by Rituximab monotherapy (FLIRT trial, NCT02303119), looking for the impact of malignant B cells on BM T cell profile and for the T-cell niche supporting drug-resistant persister cells.
 Paired BM aspirates were obtained from 19 low tumor-burden FL patients at diagnosis (M0) and in remission at one year (M12) of Rituximab monotherapy. BM aspirates from 5 age-matched healthy donors (HD) were incorporated as controls. We generated a single-cell dataset combining gene expression and BCR/TCR repertoires (10X Genomics) from purified B and T cells. Quantification of the t(14;18) frequency by QPCR revealed a systematic, yet variable, infiltration of FL BM at M0 and a dramatic depletion at M12, when few residual tumor cells could be detected and profiled.
 A total of 54,732 CD4 and 53,580 CD8 T cells were profiled. The BM T-cell landscape was highly heterogeneous across FL patients in contrast to the more uniform distribution in HD BM. Among the 15 T-cell clusters, 8 were differentially represented in FL BM at M0 vs HD BM with a decrease of cytotoxic CD8 T cells and naive CD4 T cells and an increase of IFN-responsive CD4 and CD8, Treg, Tfh-like, and memory CD8 T cells. Treg, IFN-responsive CD4, and CD8 EM were associated with a poorer clinical outcome, defined as a PFS<24 months and/or a time-to-next treatment (TTNT)<30 months (n=8/19 patients, P<0.05). Conversely, naive CD4 and naive CD8 T cells were associated with a favorable outcome. While exhausted CD8 T cells were not over-represented in FL BM, we identified a FL-specific subset of IL-10+ CD8 T cells co-expressing CD8 Treg markers. Furthermore, cytotoxic T cell transcriptional profile was characterized by a reduced expression of genes/pathways associated with T-cell activation and cytotoxicity, while the TGFb pathway was enriched, collectively highlighting a shift towards local immune suppression.
 At M12, IFN-responsive CD4, Treg, naive CD4 and CD8 T cells returned to levels similar to those found in HD BM, suggesting that their alteration at M0 was dependent on tumor B cell infiltration. However, M0 and M12 FL BM Treg retained a similar activated TNFRSF9hi Treg signature, which was associated with a poor prognosis when scored on bulk RNAseq of FLIRT FL LN biopsies at diagnosis (P=0.0048, n=122). Furthermore, the defective cytotoxic CD8 response persisted both quantitatively and qualitatively upon B-cell depletion.
 Finally, the Tfh-like cluster remained high at M12 in FL BM, regardless of the presence of residual tumor B cells. Analysis of BM malignant B cell heterogeneity using an unsupervised metaclustering approach identified 7 metaclusters (Mcl) co-occurring across FL patients and co-opting distinct gene expression programs, resembling the B cell developmental hierarchy in the LN from dark zone GC-like, light zone (LZ) GC-like, and memory-like FL B cells. Interactome analysis revealed a preferential interaction between BM Tfh-like cells and BM LZ GC-like tumor B cells. Interestingly, M12 residual tumor B cells were enriched for LZ GC-like Mcl, in agreement with the persistence of Tfh-like T cells.Our data describe the T-cell landscape within FL BM TME, unveiling a profound enrichment of regulatory T cell subsets and Tfh-like cells, alongside a defective cytotoxic immune response. Following B cell depletion using a B-cell targeted monotherapy, the tumor supportive T-cell niche persists within the BM. This preserved niche may support the survival of rare residual GC-like CPC and contribute to subsequent relapses, thereby identifying a new therapeutic vulnerability in FL.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d16f58ff8a6623ee2cd2b85985d1b1b79e14836" target='_blank'>
              Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma
              </a>
            </td>
          <td>
            Karin Tarte, A. Beyou, S. Léonard, J. Dulong, Stephane Rodriguez, N. Mossadegh-Keller, G. Brisou, Charles Brottier, L. Xerri, B. Nadel, Camille Laurent, Guillaume Cartron, Sandrine Roulland
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets. Methods Ccl7 myeloid cell-specific knockout mice and MC38 tumor-bearing mouse models were established to investigate the role of Ccl7 during CRC progression. Proteomic analysis, RNA-seq, and flow cytometry analysis were used to determine the role of Ccl7 in the tumor immune microenvironment. Results Herein, we found that elevated CCL7+ tumor-associated macrophages (TAMs) in tumors correlated with tolerance to ICIs blockage therapy in patients with CRC. Deletion of CCL7 in myeloid cells resulted in reduced accumulation of immunosuppressive TAMs and increased infiltration of activated CD8+ T cells within the tumor. Mechanistically, CCL7 modulates peroxisome biogenesis and fatty acid oxidation, thereby promoting the immunosuppressive functions of TAMs via the PI3K-AKT-PEX3 signaling pathway. Furthermore, CCL7 inhibits the expression of chemokine CXCL10 by suppressing the AKT2-STAT1 signaling pathway, which reduces the infiltration of activated CD8+ T cells in the tumor. Blocking CCL7 delays CRC progression and enhances the therapeutic efficacy of PD-L1. Conclusion Our study highlights the novel role and regulatory mechanisms of CCL7+ TAMs in ICIs immunotherapy resistance, suggesting that CCL7 may serve as a potential combined therapeutic target for ICIs immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53a194d2240d9d29b67527ded8020c64d8c9fb2a" target='_blank'>
              Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells
              </a>
            </td>
          <td>
            Yijiao Chen, Xudong Liu, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, Yongsheng Li, Lei Wu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality globally, with metastasis and recurrence as the primary determinants of poor prognosis. Despite advances in immunotherapy, intrinsic and acquired resistance to immune checkpoint inhibitors (ICIs) underscores the need to explore alternative immunomodulatory strategies. Emerging evidence highlights the critical yet dual roles of innate and adaptive immune cells within the tumor microenvironment (TME) in either restraining or facilitating metastatic dissemination. Adaptive immunity, dominated by T and B cells, orchestrates context-dependent antitumor responses or immunosuppression, while innate immune dysregulation fosters metastatic niches. We highlight translational opportunities, such as natural killer (NK) cell activation, macrophage reprogramming, and dendritic cell (DC)-based vaccines, alongside prognostic biomarkers like peripheral NK activity and tryptase+ mast cell infiltration. This review summarizes the interplay of immune cell subsets, including T and B lymphocytes, macrophages, DCs, NK cells, and mast cells, in lung cancer progression. By synthesizing preclinical and clinical insights, this review identifies unresolved challenges and proposes targeting innate immunity as a promising avenue to augment current therapies and mitigate metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42946b2788d2e767cb68fa124579a584984286cc" target='_blank'>
              Targeting innate and adaptive immunity to suppress lung cancer metastasis
              </a>
            </td>
          <td>
            Rong Qin
          </td>
          <td>2025-11-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Despite effective viral suppression with antiretroviral therapy (ART), people living with HIV (PLWH) experience persistent inflammation, immune dysfunction, and premature onset of cardiovascular and aging-related comorbidities. To define the underlying mechanisms, we performed longitudinal transcriptomic profiling in peripheral blood mononuclear cells (PBMCs) from a cohort of simian immunodeficiency virus (SIV)-infected rhesus macaques spanning four key stages: pre-infection, acute infection, short-term ART, and long-term ART. Bulk RNA sequencing revealed dynamic immune remodeling across infection and treatment. Acute SIV infection induced robust antiviral and inflammatory programs, with upregulation of interferon-stimulated genes (ISGs), IL-27, JAK/STAT, and NF-κB signaling, coupled with suppression of T- and B-cell activation pathways. Short-term ART effectively reversed these transcriptional perturbations, restoring adaptive immune gene expression and reducing innate antiviral responses to near-baseline levels. In contrast, chronic SIV infection on long-term ART maintained viral suppression but was characterized by reactivation of innate immune pathways, including TLR2/TLR4/MYD88, NF-κB, and inflammasome (NLRP3/or NLRP12, caspase-1) signaling, along with sustained macrophage activation, platelet/coagulation signaling, and senescence-associated secretory phenotype. Protein analyses confirmed persistent CASPASE-1 and NF-κB activation in spleen tissue. Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART– treated macaque revealed macrophage-rich plaques with p21⁺ senescent cells with intraluminal thrombus formation, recapitulating key features of HIV-associated atherogenesis. Together, these findings demonstrate that while ART normalizes acute infection–induced immune dysregulation, chronic SIV infection sustains a chronic, macrophage- and TLR-driven inflammatory state linked to vascular injury and aging process regardless of long-term suppression of viremia. Targeting inflammasome, NF-κB, and senescence pathways may mitigate non-AIDS comorbidities in PLWH.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7a8f96a2324d1327914a92bba9009e04dbf070e" target='_blank'>
              Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART
              </a>
            </td>
          <td>
            Yilin Chen, Xiaofeng Ding, Sonalika Ray, Siva Thirugnanam, Robert V. Blair, Ahmad Saied, S. Sukhanov, J. Kolls, Woong-ki Kim, P. Delafontaine, Jay Rappaport, Xuebin Qin, Namita Rout
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/686609950c5f9a2748b6c9d3a59879f149b910cb" target='_blank'>
              Autoantibody origins in lupus and in relapse post CAR-T therapy
              </a>
            </td>
          <td>
            Amalie Grenov, J. Yoon, Daniel M. Snell, Anna Mikolajczak, Hao Wang, Erdem Gürel, Ana Rodriguez Ronchel, G. Yegen, Lydia Lee, B. Esen, Anisur Rahman, P. Maciocia, Carola G. Vinuesa
          </td>
          <td>2025-10-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Lung mononuclear phagocyte (MNP) subsets differ in their ability to restrict Mycobacterium tuberculosis (Mtb) during chronic infection, yet the mechanisms underlying this difference are not well defined. Here, we show that CD11clo monocyte-derived cells (MNC1), the subset of lung cells that is most permissive for Mtb viability during chronic infection, express lower levels of interferon-gamma (IFNγ) signaling proteins, resulting in reduced responses to IFNγ compared to alveolar macrophages (AM) and CD11chi MNC2. Moreover, type I IFN signaling suppresses IFNγ-mediated MHC-II expression, impairing CD4 T cell activation by MNC1 cells. Importantly, prior immunity conferred by contained Mtb infection enhances IFNγ responsiveness of monocyte-derived cells, reducing bacterial burdens in lungs and within MNC subsets. Our findings indicate that heterogeneous IFNγ responsiveness is exploited by Mtb for persistence in vivo. Overcoming or bypassing impaired IFNγ responsiveness may guide the development of more effective TB vaccines and host-directed therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1185bf27cd38b33e534c27d9aa87381e2cd898fa" target='_blank'>
              Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis
              </a>
            </td>
          <td>
            Weihao Zheng, J. Limberis, Zachary P. Howard, Alexander Mohapatra, E. Takagi, J. Ernst
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Administration of IL-2 may promote the suppressive function and proliferation of Treg cells that cause immune tolerance in patients with cancer, which causes low-dose IL-2 to fail in achieving an optimal anti-tumor effect. Here, we designed an immunocytokine by fusing IL-2 and an anti-TIGIT monoclonal antibody, named αTIGIT-IL2, that targets Treg cells and promotes their fragility in the tumor milieu. These fragile-like Treg cells show impaired suppressive function and high IFN-γ production, triggering an immune-reactive tumor microenvironment. Such inflammation leads to the recruitment and functional reprogramming of intratumoral neutrophils, improving cross-talk between neutrophils and CD8+ T cells and enhancing the antitumor ability of CD8+ T cells. Combination therapy with αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer (TNBC) tumors resistant to immune checkpoint blockade (ICB) therapy. These findings provide the basis for developing a new generation of immunocytokines that target Treg cells and promote their fragility in the tumor milieu, resulting in robust antitumor immunity. Interleukin-2 (IL-2) and checkpoint inhibitors such as anti-TIGIT have been used individually as tumour therapies. Here the authors fuse IL-2 and anti-TIGIT in a combined therapeutic and show that this promotes Treg cell fragility in the tumour environment which in turn promotes neutrophil function to enhance CD8 T cell anti-tumour function in mouse models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a8f381b44371297ad7f4ba1f04d5155ffd6052c5" target='_blank'>
              αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
              </a>
            </td>
          <td>
            Tianci Wang, Yupu Xu, Zhengfeng Zhang, Yaqi Wu, Long Chen, Xiaodong Zheng, Hui-Min Peng, Qiang Zou, Rui Sun, Hongdi Ma, Haoyu Sun, Zhigang Tian, Xiaohu Zheng
          </td>
          <td>2025-10-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e312c1a3a9dbed5ee9046577d5060ddafb93654" target='_blank'>
              Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment
              </a>
            </td>
          <td>
            Yue Zhang, Sophia Peng, Hamid Akhbariyoon, Suzi Kim, Ellie Lai, En Cai
          </td>
          <td>2025-10-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Recent studies in murine disease models have identified Siglec-F+ neutrophils, which express a marker traditionally associated with eosinophils, as a functionally distinct population characterized by extended lifespans and context-dependent roles. While conventional neutrophils typically return to the bone marrow or undergo apoptosis at the site of inflammation, these cells remain in tissues for extended periods. These cells demonstrate remarkable functional plasticity, promote bacterial clearance and immune activation during infections, foster immunosuppression and tumor progression in cancer, and contribute to tissue remodeling in fibrotic diseases. In this review, we examine the key features governing Siglec-F+ neutrophil differentiation and function—including Siglec-F signaling, metabolic programming, and upstream cytokine cues—and explore how targeting these pathways may offer promising avenues for precision immunomodulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f85d27981564af58b267b87dc5389351cceb464b" target='_blank'>
              Context-Dependent Roles of Siglec-F+ Neutrophils
              </a>
            </td>
          <td>
            Kisung Sheen, Taesoo Choi, Man S Kim
          </td>
          <td>2025-10-24</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/842af96f572eb3d970548668b36cfda84da5efb2" target='_blank'>
              Glucocorticoid Receptor Signaling in Myeloid Cells Orchestrates Inflammation Resolution and Muscle Repair
              </a>
            </td>
          <td>
            Sirine Souali-Crespo, Joe G. Rizk, Emilia Calvano, Rajesh Sahu, Emina Colovic, Imane Chabba, Valentine Gilbart, Erwan Grandgirard, Bastien Morlet, Qingshuang Cai, Daniel Metzger, D. Duteil
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="T-cell exhaustion is a terminal state of immune dysfunction characterized by impaired proliferation and effector functions, diminished cytokine secretion, and sustained expression of inhibitory receptors. In coronavirus disease 2019 (COVID-19), increasing evidence links exhausted T-cell phenotypes with poor clinical outcomes, including severe disease, delayed viral clearance, and persistent symptoms associated with Long COVID. Exhaustion results from prolonged antigenic stimulation and inflammatory signals and is marked by transcriptional reprogramming, metabolic and epigenetic dysregulation, and co-expression of inhibitory receptors such as programmed cell death protein-1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Notably, exhausted phenotypes in COVID-19 frequently coexist with hyperactivation, raising the unresolved question of whether inhibitory receptor expression reflects transient activation or irreversible dysfunction. Emerging therapeutic strategies to reverse these dysfunctional states include immune checkpoint inhibitors, cytokine modulation, metabolic interventions, and epigenetic therapies, although their clinical translation remains at an early stage. Critical research gaps include the scarcity of longitudinal data, incomplete profiling of T-cell subsets across disease stages during COVID-19 and Long COVID-19, and contradictory evidence of vaccine-induced exhaustion with limited understanding of its consequences. This non-systematic literature review synthesizes current advances in COVID-19 immunopathology and therapeutic strategies, underscoring that understanding T-cell exhaustion is crucial to improving outcomes and shaping next-generation immunotherapies and vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcda848fedb31d45bcaf7a6be07292887c93eed0" target='_blank'>
              T-cell exhaustion in COVID-19: what do we know?
              </a>
            </td>
          <td>
            Roderick Chen-Camaño, Rodrigo DeAntonio, S. López-Vergès
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Immunotherapy has potential for impactful cancer cures by empowering patients’ own immune cells. We developed a radio-immunotherapy regimen that can cure large immunologically hot and cold murine tumors. Here we explored the divergent role of CD8 T cells during this radio-immunotherapy in contrasting hot colon carcinoma versus cold melanoma models. We introduced an immunocompetent mouse model with mCherry expressing CD8 T cells to provide immune cell tracking in vivo. We investigated single-cell function, metabolism, and gene expression changes with temporal context using flow cytometry, in vivo multiphoton imaging, single-cell RNA sequencing, and multiplexed immunofluorescence to determine the underlying mechanisms. We found that in contrast to the hot colon carcinoma model, CD8 T cells from the cold melanoma model do not drive tumor cures, despite getting activated, possibly due to a static oxidative metabolism and exhausted phenotype as well as down regulation of tumor MHC-I expression. These findings have implications for improving immunotherapy response in immunologically cold cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b84b993daf38493e48753044d461ef43b7961296" target='_blank'>
              Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors
              </a>
            </td>
          <td>
            Alexa R. Heaton, Nathaniel J Burkard, Anqi Gao, A. Hoefges, AS Feils, Samantha K. Burkard, Mildred A. Felder, N. Tsarovsky, Dan V. Spiegelman, Garrett M. Lublin, Alina A. Hampton, Aurora D’Amato, Huy Q. Dinh, A. Rakhmilevich, AK Erbe, Paul M. Sondel, Melissa C. Skala
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Cancer remains a leading cause of mortality worldwide, with rising incidence and death rates continuing to rise. While conventional treatments such as surgery, radiotherapy, and chemotherapy form the backbone of cancer care, they are often limited by adverse effects, recurrence risk, and incomplete tumor eradication. Tumor immunotherapy—particularly immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy—has emerged as a transformative approach by activating and reprogramming anti-tumor immune responses. Despite these advances, significant challenges persist, including limited response rates to checkpoint inhibitors, the immunosuppressive nature of the tumor microenvironment (TME), and resistance mechanisms employed by tumor cells. Growing evidence suggests that immune cell senescence is a critical contributor to TME-driven immunosuppression. Senescent immune cells exhibit functional decline, elevated expression of inhibitory immune checkpoint molecules, and increased secretion of pro-inflammatory cytokines, collectively impairing anti-tumor immunity and reducing the efficacy of immunotherapy. This review highlights the role of immune cell senescence in shaping the immunosuppressive TME and driving resistance to immunotherapy. It further discusses emerging therapeutic strategies that combine immunotherapy with senescence-targeting interventions, aiming to provide novel insights into the development of more effective cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56cdaa455cdfae646c5bce11b54ada6d03f2699c" target='_blank'>
              Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance
              </a>
            </td>
          <td>
            Duolun Gao, Peiyan Kan, Yanjie He, Siyu Sun, Lei Tang, Fan Yang
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>170</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73a6affa626cddbc311a72d5431b139dc8c83520" target='_blank'>
              IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death
              </a>
            </td>
          <td>
            Kais Almohammad, Marc Young, S. Vettorazzi, Franziska Greulich, Mahmoud Alkhatib, J. Tuckermann, H. Jumaa, Corinna S. Setz
          </td>
          <td>2025-10-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="


 Introduction:
 Chronic Lymphocytic Leukemia (CLL) results in the expansion of immunosuppressive B-cells leading to risk for secondary malignancies, infection, and suboptimal T-cell based immunotherapeutic responses. Treatments that restore immune function (e.g. ibrutinib) may improve the efficacy of CD19 CAR T-cell (CART) therapies. We previously demonstrated that venetoclax (Ven) causes complex immunologic changes which broadly improve circulating immune cell (including T-cell) function. While we found that Ven appears to improve CD19 CART cytotoxicity in most patients, some CD19 CAR T-cells manufactured after Ven treatment did not perform as well in ex vivo cytotoxicity assays. We performed a multiomic correlation analysis to elucidate germane molecular features that may help predict and optimize Ven-enhanced CD19 CART cytotoxicity.
 Methods:
 We collected peripheral blood mononuclear cells (PBMCs) and serum from 13 consented CLL patients initiating standard of care Ven-based therapy (Ven-monotherapy N = 9, Ven+ɑCD20 N = 4; BDR-164122). Specimens were collected before treatment (D0) and after 30 days (D30) of therapy. CD19 CART were manufactured for 6 patients at both timepoints using an ɑCD19 construct (scFv/CD28/TCRζ via retroviral transduction). Cytotoxicity was measured against Raji-Luciferase cells. D0 and D30 specimens were analyzed by flow cytometry (including T-cell subsets and exhaustion markers) and RNA-seq (with xCell for cell-type deconvolution, rMATS for splicing, LISA for master regulator analysis). Enrichment analysis identified biological processes linked to cytotoxicity with statistical significance calculated as False Discovery Rate (FDR) adjusted P value. Metabolomics were performed with the Biocrates MxP Quant 500 XL assay. For each multiomic feature, magnitude change from D0 to D30 was calculated. These changes were correlated with changes in CD19 CART ytotoxicity across 7 effector-to-target ratios (1:8 through 8:1) using Spearman's correlation.
 Results:
 Enhanced CD19 CART cytotoxicity correlated with increased NK-cell frequency (CD56+/CD57+, CD56-/CD57+) determined by flow cytometry and cell-type deconvolution. In addition, RNA sequencing studies demonstrated that CD19 CART activity correlated with gene expression changes in interferon-ɑ (IFNA1, FDR<0.001) and interferon-ɣ (IFNG, FDR<0.002) response pathways. Specifically, an increase in key interferon signaling genes (GZMA, STAT1, CASP1) were associated with improved CD19 CART cytotoxicity. Moreover, a decrease in some interferon signaling genes (JAK2, STAT2, IFNAR2) was associated with a decrease in CD19 CART activity. LISA analysis identified POU2F2 and HDAC1 as key transcriptional regulators of genes associated with enhanced post-Ven CD19 CART killing. Elevated anti-inflammatory metabolites (cortisol, cortisone), as well as cysteine and phosphatidyl lipids correlated with improved CD19 CART cytotoxicity. Diminished CD19 CART cytotoxicity correlated with increased CD4+ LAG3+ T-cells coexpressing TIM3/TIGIT, and total CD3+ T-cells. Cell-type deconvolution demonstrated an inverse correlation between regulatory T-cells (T-regs) and CD19 CART cytotoxicity. Increase in NFκB signaling and splicing factor genes (e.g. RELA, RELB, NFKB1, NFKB2, TNF, U2AF1, U2AF2) were associated with a decrease in CD19 CART cytotoxicity (FDR<0.001). Alternative splicing by rMATS analysis identified a MAP3K7 (TAK1) event resulting in a TAK1 variant lacking its negative regulatory domain. This alternative splice form of TAK1 enhances NFκB signaling and impacts CD19 CART activity. Elevated serum triacylglycerols, GABA, spermine, and taurine detected by metabolic studies correlated with diminished CD19 CART cytotoxicity. Conclusion: Using a comprehensive multiomic approach we uncovered signaling pathways associated with improved CD19 CART activity following Ven-based therapy in CLL patients. The activation of the interferon-ɑ, interferon-ɣ and glucocorticoid signaling pathways enhance CART activity. In contrast, NFκB signaling and spliceosome-related pathways contribute to sustained immune activation and negative impacts on CAR T-cell function. Venetoclax treatment appears to alter T-cell (especially T-reg) and NK-cell subtypes, which influence the anti-tumor activity of CD19 CAR T-cells. Our work provides a foundation for further mechanistic inquiry into Ven-related immunologic impacts, which can improve synergistic combination treatments using CART for CLL patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be9262399f1e435c641b61481400c69897fe78fa" target='_blank'>
              Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Jacob P Wright, F. Hernandez-Ilizaliturri, C. Mavis, Joseph Tario, Alex Niu, Taylor K Mandeville, Dorothy C. Pan, Grant Schofield, Dae-Kyum Kim, Joseph Barbi, Hua-Hsin Hsiao, Spencer Rosario, M. Cortese
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 IntroductionChronic lymphocytic leukemia (CLL) is marked by profound immune dysregulation, which compromises both the numerical and functional integrity of the T cell compartment, posing significant challenges for chimeric antigen receptor (CAR) T-cell therapy. CLL patients often exhibit an elevated expression of inhibitory receptors such as PD-1 and CTLA-4 on their T cells. Additionally, the immunosuppressive microenvironment in these patients is marked by the predominance of effector and effector memory T cells, which are less capable of sustaining long-term immune responses. Prior studies, including work from our group (Fraietta JA et al., 2018), have highlighted the importance of early memory T cell subsets in promoting CAR T cell expansion, persistence, and anti-tumor efficacy. However, these subsets are intrinsically rare in CLL, limiting the success of manufacturing strategies that rely on their enrichment or ex-vivo expansion. Studies by Ludwig LM et al. (2021) and van Bruggen JAC et al. (2022) demonstrated that short-term Venetoclax treatment selectively depletes naive T cells, but prolonged therapy led to their numerical recovery along with upregulation of OXPHOS and glycolysis pathways. However, the effects of Venetoclax on T-cell functionality and its implications for CAR T-cell manufacturing remain uncertain. We aimed to study if treatment with Venetoclax could improve the qualitative and quantitative defects in the T cells in CLL patients ensuring better CAR T-cells and identify the ideal timepoint following treatment to collect T cells for CAR T manufacturing.
 MethodsWe analyzed peripheral blood samples from discovery (n=14) and validation (n=23) cohorts of CLL patients, with one or more prior lines of therapy, treated with Venetoclax monotherapy or in combination with the anti-CD20 antibody Obinutuzumab. Deep phenotyping of T cells and their response to activation with PMA and Ionomycin was performed using a spectral flow cytometry panel. CD19-directed CAR T cells (incorporating the 4-1BB costimulatory domain) were manufactured, and their proliferation and anti-tumor efficacy were assessed by flow cytometry and restimulation assays in vitro. Statistical analyses were performed using the Friedman test, 2-way ANOVA or Kruskal Wallis test, as appropriate.
 ResultsTreatment with Venetoclax improved the qualitative and quantitative T cell defects with a significant increase in the proportion of naïve (CD45RA+CD27+CCR7+) T cells (both CD4+ and CD8+) and decrease in the effector memory (CD45RA-CD27-CCR7-) compartment. Both manual gating and unsupervised clustering analysis showed a significant decrease in the frequency of regulatory T cells (Tregs) and T cells expressing markers of effector differentiation (KLRG1, CD244, EOMES) and inhibition/exhaustion markers (PD1, CD39, CTLA4, TIGIT). The differences were more pronounced after 1 year of treatment and the findings were confirmed in an independent validation cohort. Upon activation, the treatment-naive samples showed a significant increase (percentage or absolute) in the expression of activation-exhaustion markers (ICOS, PD1, TIM3, TIGIT, CTLA4) while the increase was more restrained after Venetoclax treatment. CAR T-cells were manufactured and functionally assessed through co-culture and repeated stimulation with the aggressive, MHC-deficient CD19+ leukemia cell line NALM6. CAR T-cells manufactured with samples one year post treatment with Venetoclax exhibited greater fold expansion and population doublings on repeat stimulation with NALM6 cells compared to their paired treatment-naive samples. Cytokine analysis and cytotoxicity assays are currently being performed to strengthen our findings.
 ConclusionOur findings strongly suggest that the BCL2 inhibitor Venetoclax exerts beneficial immunomodulatory effects beyond their primary anti-tumor activity. By reducing tumor burden and potentially directly influencing T cell biology, Venetoclax facilitates not only quantitative T cell recovery but also qualitative improvements. Such improvements include phenotypic shifts away from exhaustion and towards less differentiated states (potentially enriching for early memory precursors) and the restoration of key T cell functions like proliferation and cytokine production - factors that may significantly improve CAR T cell manufacturing and therapeutic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b0f58a6bf6fe69cb96d274bc1c6f4165ac0c965" target='_blank'>
              Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Arun Arunachalam, Beatriz Coutinho de Oliveira, Céline Grégoire, Ziran Zhao, Lily Simpson-Heavey, John C. Molina, A. Kater, F. Peters, A. Wiestner, J. Woyach, J. Melenhorst
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Aberrant and sustained activation of microglia is implicated in the progression and severity of multiple sclerosis (MS). However, whether intrinsic alterations in microglial function impact the pathogenesis of this disease remains unclear. We conducted transcriptomic and functional analyses of microglia-like cells (iMGLs) differentiated from induced pluripotent stem cells (iPSCs) from patients with MS (pwMS) to answer this question. We generated iPSCs from six pwMS showing increased microglial activity via translocator protein (TSPO)-PET imaging. We demonstrated that the differentiated iMGL transcriptional profile resembled the microglial signature found in MS lesions. Importantly, compared with healthy controls, MS iMGLs presented cell-autonomous differences in their regulation of inflammation, both in the basal state and following inflammatory lipopolysaccharide challenge. Through transcriptomic profiling, we showed that MS iMGLs display increased expression of genes known to be upregulated in MS microglia. Furthermore, upregulated genes in MS iMGLs were associated with immune receptor activation, antigen presentation, and the complement system, with known MS implications. Finally, functional analyses indicated that the transcriptional changes in MS iMGLs corresponded with alterations in the secretion of inflammatory cytokines and chemokines and increased phagocytosis. Together, our results provide evidence of putative cell-autonomous microglial activation in pwMS and identify transcriptomic and functional changes that recapitulate the phenotypes observed in vivo in microglia from pwMS. These findings indicate that MS disease-specific iPSCs are valuable tools for studying disease-specific microglial activation in vitro and highlight microglia as potential therapeutic targets in MS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce483627b1620ca8e2ea90bf499e8cad452ba523" target='_blank'>
              Microglia from patients with multiple sclerosis display a cell-autonomous immune activation state
              </a>
            </td>
          <td>
            Tanja Hyvärinen, J. Lotila, Luca Giudice, Iisa Tujula, M. Nylund, S. Ohtonen, Flavia Scoyni, Henna Jäntti, Sara Pihlava, H. Skottman, Susanna Narkilahti, L. Airas, T. Malm, S. Hagman
          </td>
          <td>2024-12-11</td>
          <td>Journal of Neuroinflammation</td>
          <td>2</td>
          <td>47</td>
        </tr>

        <tr id="Radiation-induced skin injury (RISI) is a common and debilitating complication of radiotherapy, characterized by persistent inflammation and delayed wound healing. Macrophages play a central role in this process; however, the molecular mechanisms governing their dysfunction under radiation stress remain poorly understood. To elucidate the role of triggering receptor expressed on myeloid cells 2 (TREM2) in macrophage regulation after irradiation, we combined single-cell RNA sequencing, in vivo mouse models, and in vitro macrophage assays. Conditional knockout mice (LysMCreTrem2flox/flox) were used to selectively delete Trem2 in macrophages. Radiation induced a distinct TREM2+ macrophage subset; however, despite elevated Trem2 mRNA, protein levels declined due to ADAM17-mediated shedding driven by radiation-induced reactive oxygen species (ROS) accumulation and NRF2 activation. Inhibition or small interfering RNA (siRNA)-mediated knockdown of ADAM17 restored TREM2 protein expression, reduced soluble TREM2 release, improved macrophage survival, and promoted anti-inflammatory M2 polarization. Conversely, Trem2 deficiency enhanced apoptosis, sustained inflammation, and delayed wound healing, whereas Trem2 overexpression or local adoptive transfer of TREM2+ macrophages accelerated tissue repair. Mechanistically, TREM2 conferred radioprotection through extracellular signal-regulated kinase (ERK) pathway activation, linking the ROS–NRF2–ADAM17 axis to TREM2–ERK signaling in macrophage survival and polarization. Collectively, these findings identify a novel regulatory cascade, ROS–NRF2–ADAM17–TREM2–ERK, that governs macrophage fate under irradiation. Targeting this pathway or supplementing TREM2+ macrophages may offer promising therapeutic strategies for mitigating RISI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5e8bb0105bfc306e09e4c0af1d74cb3671e412a" target='_blank'>
              TREM2 Deficiency Regulates Macrophage Apoptosis and Repair in Radiation-Induced Skin Injury
              </a>
            </td>
          <td>
            Zijian Chen, siyuan cai, Pengfei Li, ziyi zhou, zhenxing huang, juntao deng, Linbo Jin, Zucheng Luo, Dongli Fan, Junli Zhou, Fazhi Qi, Yiming Zhang
          </td>
          <td>2025-11-13</td>
          <td>Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Autoimmune diseases represent a broad group of chronic conditions characterized by loss of immune tolerance, autoreactive lymphocyte activation, and pathogenic autoantibody production. CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematologic malignancies, has emerged as a promising strategy to directly eliminate autoreactive B cells and reprogram immune function. CD19-CAR T infusion can induce rapid remission, reduce autoantibody levels, and sustain drug-free disease control. Despite these encouraging results, current evidence is limited to small patient cohorts with short follow-up, leaving uncertainties regarding long-term safety, durability of remission, and the stability of immune reconstitution. Most studies implicitly assume that quantitative B-cell recovery equates to restored immune health, yet the functional resilience of the post-CAR-T immune system—its ability to protect against infection, respond to vaccines, and maintain durable tolerance—remains unexplored. To address this gap, we propose an integrated framework for evaluating the functional competence of immune reconstitution following CAR T-cell therapy and for designing next-generation targeting strategies. Functional recovery should be assessed not only by quantitative B-cell repopulation but also by vaccine responsiveness, infection surveillance, and immune repertoire diversity. Vaccine challenge studies and infection monitoring can reveal whether protective immunity is restored, while sequencing-based profiling of B- and T-cell repertoires can clarify whether regulatory balance and clonal diversity are re-established. In parallel, translational innovations such as dual-target CAR constructs (e.g., CD19 + BAFF-R) and chimeric autoantibody receptor (CAAR) T cells offer complementary solutions to broaden target coverage and improve selectivity. Moreover, Epstein–Barr virus (EBV)–mediated immortalization of patient-derived autoreactive B cells provides a feasible ex vivo platform for generating physiologically relevant antigenic stimuli during CAR engineering. This approach could yield T cells that are functionally “educated” to eliminate pathogenic clones while preserving protective immunity, thereby addressing the central challenge of rebuilding a resilient and tolerant immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/803ca15907028d5ecd42afcef39a38a8ff458830" target='_blank'>
              Application of CD19-CAR T cell therapy in autoimmune diseases
              </a>
            </td>
          <td>
            Lynn Choi
          </td>
          <td>2025-10-24</td>
          <td>Journal of High School Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Despite major advances in immunotherapy, respective treatments often show only limited benefit in patients with chronic lymphocytic leukemia (CLL). Immune checkpoint blockade, which has shown durable responses in multiple malignancies, has yielded inferior efficacy in CLL. Similarly, adoptive CAR-T cell therapy, which has achieved remarkable success in other B cell malignancies, resulted in lower response rates in CLL. The lack of success of these immunotherapies is likely due to the profound T cell dysfunction and immune suppressive microenvironment, typical characteristics of this disease. The so-called “exhaustion” of T cells is marked by impaired effector capacity, sustained inhibitory receptor expression, and loss of progenitor exhausted (TPEX) populations, cell subsets which are critical for responses to PD-1 blockade. This suggests that reversing T cell exhaustion could be key to improving outcomes.
 Emerging evidence implicates the immunoregulatory cytokine interleukin-10 (IL-10) as a context-dependent modulator of T cell exhaustion. While traditionally viewed as an immunosuppressive mediator that limits tissue damage during chronic inflammation and suppresses antiviral immunity, IL-10 may, in cancer, enhance tumor-infiltrating CD8⁺ T cell function, prolong their survival, and delay T cell exhaustion.
 Using the Eµ-TCL1 adoptive transfer (TCL1-AT) mouse model of CLL, we previously identified a role for IL-10 receptor (IL-10R)–STAT3 signaling in sustaining CD8⁺ TPEX cells, preventing terminal exhaustion, with loss of signaling accelerating CLL progression (Hanna et al., Immunity 2021). As IL-10 expression is linked to better outcome in CLL patients and IL-10R loss is associated with DLBCL development early in life, we hypothesize that IL-10 improves the fitness of cytotoxic T cells thereby preventing immune escape in CLL and likely other B cell malignancies.
 To test the potential of IL-10 in modulating T cell responses against CLL, we generated a stabilized IL-10 fusion protein (IL-10-Fc) and demonstrated that treatment of TCL1-AT mice with IL-10-Fc slowed CLL progression, reduced exhausted effector T cells, and preserved TPEX populations.
 To dissect T cell-intrinsic effects, we employed an in vitro exhaustion assay by repetitive antigen-specific stimulation of T cell receptor (TCR)-transgenic murine CD8⁺ T cells with peptide-loaded target cells. IL-10 treatment maintained effector T cells in these cocultures, reduced terminal exhaustion markers TIM-3 and CD39, and promoted a polyfunctional phenotype with robust cytokine production and CD107a expression, demonstrating a direct effect of IL-10 on T cell fitness.
 To gain a broader view of IL-10-mediated immune modulation in the TCL1-AT model, we performed spectral flow cytometry and single-cell RNA-sequencing following short-term IL-10-Fc treatment. Both T cell and myeloid compartments displayed therapy-induced alterations, including shifts in regulatory T cells, CD8⁺ T cells, neutrophils, and monocytes. Notably, IL-10-Fc reduced PD-L1⁺ patrolling monocytes, which were linked to immune suppression in CLL, and increased inflammatory monocytes, which suggests a reversal of pro-tumoral myeloid activity.
 Finally, a pilot combination treatment study revealed that IL-10-Fc synergized with the BTK inhibitor ibrutinib, achieving profound disease control in the TCL1-AT mouse model beyond either agent alone. These findings position IL-10 as a promising immunomodulatory therapy in CLL, capable of restoring T cell function and remodeling the suppressive tumor microenvironment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/189bf152f9c8c3a59e8922ef6b9ef1ab630e8fe4" target='_blank'>
              IL‑10 limits CLL progression by reprogramming T cell exhaustion and myeloid suppression
              </a>
            </td>
          <td>
            A. Floerchinger, Min Gao, Jan Philipp Schadendorf, Yuliia Borysovych, Nicolas Aubert, Hannah Briesch, L-M Pilger, Mei-Wen Peng, P. Lichter, Stella E. Autenrieth, M. Zapatka, L. Tang, M. Seiffert
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI). Methods Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated. Results In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells. Conclusion This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/854d707af7ff1d7731b63579e115f89b9c83b43b" target='_blank'>
              Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy
              </a>
            </td>
          <td>
            Salvatore Russo, Yvonne Giannoula, S. Feola, Justin Cerioni, Firas Hamdan, Jacopo Chiaro, Anja Thu Ha Dang, Paolo Bottega, Michaela Feodoroff, M. Fusciello, Virpi Stigzelius, Carmine D'Amico, Carmen Caiazza, Gabriella Antignani, Federica D'Alessio, Milda Sakalauskaite, Julia Petryk, J. Bell, C. Ilkow, M. Grönholm, Vincenzo Cerullo
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Hematopoietic stem cells (HSC) sustain lifelong blood and immune system homeostasis. This study identifies P-selectin as a pivotal regulator of HSC function under aging and inflammatory stress. We observed pronounced Selp upregulation in aged HSC and inflammatory contexts, which drives excessive proliferation and differentiation while depleting their long-term self-renewal capacity. Using tissue-specific Selp overexpression models, we demonstrate that chronic Selp elevation disrupts HSC polarity, promotes oxidative stress accumulation, and induces genomic instability. Over time, sustained Selp expression leading to LT-HSC exhaustion and impaired hematopoietic reconstitution. Single-cell transcriptomics revealed that Selp enforces a pro-inflammatory transcriptional program in HSC, hyperactivating IFN-γ and PI3K-AKT-MOTR signaling pathways. Mechanistically, P-selectin directly interacted with IFNγR1 on the HSC surface, which driving activation of JAK1-STAT1 and PI3K-AKT-mTOR signaling axes. Notably, Selp overexpression suppresses the pathogenic capacity of leukemia stem cells (LSC), highlighting potential therapeutic implications. Our findings established P-selectin as a molecular nexus linking chronic inflammation and aging to hematopoietic decline, with dual therapeutic implications: targeting P-selectin may mitigate age-related hematopoietic dysfunction while offering a strategy to selectively impair LSC activity in malignancies. Selp is significantly elevated in aged HSC and under inflammatory conditions, driving HSC into active proliferation and differentiation while diminishing their ability to maintain quiescence. Selp upregulation disrupts HSC polarity, increases oxidative stress, and promotes genomic instability, long-term Selp overexpression leads to HSC exhaustion and reduced hematopoietic reconstitution capacity. Selp overexpression exacerbates inflammatory signaling in HSC, particularly through IFN-γ-PI3K-AKT-MOTR pathways. Selp overexpression reduces the pathogenic capacity of leukemia stem cells. Selp is significantly elevated in aged HSC and under inflammatory conditions, driving HSC into active proliferation and differentiation while diminishing their ability to maintain quiescence. Selp upregulation disrupts HSC polarity, increases oxidative stress, and promotes genomic instability, long-term Selp overexpression leads to HSC exhaustion and reduced hematopoietic reconstitution capacity. Selp overexpression exacerbates inflammatory signaling in HSC, particularly through IFN-γ-PI3K-AKT-MOTR pathways. Selp overexpression reduces the pathogenic capacity of leukemia stem cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c21f4b81053b964ca22b1df90c8ef3097f1bd773" target='_blank'>
              P-selectin overexpression impairs hematopoietic stem cell homeostasis via inflammatory receptor-mediated proliferation and differentiation
              </a>
            </td>
          <td>
            Wei He, Huandi Qiu, Yun-lu Feng, Q. Qiu, Li Zheng, Congbin Pan, Xue Cui, Yuanyuan Sun, Bochuan Wang, Yiguo Hu
          </td>
          <td>2025-10-21</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Renal cell carcinoma (RCC) evolves within a chronic inflammatory renal niche, where angiogenesis, metabolism, and immune programs synergize to reshape the tumor immune microenvironment (TIME). Recurrent renal damage and tissue hypoxia sustain NF-κB/STAT3 and HIF-VEGF signaling, while a sustained IFN-γ response enhances antigen presentation while inducing inhibitory checkpoints, promoting a state of “inflammation but constrained.” Single-cell and spatial studies reveal early microenvironment heterogeneity and the chemokine-checkpoint paradox: regions enriched in CXCL9/10 coexist with endothelial inertia, cancer-associated fibroblasts (CAFs)-mediated stromal barriers, and metabolic stress, which collectively exclude functional CD8+T cells. In advanced clear cell RCC, immuno-inflammatory, immuno-excluded, and immuno-desert phenotypes often coexist and undergo transitions during treatment, leading to heterogeneity in response to immune checkpoint blockade (ICB). We propose a modular perspective-the NF-κB/STAT3, HIF-VEGF, IFN-γ circuits and auxiliary regulatory factors-to link stage-specific biology with treatment matching. Integrative biomarkers couple IFN-γ characteristics with angiogenesis/stromal modules and spatial indicators, offering superior predictive power compared to single tests. These insights support the adoption of a combined strategy: integrating vascular normalization or stromal/myeloid cell reprogramming on the basis of ICB, and encouraging the use of longitudinal “immune snapshots” to guide intervention and precision immunotherapy for renal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2bd0a59026e4807122514617a7c05a2fad79de65" target='_blank'>
              From chronic inflammation to immune escape: mapping the tumor microenvironment evolution in renal cell carcinoma
              </a>
            </td>
          <td>
            Hanjun Xu, Baojun Tu, Hui Li, Yong Shan
          </td>
          <td>2025-11-04</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7e104f926b9fda3602b303271493c55d2937a852" target='_blank'>
              Neuro-Immune Crypt-Associated Cells Drive Colorectal Carcinogenesis via REST-Mediated Phenotypic Reprogramming: Implications for Tumorigenesis and Viral Susceptibility
              </a>
            </td>
          <td>
            D. Díaz-Carballo, Adrien Noa-Bolaño, Udo Rahner, A. Acikelli, Sahitya Saka, Jacqueline Klein, Flevy D’Souza, S. Malak, Anne Höppner, Annabelle Kamitz, Carla Casula, Lalitha Kamada, Andrea Tannapfel, Jens Christmann, Sarah Albus, Enrico Fruth, Daniela Gerovska, Marcos J. Araúzo-Bravo, M. Senkal, Crista Ochsenfarth, D. Strumberg
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Immune checkpoint blockade therapies, particularly targeting PD-1/PD-L1 axis, have shown limited efficacy in glioblastoma (GBM), primarily due to the profoundly immunosuppressive tumor microenvironment dominated by glioma-associated microglia and macrophages (GAMs). While CMTM6 is known to stabilize PD-L1 in tumor cells by preventing its ubiquitin-mediated degradation, its role in microglia remains undefined. We employed a multi-omics approach to evaluate CMTM6 expression and function. By analyzing the bulk RNA-seq data sets from TCGA and CGGA, as well as single-cell data sets (TISCH2 and UCSC), the expression of CMTM6 across different glioma grades and immune cell populations was examined. Immunohistochemistry and immunofluorescence were used to validate CMTM6 expression and co-localization with microglial/macrophage markers in GBM tissues. In vitro, CMTM6 knockdown was performed in HMC3 microglial cells to assess changes in cytokine and immune checkpoint expression. In vivo, a tamoxifen-induced, microglia/macrophage-specific Cmtm6 conditional knockout mouse model was used to investigate tumor growth and survival outcomes. CMTM6 was significantly upregulated in high-grade gliomas and enriched in M2-like microglia/macrophages. Immunostaining confirmed elevated CMTM6 and CD68 expression in GBM samples, with CMTM6 co-localizing with microglial markers (CD68, IBA1, and TMEM119). By knocking down CMTM6 in HMC3 cells, the levels of CD274 (PD-L1) and TGFβ isoforms decreased, while the expression of pro-inflammatory cytokines IL6 and CCL3 increased, suggesting a shift toward an M1-like phenotype. In vivo, microglia/macrophage-specific deletion of Cmtm6 suppressed tumor growth, delayed body weight loss, and extended survival duration. This study identifies CMTM6 as a critical regulator of the immunosuppressive phenotype of microglia/macrophages in GBM. Targeting CMTM6 in microglia/macrophages may represent a novel strategy to reprogram the tumor immune microenvironment and improve the efficacy of immunotherapy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2983570a9c22d4513306860ad1a429e127cd5f00" target='_blank'>
              CMTM6 drives glioblastoma progression by promoting M2 polarization and suppressing antigen presentation in microglia/macrophages
              </a>
            </td>
          <td>
            Xiang Li, Wenbo Han, Wenpei Cai, Ruoxin Yang, Gaojie Bai, Changxiu Sun, Shiyuan Ge, Cheng Zhang, Xinyi Han, Han Yang, Yi Chen, Qiao Shan, Xiaohui Li, Xueli Tian, Yuan Lyu, Junqi Li, Xinjun Wang
          </td>
          <td>2025-10-27</td>
          <td>European Journal of Medical Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6–JAK–STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d49eb0cd9f9aa70be266360e0a4941b4deb7497" target='_blank'>
              Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies
              </a>
            </td>
          <td>
            Michael Rassner, T. Müller, Kirstyn Anne Crossley, G. Andrieux, Sabina Schaberg, Cornelia Endres, Lena Jakob, Teresa Poggio, N. Köhler, Julia Kolter, Gerhard Müller-Newen, Katharina Schönberger, N. Cabezas-Wallscheid, I. González-Menéndez, Leticia Quintanilla-Martinez, Melissa Zwick, Driti Ashok, T. N. Hartmann, Olaf Groß, O. Gorka, M. Follo, A. Illert, M. Boerries, R. Zeiser, J. Duyster
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Background and aims Atherosclerosis is a chronic immunometabolic disease driven by lipid accumulation and immune cell infiltration. Macrophages and T cells play key roles throughout plaque development. Galectin-1 (Gal-1), a glycan-binding protein, modulates immune functions in these cells and has been reported to attenuate atherosclerosis, though its mechanisms remain incompletely understood. Here, we investigated the effects of Gal-1 on macrophages and T cells during plaque formation. Methods Effects of Gal-1 on atherosclerosis, macrophages and T cells during lesion formation were studied in Apoe−/− mice treated with recombinant Gal-1. Complementary mouse peritoneal foam cell and in vitro macrophage and T cell cultures experiments were performed to study T cell differentiation, macrophage function, polarization end energy metabolism. The impact of Gal-1 on human macrophages was further evaluated in endarterectomy specimens. Results Gal-1 treatment reduced lesion size and increased circulating IL-10 levels, inversely correlating with plaque burden. Unexpectedly, IL-10 neutralization also mitigated atherosclerosis, indicating that its action is at least partially IL-10–independent. In plaques, Gal-1 promoted anti-inflammatory macrophage phenotypes, mirrored by a quiescent metabolic and anti-inflammatory profile in foamy macrophages ex vivo. The use of the Gal-1E71Q variant revealed that these effects were only partly dependent on glycan binding. Beyond IL-10, Gal-1 reshaped cytokine profiles by increasing IL-17, IL-22, and IL-23, consistent with a macrophage-driven regulatory Th17 response, alongside higher frequencies of IL-10–producing and regulatory T cells. Conclusion Gal-1 protects against atherosclerosis associated with reprogramming macrophages and tuning T cell immunity through glycan-dependent and –independent pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2bb689064d23f64e92df5e88983aeac0866276a1" target='_blank'>
              Galectin-1 induces macrophage immunometabolic reprogramming, modulates T cell immunity and attenuates atherosclerotic plaque formation
              </a>
            </td>
          <td>
            Ya Li, J. Leberzammer, X. Blanchet, R. Duan, M. Lacy, V. Triantafyllidou, Veit Eckardt, Eva Briem, A. S. Jung, R. Su, Joel Guerra, Y. Jansen, Michael Hristov, W. Enard, J. Bernhagen, C. Weber, D. Atzler, Alexander Bartelt, Yvonne Doring, D. Santovito, Herbert Kaltner, Anna-Kristin Ludwig, P. von Hundelshausen
          </td>
          <td>2025-11-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) represent a small subset of tumor cells populations characterized by their ability to self-renew and differentiate. These cells are often considered resistant to chemotherapy, radiotherapy, and immunotherapy, playing a crucial role in driving tumor progression and metastasis. To evade immune attacks, CSCs utilize various genetic and epigenetic strategies that diminish immune recognition, enhance tolerance to immune-induced cytotoxicity, and foster the development of a protective immunosuppressive microenvironment. This microenvironment is shaped by a group of key immunosuppressive cells, particularly myeloid-derived suppressor cells (MDSCs), which not only directly inhibit effector T cells and natural killer (NK) cells, facilitating the immune escape of CSCs, but also significantly contribute to the maintenance of tumor cell stemness and promote their metastasis. Conversely, the developmental signals of MDSCs are also regulated by CSCs. This complex interplay between MDSCs and CSCs adds layers of complexity to the cancer-immune cycle and the associated tumor treatment strategies. Therefore, understanding the detrimental interdependence between MDSCs and CSCs to effectively impede tumor progression has become heated topic in tumor immunology. In this review, we provide a timely summary of the latest studies on the reported characteristics of CSCs and MDSCs, discuss their interconnection during tumor progression, and evaluate various immunotherapeutic strategies targeting these cell populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f6883e12fe0f725487279c796b8b972017bb7c9" target='_blank'>
              Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy
              </a>
            </td>
          <td>
            Bo Wang, Xiaoguo Zhao, Shuxin Han, Yuekang Xu, Jinyao Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Q. Han, Yuntao Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple Myeloma (MM) is the second most frequent hematologic malignancy in adults in the Western world. The bone marrow microenvironment plays a critical role in MM progression by supporting malignant plasma cell (PC) survival, immune evasion, and proliferation. Among immune checkpoints, TIGIT has recently emerged as a relevant immunoregulatory molecule, capable of dampening cytotoxic responses and enhancing immune suppression. We investigated the expression of TIGIT in the bone marrow of newly diagnosed MM patients and its correlation with disease characteristics and microenvironmental features. We enrolled 25 consecutive patients with newly diagnosed MM. Bone marrow samples were collected for cytomorphology, cytogenetics (FISH), and immunohistochemistry using the Cytomatrix system. TIGIT expression was analyzed in bone marrow-infiltrating immune cells. Histological evaluation and confocal microscopy assessed immune cell localization, neutrophil extracellular trap (NET) formation, and proinflammatory cytokine expression. Clinical parameters, staging (ISS, R-ISS, R2-ISS), cytogenetic risk, and laboratory values were correlated with TIGIT status. TIGIT was expressed in 86% (19/22) of evaluable samples. TIGIT-positive patients had a significantly higher frequency of advanced R-ISS stages (p = 0.01), high-risk cytogenetics (100%), and elevated LDH (> 220 mU/ml, 100% TIGIT+). Among patients with PC% >60% or FLC ratio > 100, 92% were TIGIT+. Morphological differences were evident between groups: TIGIT-negative PCs were larger and altered, while TIGIT-positive PCs showed polarized nuclei and proximity to neutrophils. TIGIT-positive samples displayed increased neutrophils undergoing NETosis, as confirmed by neutrophil elastase and Ly6b co-expression (p = 0.0067). Elevated IL-6 (p = 0.0003) and IL-8 (p = 0.004) in TIGIT-positive samples suggest a proinflammatory microenvironment promoting neutrophil recruitment and NETosis. TIGIT expression in the bone marrow of MM patients is associated with more aggressive disease features and an inflammatory microenvironment enriched with NET-forming neutrophils. These findings support TIGIT as a potential biomarker of disease severity and a therapeutic target in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2db043b94ebed36b09b59ae106115395215e9302" target='_blank'>
              Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma
              </a>
            </td>
          <td>
            V. Tomarchio, Francesca Arciprete, Monica Di Cecca, G. Maricchiolo, Viola Velardi, M. Tafuri, A. Bianchi, V. Morano, Barbara Mecorio, L. Rigacci, A. Crescenzi, M. Zingariello, O. Annibali
          </td>
          <td>2025-11-01</td>
          <td>Annals of Hematology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Monocyte exhaustion is a dysfunctional state characterized by prolonged pathogenic inflammation and immune suppression, commonly observed in chronic infections and sepsis. However, the mechanisms underlying the generation and propagation of exhausted monocytes remain poorly understood. In this study, we investigate the impacts of exhausted monocytes on neighboring naïve monocytes, endothelial cells, and T cell function. Using an in vitro co-culture system, we demonstrate that exhausted monocytes induced by prolonged LPS stimulation propagate the exhaustion phenotype to neighboring naïve monocytes. Meanwhile these exhausted monocytes can promote endothelial apoptosis, upregulate adhesion molecules ICAM-1 and VCAM-1, and enhance monocyte transmigration, contributing to endothelial dysfunction. Pharmacological inhibition of CD38, a key marker of monocyte exhaustion, significantly mitigates these effects, highlighting its critical role in monocyte-driven endothelial alterations. Furthermore, we show that exhausted monocytes suppress T cell proliferation and activation, a process reversed by CD38 inhibition. We also identify mTOR signaling as a key regulator of monocyte exhaustion and its propagation, with mTOR inhibition partially restoring monocyte functionality by downregulating exhaustion markers and STAT1/STAT3/S6K signaling. Collectively, our findings highlight the CD38-mTOR axis as a central driver of monocyte exhaustion and its pathological consequences, offering potential therapeutic targets for reversing immune dysfunction in inflammatory diseases. The inhibition of CD38 can alleviate monocyte exhaustion through suppressing the sustained mTORC1-STAT1 activation. Upon LPS stimulation, TLR4 signaling is activated through the TRAM-TRIF adaptor complex, leading to the phosphorylation of Src. This activation promotes mTORC1 signaling, characterized by the recruitment of Raptor and the activation of S6K. mTORC1 activation subsequently drives STAT1/3 signaling, which further induces CD38 expression and forms a sustained positive feedback loop. Elevated CD38 levels contribute to monocyte exhaustion by depleting NAD⁺, a key metabolic cofactor. NAD⁺ depletion negatively impacts mTORC2 signaling, leading to impaired Akt phosphorylation, resulting in diminished expression of PGC1α/β, CREB and CD86, both of which are associated with exhausted monocyte immune suppression. The CD38 inhibitor 78c disrupts this exhaustion pathway, offering a potential therapeutic strategy to mitigate monocyte dysfunction during monocyte exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/339d48c34c821d9297b2f89fa7a33fe439da7b15" target='_blank'>
              Propagation of monocyte exhaustion memory and underlying mechanisms
              </a>
            </td>
          <td>
            Jing Wang, Blake A. Caldwell, Yajun Wu, Babak Razani, Liwu Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Macrophage activation markers, specifically CD163 and CD169, play pivotal roles in the modulation of immune responses within the tumor microenvironment (TME), influencing the outcome of various cancers. These markers delineate the activation states of macrophages, with CD163 associated with the protumoral phenotype and CD169 with activation of tumor immunity. This review comprehensively explores the dualistic roles of these markers in cancer progression and immune suppression, and discusses the mechanisms through which these markers influence macrophage behavior, the impact of their expression on cancer progression, and the therapeutic potential of targeting these pathways to reprogram the TME toward enhancing antitumor immunity. This review aims to underscore the therapeutic potential of macrophage activation markers as targets for cancer treatment, highlighting emerging strategies and future directions in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53fc1215ec60391859572318c1aaf77d4a3cec5e" target='_blank'>
              Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer
              </a>
            </td>
          <td>
            Yukio Fujiwara, Yoshihiro Komohara
          </td>
          <td>2025-11-01</td>
          <td>Pathology International</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation and immune dysregulation, including expansion of pro-inflammatory monocytes and effector T cells, alongside reduced regulatory T cells (Tregs). Bacillus subtilis natto, a spore-forming probiotic, has shown anti-atherosclerotic effects, though its systemic immunomodulatory mechanisms remain unclear. In this study, we employed an AAV-mPCSK9-induced murine atherosclerotic model to investigate the effects of daily B. subtilis natto NTU-18 administration over 16 weeks. High-dimensional flow cytometry using two 13-marker panels enabled longitudinal profiling of 18 peripheral immune cell subsets across lymphoid and myeloid compartments. While no significant changes in serum cholesterol and mild decrease of body weight were observed, B. subtilis natto NTU-18-treated mice presented a significant reduction in aortic lesion area compared to PBS-treated controls. Immune profiling revealed a transient expansion of peripheral myeloid cells and CD44⁺ trained CD8⁺ T cells, followed by increased frequencies of naïve CD8⁺ T cells and reduced central/effector memory subsets at longer time point treatment. In the CD4⁺ T cell compartment, a transient increase in trained cells was accompanied by a sustained enrichment of CD25⁺CD4⁺ Tregs throughout the daily B. subtilis natto NTU-18 treatment. In contrast, no significant differences were observed in Ly6C⁻ or Ly6C⁺ monocytes, neutrophils, or eosinophils. These findings suggest that B. subtilis natto NTU-18 attenuates atherosclerosis progression not through lipid lowering or broad myeloid modulation, but via targeted reprogramming of peripheral T cell responses. This work provides mechanistic insight into the immunotherapeutic potential of B. subtilis natto NTU-18 in atherosclerosis prevention and treatment. • B. subtilis natto NTU-18 significantly reduces aortic plaque burden in atherosclerotic mice without affecting serum cholesterol levels. • B. subtilis natto NTU-18 induces transient immune remodeling, marked by early expansion of trained CD8⁺ and CD4⁺ T cells, followed by increased naïve and regulatory T cells. • The atheroprotective effect is primarily mediated through adaptive immunity as myeloid subsets remain unchanged throughout B. subtilis natto NTU-18 treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45dd339de260cb5a70cef21d3c450ab6682f7820" target='_blank'>
              Bacillus subtilis natto NTU-18 attenuates atherosclerosis progression by modulating peripheral immune cell alterations
              </a>
            </td>
          <td>
            Jian-Da Lin, Yu-Zhen Ye, Sin-Ren Wang, Wen-Yi Kao, Kung-Ta Lee
          </td>
          <td>2025-10-17</td>
          <td>Applied Microbiology and Biotechnology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="ABSTRACT Background For a long time, the brain was considered an organ with “immune privilege”, where microglial cells played a phagocytic role, maintaining immune self‐sufficiency. However, recent studies have revealed the presence of immune‐related structures and immune cell infiltration in the brain, which participates in adaptive immunity. Aim of Review This review aims to synthesize recent findings on the activation and long‐term maintenance of adaptive immunity in the central nervous system (CNS), exploring how adaptive immune responses function in pathogen clearance, tumor defense, and CNS inflammation. It highlights both the protective and detrimental roles of adaptive immunity in these contexts. Key Scientific Concepts Antigen‐presenting cells (APCs) present antigen information to naive T cells, initiating adaptive immunity in the CNS. Activated T cells can differentiate into effector T cells to perform immediate immune functions or into tissue‐resident memory T cells (TRMs) that persist in the CNS, providing long‐term immune surveillance. Over the past 15 years, studies have shown that adaptive immunity is activated and maintained during intracranial pathogen infections, brain tumors, and CNS inflammation. While adaptive immunity can clear pathogens, eliminate tumor cells, and protect the brain, it can also lead to CNS inflammation under certain conditions, resulting in undesirable outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ae9b8c66ae27a4c0eba7b2cde701dacc77b251b7" target='_blank'>
              Activation and Long‐Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double‐Edged Sword?
              </a>
            </td>
          <td>
            Luojinyun Wang, Feng Zhang, Jiehong Wu, Sibo Yang, Daqiang Zhou, Xiaodi Sun, Bohao Chang, Bo Hu, Yifan Zhou
          </td>
          <td>2025-12-01</td>
          <td>CNS Neuroscience & Therapeutics</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background: Chronic lymphocytic leukemia (CLL) is characterized by malignant B lymphocyte accumulation and progressive immune dysfunction. The immune checkpoint molecule TIM-3 and its ligand galectin-9 (Gal-9) contribute to T cell exhaustion, impairing anti-tumour immunity. Interleukin-27 (IL-27) has pleiotropic immunomodulatory properties, but its impact on TIM-3 and Gal-9 expression in CLL remains unclear. Methods: Peripheral blood mononuclear cells (PBMCs) from 20 treatment-naive CLL patients were cultured with or without IL-27 (100 ng/mL) for 72 h. Flow cytometry assessed TIM-3 and Gal-9 expression on CD4+, CD8+, and CD19+ cells. Results: IL-27 stimulation significantly increased TIM-3 expression on CD8+ T cells (2.18 ± 0.32% vs. 3.09 ± 0.49%, p = 0.009), a hallmark of T cell exhaustion. IL-27 also modestly increased intracellular Gal-9 levels in total lymphocytes (93.91 ± 1.17% vs. 96.55 ± 0.67%, p = 0.005). Additionally, IL-27 reduced CD4+ T cell proportions (26.71 ± 4.19% vs. 22.01 ± 3.23%, p = 0.010). Although numerically modest, these changes may be biologically pertinent in the context of checkpoint-mediated CD8+ T-cell exhaustion. Conclusions: IL-27 may enhance immunosuppressive mechanisms in CLL by modulating immune checkpoint expression, potentially contributing to disease progression. These ex vivo findings in PBMCs from CLL patients indicate the IL-27-associated modulation of checkpoint expression under the conditions tested. In the absence of parallel healthy-donor controls, CLL specificity cannot be established in this study.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/58d00c9f01ecefffef026fe6257bcd71c012fd04" target='_blank'>
              Expression of TIM-3 and Gal-9 Immune Checkpoints in Chronic Lymphocytic Leukemia: The Potential Role of Interleukin-27
              </a>
            </td>
          <td>
            E. Wędrowska, Tomasz Wandtke, Bartosz Ulaszewski, E. Cichocka, R. Dębski, Piotr Kopiński, J. Styczyński, Grzegorz Przybylski
          </td>
          <td>2025-10-23</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation1–4. How naive CD8⁺ T cells develop into memory T cells that bifurcate into long-lived central (TCM) versus effector (TEM) subsets after such an antigen encounter remains ill-defined at the molecular level. To address this gap, here we dissect the functional T-cell receptor (TCR) repertoire of 242 murine CD8⁺ TCRαβ clonotypes specific for the peptide-major histocompatibility complex molecule (pMHC) comprising an immunodominant influenza A virus (IAV) oligopeptide epitope NP366–374 presented by H-2Db 5,6. Using single-cell transcriptomics with TCR sequencing, biophysical measurements of force-dependent TCR-pMHC interactions, in vivo memory development, and structural analyses, we integrate these data to define relationships between signaling polarity and memory fate. We find that TCM and TEM polarities are reflected in distinct subunit-related mechanotransduction biases: TCM-associated TCRs favor TCRβ-driven pMHC engagement, whereas TEM-associated TCRs preferentially favor TCRα-driven pMHC engagement. Moreover, “bipolar” clonotypes (TBP) capable of generating both memory subsets exhibit more balanced signaling, the largest average clonal expansions, and broadest heterosubtypic crossreactivities. By contrast, variegated TCM TCR sequences foster mostly clonal singlets with the greatest IAV mutant recognition potential within the overall memory repertoire, thus revealing two complementary memory niche crossreactivity strategies. Weak, force-sensitive TCR bonds are pervasive for this entire repertoire, being most conspicuous amongst TCM clonotypes. At the atomic level, highly nuanced variation in TCRαβ bonding to either peptide and/or MHC modulates mechanical load transmission across the holoreceptor’s ectodomains, transmembrane segments, and CD3 cytoplasmic tails to differentially influence downstream tyrosine phosphorylation and memory development. Collectively, TCR diversity anticipates epitope-specific pathogen evolution, whereas divergent TCR signaling regulates memory fate with implications for adoptive T-cell immunotherapies seeking to maximize persistence and minimize functional exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H. Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00ed13bb7acb39c5e98a4fa14592f332d5a91492" target='_blank'>
              A narrative review of therapy-induced senescence in cancer: mechanisms, immune interplay, and therapeutic opportunities
              </a>
            </td>
          <td>
            Henry Sutanto, Alfan Ahkami, D. Fetarayani, P. Z. Romadhon
          </td>
          <td>2025-12-01</td>
          <td>Journal of the Egyptian National Cancer Institute</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Fungal communities in the gut influence host immunity, yet most studies have focused on cell wall components rather than genetic materials. Here, we explore how fungal genomic DNA (gDNA) from Candida albicans, Saccharomyces cerevisiae, and Cryptococcus neoformans modulate immune responses in human CD4+ T cells, murine splenocytes, and THP-1-derived macrophages. We find that C. albicans gDNA promotes the development of regulatory T cells and increases IL-10, fostering immune tolerance and preserving CD4+ T cell viability in an inflammatory setting. S. cerevisiae gDNA induces moderate Treg responses with restrained effector T cell expansion and higher checkpoint gene expression, entirely consistent with its commensal nature. In contrast, C. neoformans gDNA elicits a strongly inflammatory profile, promoting Th1/Th17 cells and driving high cytokine production. Mechanistically, C. albicans and S. cerevisiae gDNA dampen DNA-sensing pathways and enhance immune checkpoint molecules that act as brakes against overactivation, while C. neoformans gDNA robustly activates innate sensing pathways with limited checkpoint induction. These species-specific signaling profiles reveal that fungal gDNA itself can influence whether the immune system adopts a tolerant or inflammatory response toward fungi. This discovery highlights fungal genomic DNA as a previously underappreciated regulator of host–fungus interactions, offering new insight into commensal persistence, pathogenic invasion, and the potential for DNA-based antifungal interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc70eaeb8599dabbca9b1f79f2645699f524d2e1" target='_blank'>
              Divergent Immunomodulatory Roles of Fungal DNA in Shaping Treg and Inflammatory Responses
              </a>
            </td>
          <td>
            Dongmei Li, Idalia Cruz, Yahui Feng, Maha Moussa, Jie Cheng, Digvijay Patil, Alexander Kroemer, Joseph A. Bellanti
          </td>
          <td>2025-10-22</td>
          <td>Journal of Fungi</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Megakaryocytes (MKs) have traditionally been viewed as terminal hematopoietic cells responsible solely for platelet production. However, recent advances in imaging and single-cell transcriptomics have revealed substantial heterogeneity among MK populations and diverse functions beyond thrombopoiesis. MKs actively participate in innate and adaptive immunity, modulate the hematopoietic stem cell (HSC) niche, and adapt to physiological and pathological stimuli. Located in distinct anatomical sites such as bone marrow and lung, MKs exhibit compartment-specific specializations that enable them to serve as critical integrators of hemostatic, immune, and regenerative processes. Experimental models using human pluripotent stem cells and inducible MKs have enhanced mechanistic insights, while innovative bioreactor platforms and xenotransplantation strategies advance translational applications in platelet production and therapy. Furthermore, immune MK subsets derived from pluripotent stem cells show promising therapeutic potential for modulating inflammation and autoimmune diseases. Continued exploration of MK diversity, tissue-specific roles, and intercellular communication will unlock new opportunities for leveraging MK plasticity in regenerative medicine, immunotherapy, and hematologic disorders, repositioning these versatile cells as central players in systemic homeostasis and defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a42ed6c49b37f5e87fc8596501cc105433a716fc" target='_blank'>
              Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects
              </a>
            </td>
          <td>
            Seungjun Kim, Kiwon Lee
          </td>
          <td>2025-10-27</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Innate immune memory, or trained innate immunity (TII), represents a form of immunological adaptation in which innate immune cells, including myeloid and lymphoid cells, retain a trained state following prior exposure to immunological stimuli. This long-lasting modification either enhances or reduces the innate immune response to subsequent heterologous infections or inflammatory insults. While TII often provides protective benefits, including enhanced protection against pathogens and tumors, it can contribute to maladaptive inflammation in certain conditions. Epigenetic changes and metabolic reprogramming are key drivers of innate immune memory, but it is important to distinguish between transient acute changes and persistent modifications that define bona fide innate immune memory. Innate immune memory can be induced centrally, through systemic events that train hematopoietic progenitors in the bone marrow, or locally, via tissue-resident cells such as macrophages. The presence of trained tissue-resident immune cells offers significant advantages, but their responses may not always result in universally enhanced protection. This review explores recent advances in the understanding of tissue-resident memory macrophages and TII at barrier tissue sites, including the lung, skin, gut, and peritoneum, highlighting the implications for vaccine and immunotherapeutic strategies. Ongoing research promises to accelerate progress in this field and inform new clinical and vaccinology approaches.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dad483cb563d2abbfc8d7331355d2845f3dd790e" target='_blank'>
              Resident memory macrophages and trained innate immunity at barrier tissues
              </a>
            </td>
          <td>
            A. Kang, M. D’Agostino, S. Afkhami, M. Jeyanathan, Zhou Xing
          </td>
          <td>2025-10-20</td>
          <td>eLife</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 CAR-T cells have emerged as a therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus (SLE). One open question is the impact of preconditioning on therapeutic responses. In preliminary experiments using pre-irradiated lupus-prone New Zealand Black/New Zealand White (NZB/W) mice, second-generation anti-mCD19 CAR-T cells positively impacted many disease features. Significant bone marrow (BM) B-cell depletion and lower proteinuria were observed across irradiated groups, suggesting an immunosuppressive effect. Based on these findings, we aimed to demonstrate the impact of CAR-T cells over irradiation on various immunologic and clinical features by modifying the conditioning regimen in these mice. Twenty two-week-old pre-irradiated mice were treated with PBS or CAR-T cells+IL-2. Lymphocytes were assessed in blood, BM, and spleen 4-weeks post treatment. The engraftment of CAR-T cells was documented in all samples. CAR-T cell-treated mice showed persistent B cell decrease in various subsets (marginal zone/naïve B cells and plasma cells). Furthermore, increases in CD4+ and CD8+ T cells, with a lower percentage of effector/central memory T cells and higher naïve T cells were observed as an outcome of CAR-T treatment. CAR-T treated mice also displayed lower anti-dsDNA antibodies and proteinuria. Thus, CAR-T cells showed a differential impact on lupus beyond irradiation. Other disease features to ascertain CAR-T cell efficacy for SLE are being explored.



 Supported by Kyverna Therapeutics, Inc., Emeryville, CA.



 Therapeutic Approaches to Autoimmunity (THER)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48e017f60a3235e38047b172faeb8b5872f707d" target='_blank'>
              Efficacy and engraftment of anti-CD19 CAR-T cells in murine lupus 4343
              </a>
            </td>
          <td>
            J. Romo-Tena, Shouvonik Sengupta, William Ambler, S. Nakabo, C. Carmona-Rivera, Eduardo Patino Martinez, L. P. Blanco, Shairaz Shah, Jennifer Zeng, Ashley E. Mahne, Joseph K Cheng, T. Van Blarcom, Mariana J. Kaplan
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background: CML, a blood cancer characterized by excessive myeloid cell proliferation, stems from the BCR-ABL1 gene fusion. This research aimed to uncover why leukemic stem cells resist treatment and explore innovative immune-based therapies to improve patient outcomes. Methods: This study investigated the immunologic phenotypes (CD8, CD27, CD197, and CD45RA) of T cell subsets (TN, TCM, TEM, and TEF) in the peripheral blood of chronic myeloid leukemia patients in the chronic phase who achieved a complete molecular response to tyrosine kinase inhibitors. The treatment-free remission (TFR) patients were compared to age- and gender-matched healthy volunteers using multicolor flow cytometry for analysis. Results: Flow cytometry analysis unveiled notable shifts in CD8+ T cell subsets. CML-CP patients showed a marked decrease in central memory T cells (TCM), dropping to 7.2% of the CD8+ population. Conversely, these patients exhibited substantial increases in effector memory T (TEM) and effector T (TEF) cells, rising to 37.6% and 24.4% respectively. The most statistically significant change occurred in the CD8+ TEF subset. CML-CP patients displayed a 24.4% presence of these cells, compared to only 15.7% in control groups. These findings suggest a distinct immunological profile in CML-CP, potentially impacting disease progression and treatment strategies. Conclusion: Tyrosine kinase inhibitors restore the distribution of memory T cells in patients with chronic myeloid leukemia (CML), but T cell exhaustion remains an issue. This situation highlights the need for alternative activation strategies to enhance immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c752b15c364f0e75b414f64a2b80255ba870b4ad" target='_blank'>
              Reshape memory T cell landscape in CML patients' blood by tyrosine kinase inhibitors
              </a>
            </td>
          <td>
            Haneen Ali Kareem, Haydar Hassan Ghadi
          </td>
          <td>2025-10-18</td>
          <td>Caspian Journal of Internal Medicine</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8+ T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863d3f6179309aee5c3016baab1955820d8c1527" target='_blank'>
              The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
              </a>
            </td>
          <td>
            Soyoung Kim, IkJoon Han, Suin Lee, Sujin Park, Jae-Won Jeon, Hyunsu Bae
          </td>
          <td>2025-11-25</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0895fbd19269fbdc4298e324e79791c8a18caebd" target='_blank'>
              CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.
              </a>
            </td>
          <td>
            J. Boldison, P. Leete, E. Robinson, Wendy Powell, Joanne Davies, Conor McMullan, Sophie L Walker, Noel G Morgan, S. Hanna, F. S. Wong
          </td>
          <td>2025-11-22</td>
          <td>Diabetologia</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background/Objectives: Extracellular vesicles (EVs) are key mediators of intercellular communication and are implicated in the neuropathogenesis of HIV-associated brain injury (HABI). However, their direct effects on glial cells, particularly in the context of antiretroviral therapy (ART), remain incompletely understood. Methods: In this study, we investigated how EVs from naïve, Simian Immunodeficiency Virus (SIV)-infected, and SIV-infected ART-treated rhesus macaques impact primary mixed glial cultures. Results: Through multiple, sequential applications mimicking chronic exposure, we found that EVs from SIV-infected animals significantly reduced glial expansion and induced a simplified, reactive astrocyte morphology indicative of neuroinflammatory stress. In contrast, EVs from naïve animals supported glial health. EVs derived from ART-treated animals provided partial protection from SIV-induced effects, yet still suppressed glial proliferation and failed to fully restore normal morphology. Furthermore, cytokine profiling revealed that both SIV and SIV + ART EVs induced a sustained proinflammatory secretory phenotype, characterized by elevated IL-6, IL-8, and IFN-γ. Conclusions: Our findings demonstrate that systemically circulating EVs in SIV infection are potential drivers of glial dysfunction. The persistence of these pathogenic EV effects despite ART suggests a vesicle-mediated mechanism that may contribute to chronic neuroinflammation and cognitive impairment in virally suppressed individuals.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67fab60169c13d075bcfdc8d7c00be88b51107c6" target='_blank'>
              Simian Immunodeficiency Virus-Derived Extracellular Vesicles Induce a Chronic Inflammatory Phenotype in Healthy Astrocytes Unresolved by Anti-Retroviral Therapy
              </a>
            </td>
          <td>
            Alison R Van Zandt, Miranda D. Horn, Ryan P. McNamara, Tiffany A. Peterson, N. Maness, Blake Schoest, Elise M. Frost, Yijun Zhou, Matilda J. Moström, D. P. Dittmer, Andrew G. MacLean
          </td>
          <td>2025-10-24</td>
          <td>Pharmaceutics</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Natural killer T (NKT) cells play a complex role in hepatocellular carcinoma (HCC) progression. Using a diethylnitrosamine (DEN)-induced HCC mouse model, we observed a significant reduction in NKT cells within malignant liver tissue due to apoptosis, with the remaining cells exhibiting impaired cytokine production and cytotoxic potential. CD1d-deficient mice, which lack NKT cells, showed delayed tumor initiation and fewer tumors, yet the tumors that did form were larger and exhibited enhanced proliferation and immunosuppression. Notably, adoptive transfer of healthy NKT cells after tumor establishment reduced tumor burden, suggesting a protective role in later disease stages. These findings indicate that NKT cells contribute to early tumor development but may help control tumor progression in later stages. Their functional impairment in HCC underscores the need for strategies to restore their anti-tumor activity. Understanding the dual role of NKT cells in liver carcinogenesis may pave the way for novel immunotherapeutic approaches to improve HCC treatment and patient outcomes. In HCC, NKT cells promote early tumor development but restrain later growth. Adoptive transfer of healthy NKT cells after tumor establishment reduces tumor burden, highlighting their potential as immunotherapeutic targets in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a90f2e66dfb37d54c65e9f253685e5ee9a14d1c9" target='_blank'>
              Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma
              </a>
            </td>
          <td>
            Maria Papanastasatou, Marianthi Gioulbasani, Evangelia Nakou, A. Galaras, Teresa Rubio-Tomás, I. Talianidis, Aristides G. Eliopoulos, P. Hatzis, Mihalis Verykokakis
          </td>
          <td>2025-10-20</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a clonal malignancy of plasma cells that remains largely incurable despite major advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Chimeric antigen receptor (CAR)-engineered immune cells have transformed the therapeutic landscape, but CAR-T cell therapy faces challenges such as severe cytokine release syndrome (CRS), neurotoxicity, limited persistence, and logistical complexity. In recent years, natural killer (NK) cells have emerged as a promising platform for next-generation cellular immunotherapy, offering innate antitumor activity, a reduced risk of graft-versus-host disease (GvHD), and the feasibility of “off-the-shelf” allogeneic production. This review summarizes current advances in CAR-NK cell therapy for MM, focusing on two major aspects: the diversity of cell sources—including NK-92, peripheral (PB) and cord blood (CB), and induced pluripotent stem cell (iPSC)-derived NK cells—and the expanding repertoire of target antigens such as BCMA (B-cell maturation antigen), NKG2D, CD38, CD70, SLAMF7, CD138, and GPRC5D. We highlight preclinical and early clinical studies demonstrating potent cytotoxicity, favorable safety profiles, and innovative multi-targeting strategies designed to overcome antigen escape and enhance persistence. Emerging clinical data suggest that CAR-NK cell therapy may combine the specificity of CAR recognition with the inherent safety and versatility of NK biology, offering a potential paradigm shift in the treatment of relapsed or refractory MM. Further clinical validation will determine whether CAR-NK cell therapy can achieve durable remission and complement or surpass current CAR-T modalities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6c564648f2cac8ed7d5dc089469d07120d75f71b" target='_blank'>
              State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens
              </a>
            </td>
          <td>
            Asya Bastrich, Kamilla Vinogradova, D. Mokrousova, Anna Efremova, O. Makhnach, D. Goldshtein
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Introduction: Aging impairs immune function and leads to increased vulnerability to infection, malignancy, and vaccine failure.Immunosenescence, marked by reduced thymic output, naive T cell attrition, and progenitor exhaustion, undermines vaccine responses and anti-tumor immunity in aged individuals. While cytokine-based and stem cell-modifying therapies have attempted to reverse this decline, they remain limited by toxicity, durability, or translational feasibility. Here, we present an mRNA approach that transiently reconstitutes thymic signaling pathways in an unrelated organ. By expressing Delta-like ligand 1 (DLL1), Fms-like tyrosine kinase 3 ligand (FLT3-L), and interleukin-7 (IL-7) - collectively termed DFI - in the liver, we observed rejuvenated aged immunity via coordinated modulation of thymopoiesis, lymphoid progenitors, and immune function.
 Methods: We identified age-related decline of Notch, IL-7, and FLT3-L signaling in thymic epithelial cells and peripheral T cells using spatial transcriptomics (Slide-seq v2) and single-cell RNA-seq across the human and murine lifespan. Modified mRNAs encoding DFI were encapsulated in SM-102 lipid nanoparticles (LNPs) and administered to aged mice (72 weeks). Hepatic expression, pharmacokinetics, and tissue specificity were assessed via RIBOmap and immunofluorescence. Functional impact on thymopoiesis, hematopoiesis, and immune function was assessed via flow cytometry, V(D)J sequencing, TREC analysis, peptide vaccination, tumor challenge (B16-OVA and MC38-OVA), and immune checkpoint inhibitor (ICI) therapy. Autoimmune safety was evaluated in NOD, Act-mOVA, and EAE models.
 Results: DFI mRNA was selectively translated in hepatocytes, yielding membrane-bound DLL1 and secreted IL-7 and FLT3-L without off-target organ expression. This induced expansion of naïve CD4⁺ and CD8⁺ T cells, increased TRECs, and restored thymic cellularity in aged mice. Mechanistically, DFI did not reprogram hematopoietic stem cell (HSC) fate or reverse myeloid bias but significantly expanded common lymphoid progenitors (CLPs) in the bone marrow. These CLPs exhibited increased CCR9 expression and thymus-homing potential, consistent with peripheral DLL1-mediated Notch signaling and improved thymic seeding. Early thymocyte subsets (DN1-DN3) were selectively enriched, accompanied by rapid induction of Rag2 and Nur77 in thymocytes, supporting enhanced de novo thymopoiesis. Despite HSC aging signatures remaining intact, DFI circumvented upstream deficits by expanding committed lymphoid progenitors and reinvigorating thymic output.
 Beyond the T cell compartment, DFI restored conventional dendritic cell type 1 (cDC1) populations and boosted co-stimulatory molecule expression (CD40, CD83, CD86). In parallel, it decreased dysfunctional age-associated B cells and increased follicular B cells, resulting in more robust antigen-specific IgG responses and IgM-to-IgG class-switching after peptide vaccination.
 Functionally, DFI pre-treatment doubled vaccine-specific CD8⁺ T cells in aged mice and improved antigen recall cytokine production (IFN-γ, IL-2). In tumor models, DFI conditioning enhanced spontaneous rejection of MC38-OVA and B16-OVA tumors and improved survival. It restored intratumoral CD8⁺ T cell infiltration and diversity and reversed age-associated T cell exhaustion signatures. When combined with ICI, DFI synergistically enhanced tumor control and survival in aged mice with established tumors.
 Importantly, DFI did not trigger autoimmune responses. In NOD mice, DFI did not accelerate type 1 diabetes or increase autoreactive TCRs. In Act-mOVA mice, tolerance to endogenous OVA was preserved. In the EAE model, DFI increased peripheral MOG-specific T cells but did not worsen CNS inflammation or clinical scores. DFI's immunostimulatory effects were strictly transient, dissipating 4 weeks post-treatment without long-term adverse effects.
 Conclusions: Transient hepatic expression of DLL1, IL-7, and FLT3-L safely and effectively reactivates thymopoiesis, expands functional T cell pools, and enhances antigen-specific immune responses in aged hosts. By bypassing stem cell-intrinsic defects and rejuvenating the thymic niche via liver-derived trophic cues, DFI overcomes major roadblocks of immune aging. This mRNA-based, non-integrating platform supports scalable, cyclic immunostimulation without autoimmunity, suggesting a viable strategy to enhance vaccine efficacy and cancer immunotherapy in elderly patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ca64b5c3c124926369d482741b8ee751943695e" target='_blank'>
              Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts
              </a>
            </td>
          <td>
            M. Friedrich, Julie Pham, Jiakun Tian, Hongyu Chen, Jiahao Huang, N. Kehl, Sophia Liu, Blake Lash, Fei Chen, Xiao Wang, Rhiannon K. Macrae, Feng Zhang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="


 Background: Treatment resistance and relapse in myeloma and lymphoma are driven by diverse immunosuppressive mechanisms within the tumor microenvironment (TME), including expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells, upregulation of immune checkpoints, and suppression of antigen presentation, which collectively impair cytotoxic T and natural killer (NK) cell function. Heat shock protein 70 (HSP70), highly expressed in many hematologic malignancies, including multiple myeloma and lymphoma, plays a central role in these processes by stabilizing oncoproteins, inhibiting apoptosis, and promoting immune escape. Extracellular HSP70 released from tumor cells, often bound to tumor-derived antigens, can induce pro-tumorigenic inflammation and facilitate recruitment of immunosuppressive cells, and interfere with antigen processing and stress-induced cell death. Prior attempts at HSP70–based vaccination showed limited clinical efficacy due to challenges in purifying material and efficiently targeting APCs, highlighting the need for novel strategies to leverage this pathway in myeloma and lymphoma immunotherapy.
 Methods: We developed a panel of murine monoclonal antibodies to HSP70 by immunizing BALB/c mice with murine fibroblast L-cells expressing human HSP70 fused to green fluorescent protein. This panel was then screened in immune-competent BALB/c mice injected with luciferase (luc)-expressing MOPC315.BM murine myeloma cells, selected due to the 95% homology between murine and human HSP70. Clone 77A was identified from this screen as showing the most robust in vivo anti-tumor activity and subjected to further in vitro and in vivo testing.
 Results: Clone 77A enhanced antigen-presenting cell (APC) uptake of HSP70 tumor antigen complexes, promoted cross-priming of antigen-specific T cells, and engaged FcγRIII on NK cells and antigen presenting cells and thus modulated both innate and adaptive immunity.
 In immunocompetent myeloma models (MPC11 and Vk*MYC), 77A remodeled the immunosuppressive TME by inhibiting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). Also, 77A promoted dendritic cell (DC) infiltration and expanded central memory CD4+ and CD8+ T- and NK-cell populations, subsequently generating a potent anti-tumor activity. Bulk RNA-seq and pathway analysis confirmed activation of antigen processing/presentation and NK cell-mediated cytotoxicity pathways.
 In the EG7.OVA (chicken ovalbumin) lymphoma model, 77A reshaped the TME to favor tumor-specific immune activation, including expansion of OVA presenting DCs and proliferation of OVA323–339-specific CD4+ T cells and OVA257-264- specific CD8+ T cells with enhanced effector function. These antigen specific T cells from 77A-treated tumor bearing mice exerted significant ex vivo cytotoxicity against EG7.OVA cells. Moreover, 77A augmented proliferation and effector function of OVA257-264- specific CD8+ T cells administered into the EG7.OVA lymphoma bearing mice, supporting its potential for a combined regimen with adoptive T cell therapy (ACT). We also found that HSP70 subcutaneous co-administration into established lymphoma tumors enhanced 77A's therapeutic efficacy in the EG7.OVA model. Additionally, 77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib), radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. Its activity extended to solid tumors, including 4T1 breast cancer, and was further potentiated by tumor expression of immunogenic antigen hemagglutinin. or PD-1 immune checkpoint blockade.
 In the MM1.S xenograft model, 77A retained activity under NK cell depletion, likely due to myeloid polarization toward an M1 phenotype. The activity was more modest compared with that seen in more immune competent models, highlighting its long-term efficacy relied on T cell priming and effector function. Finally, 77A directly enhanced human immune function by boosting MART-1 specific CD8+ T cell expansion and enhancing NK cell cytotoxicity in healthy donor samples.
 Conclusion: 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridge innate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic and solid tumor models, and synergizes with multiple immunomodulatory and standard therapies, supporting its clinical translation as a novel immunotherapy platform.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a887ea64b847a742d0e834756a184372d82443b" target='_blank'>
              First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models
              </a>
            </td>
          <td>
            Jun Wei, Richard J. Jones, I. Kuiatse, Hua Wang, R. Orlowski
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>93</td>
        </tr>

        <tr id="


 Introduction: Emerging evidence suggests that the immunosuppressive tumor microenvironment is a major limiting factor impairing CAR-T cell function. Recent studies have identified immunosuppressive erythroid precursor cells (EPCs) – a novel cell population that accumulates in pathological contexts (including neonates, cancer-bearing hosts, and infected individuals) – which potently suppress immune responses and diminish upon maturation. In this study, we aim to investigate the impact of these immunomodulatory EPCs on CAR-T cell function and explore potential strategies to overcome their suppressive effects, thereby enhancing CAR-T cell efficacy.
 Methods: We established KA539 lymphoma models in irradiated C57BL/6 mice and collected clinical peripheral blood samples from hematologic malignancy patients to quantify EPCs accumulation in extramedullary tissues. Functional profiling was performed via RNA-seq on FACS-sorted CD45⁺ versus CD45⁻ EPCs, validated by scRNA-seq. To assess EPCs-mediated CAR-T cell suppression, CD19 CAR-T cells were co-cultured with EPCs followed by multiparameter analysis including proliferation, cytokine secretion, exhaustion, and tumor-killing capacity of CAR-T cells. Mechanistically, we performed RNA-seq and Cut&Tag with erythroid precursors upon BRD4 inhibition, and genetic validation in erythroid-specific BRD4 cKO mice to demonstrate that BRD4 regulates the immunity of CD45+ EPCs.
 Results: We confirmed that both tumor-bearing mice and patients with hematologic malignancies showed significantly increased EPCs proportions in extramedullary tissues, including peripheral blood, spleen, and liver. RNA-seq analysis revealed that CD45+ EPCs exhibited elevated expression of immunosuppressive genes, including VISTA, PD-L1, LGALS3. Notably, tumor-bearing mice exhibited increased EPCs levels following CAR-T treatment, particularly in the poor-response group, suggesting a potential link between EPCs expansion and therapeutic resistance. Coculture with CD45+ EPCs significantly impaired CAR-T cell function, reducing both TNF-α secretion and proliferative capacity. Consistent with our previous findings on BRD4's role in blocking erythroid maturation, we observed that BRD4 similarly impeded EPCs' maturation in tumor-bearing mice and patient-derived samples. Furthermore, BRD4 inhibition downregulated immune-related genes and pathways in EPCs. Integrated analysis of Cut&Tag and RNA-seq data revealed that BRD4 directly transcriptionally activated immune regulatory genes in EPCs, including PD-L1 and VISTA. Besides, experiments with BRD4conditional knockout mice further confirmed that BRD4 inhibition promoted maturation of CD45+ EPCs and repressed expression of novel immune checkpoint VISTA. Importantly, flow cytometry analysis demonstrated that BRD4 inhibition significantly alleviated EPCs-induced CAR-T cell exhaustion, as evidenced by reduced expression of the exhaustion markers PD-1 and LAG-3, supporting BRD4 inhibition as a viable strategy to potentiate CAR-T cell function by modulating EPCs' immunosuppressive activity.
 Conclusion: Our study establishes that immunosuppressive EPCs directly impair CAR-T cell function. We demonstrate that BRD4 transcriptionally activates VISTA expression in EPCs, and targeting BRD4 reverses EPC-mediated CAR-T suppression. These findings unveil a novel mechanism of the immunosuppressive microenvironment in CAR-T therapy and provide a potential approach to enhance clinical efficacy against hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c440cfd119e2a331ecd6f4081b0a4605fb549576" target='_blank'>
              BRD4 sustains immunosuppressive erythroid precursors to compromise CAR-T cell function
              </a>
            </td>
          <td>
            Meng Zhang, Mengmeng Huang, Yijin Chen, Haiqiong Zheng, Yanjuan Liu, Dawei Huo, Yong-xian Hu, Pengxu Qian, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Immune responses are finely regulated by multiple mechanisms, among which immune regulatory coreceptor family molecules play a central role in both enhancing and suppressing immune responses. Traditionally, T cells have been considered the primary cell type expressing these receptors, through which their responses are modulated. This understanding led to the emergence of the field of ‘immune checkpoint blockade’, which aims to rejuvenate T cells that have become exhausted in the context of chronic infections or the tumor environments. The molecules targeted by such approaches include PD1, CTLA4, Lag3, Tim3 and TIGIT, coinhibitory receptors predominantly expressed on conventional T cells exhibiting functionally impaired, exhausted phenotypes. Interestingly, an expanding array of non-T cell types also express these receptors, although their specific roles remain largely elusive. Here we explore the immune regulatory functions of these coreceptors as expressed on non-conventional T cells, such as myeloid cells and B cells, highlighting their potential contributions to immune regulation. The immune system is a complex network of cells and molecules that protect the host from infection and disease. Dysregulation of these processes can result in pathological conditions, including chronic infections or cancer. Coinhibitory receptors such as PD1, CTLA4, Lag3, Tim3 and TIGIT are well established as key regulators of T cell-mediated immune responses. Emerging evidence indicates that these receptors are also expressed on non-T cell populations, including myeloid lineage cells and B cells, although their functional contributions in this context remain poorly understood. This review summarizes current knowledge on the expression and function of coinhibitory receptors in non-T cells and discusses how their therapeutic targeting beyond T cells may offer novel opportunities for restoring immune function in cancer and other diseases. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6e6477a49b57b3179507b32f0c0886477fad207f" target='_blank'>
              The role of coinhibitory receptor-expressing non-T cells in inflammation and immunity: unsung heroes or peripheral players?
              </a>
            </td>
          <td>
            Chaimae Khaled, Mijin Kim, Booki Min
          </td>
          <td>2025-11-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 The neuropathology observed during Venezuelan equine encephalitis virus (VEEV) infection, including blood-brain barrier (BBB) breakdown, is linked to an overwhelming immune response in the brain, but the roles of specific cell types are not fully elucidated. Here we temporally profiled the immune response to VEEV by performing single cell RNA sequencing on brains of infected mice. This data revealed activation of microglia subsets and their sequential decline in abundance concurrent with infiltration of immune cells, including cytotoxic lymphocytes NK cells and CD8+ T cells. Targeting these cells, we found depletion of NK cells and CD8+ T cells synergistically improved BBB integrity and survival. NK cell-depleted brains have fewer CD8+ T cells and both NK cell-depleted and double-depleted brains have increased microglia. NK cell-depleted infected brains had similar levels of elevated cytokines IFN-a, CCL2, CCL5, and IFN-g, chemokines CXCL1 and CXCL10, and interleukins IL-6 and IL-1b, while having higher IFN-b. Double-depleted brains had strikingly higher levels of each of these proteins, in addition to IL-10, IL-12, GM-CSF, and TNF. Through this work, we have begun profiling immune signatures associated with improved outcomes of VEEV infection, underscoring the utility in understanding complex immune responses for the development of immunomodulatory therapies aimed at limiting BBB dysfunction and improving infection outcomes.



 [1] This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory under Contract DEAC52-07NA27344.



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3abebda82cc25e9b9ebfbc8beda7bf7d191a43b9" target='_blank'>
              Depletion of cytotoxic lymphocytes shifts brain immune response, promoting blood-brain barrier integrity and survival in Venezuelan equine encephalitis virus infection 3984
              </a>
            </td>
          <td>
            Margarita V. Rangel, A. Sebastian, N. Leon, Ashlee M. Phillips, D. Murugesh, N. Hum, D. Weilhammer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0fb447bcefcdb90c4999356e9caf6fb1b2e1509" target='_blank'>
              Proinflammatory circulating extracellular vesicles from type 1 diabetes patients contribute to beta cell cytotoxicity and disease pathogenicity
              </a>
            </td>
          <td>
            Nagesha Guthalu Kondegowda, Zelda Cisneros, Daniel Roeth, Jeong-su Do, Joanna Filipowska, Rosemary Li, Shihong Zhang, Selassie J. Ogyaadu, C. S. Jayasena, Tijana Jovanovic-Talisman, Clive Wasserfall, Yate-Ching Yuan, Helena Reijonen, Markus Kalkum, Carol Levy, Fouad Kandeel, Susmita Sahoo, R. Vasavada
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Mechanisms of T cell aging involve cell-intrinsic alterations and interactions with immune and stromal cells. Here we found that splenic T cells exhibit greater functional decline than lymph node T cells within the same aged mouse, prompting investigation into how the aged spleen contributes to T cell aging. Proteomic analysis revealed increased expression of heme detoxification in aged spleen-derived lymphocytes. Exposure to the heme- and iron-rich aged splenic microenvironment induced aging phenotypes in young T cells, including reduced proliferation and CD39 upregulation. T cells survived this hostile niche by maintaining a low labile iron pool, at least in part, via IRP2 downregulation to resist ferroptosis but failed to induce sufficient iron uptake for activation. Iron supplementation enhanced antigen-specific T cell responses in aged mice. This study identifies the aged spleen as a source of hemolytic signals that systemically impair T cell function, underscoring a trade-off between T cell survival and function and implicating iron metabolism in immune aging. In their study, Ezuz et al. show that the aged spleen contributes to T cell aging through hemolytic stress and an increasingly heme- and iron-rich microenvironment. T cells adapt by limiting their iron levels. This protective response impairs cell function but can be reversed in vivo by iron supplementation during activation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f5ac7726f5c896994db5206eecbff0794325c65" target='_blank'>
              Heme and iron toxicity in the aged spleen impairs T cell immunity through iron deprivation
              </a>
            </td>
          <td>
            David Ezuz, Heba Ombashe, Lana Watad, Akmaral Rakhymzhanova, Satyarth Pandey, Orna Atar, E. Meyron-Holtz, Noga Ron-Harel
          </td>
          <td>2025-10-17</td>
          <td>Nature Aging</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="ABSTRACT Trained immunity is a long-term functional reprogramming of innate cells that allows for the formation of immune memory akin to adaptive responses, but with a more rapid nonspecific response. We recently identified an anti-inflammatory trained immunity response, termed trained tolerogenic immunity (TTI), induced by low virulence Candida dubliniensis, that protects against acute lethal polymicrobial sepsis via myeloid-derived suppressor cells (MDSCs). Trained immunity and MDSCs arise following hematopoietic stem and progenitor cell (HSPC) expansion in the bone marrow. Here, we show that C. dubliniensis induces inoculum-dependent protection and HSPC expansion, whereas depletion of HSPCs following C. dubliniensis immunization abrogates protection. We further show that myeloid progenitors and putative MDSCs are increased in the bone marrow following C. dubliniensis immunization, and that HSPC depletion results in reduced MDSC influx into the peritoneal cavity following lethal challenge. Bone marrow cytokine analysis revealed that mediators associated with MDSC development and trafficking, including G-CSF, CXCL2, and CCL2, are upregulated following C. dubliniensis immunization. Finally, we find that the C-type lectin receptor adaptor protein Card9 is required for C. dubliniensis-induced protection and HSPC expansion, but not fungal trafficking to the bone marrow. Taken together, these results suggest that Card9-dependent fungal recognition in the bone marrow drives myelopoiesis and the induction of immunosuppressive MDSCs that are protective against lethal inflammation and sepsis. IMPORTANCE Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses. Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/28ef5d4d2e11b7eea19c57b43a1c7a076c5b6b77" target='_blank'>
              Induction of myelopoiesis by Candida dubliniensis drives protective trained immunity against sepsis in a Card9-dependent manner
              </a>
            </td>
          <td>
            S. Righi, E. Lilly, A. J. Harriett, Patrick W. Daly, MaryJane Jones, Chad Steele, Mairi C. Noverr, Paul L Fidel
          </td>
          <td>2025-10-31</td>
          <td>mBio</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d337f9005b90e93fdf29316d67b193863ed97ca" target='_blank'>
              CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death
              </a>
            </td>
          <td>
            Yarden Aharony-Tevet, O. Ravid, A. Yanir, Amilia Meir, Hadar Levi, Daniel Burstein, Aviya Amram, Tamar Feuerstein, S. Izraeli, Itzik Cooper, E. Jacoby
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bcfd3df2c5d1e60c0a8518093894d3b787fd6a7" target='_blank'>
              Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.
              </a>
            </td>
          <td>
            Limin Jia, Zhaoyang Wang, Jinfa Du, Zhigang Ren, Jiandong Jiang, Pan Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers of medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Glucocorticoid (GC)-resistant, acute graft-versus-host-disease (GVHD) is a major cause of mortality following allogeneic hematopoietic stem cell transplantation. Second line treatment with Ruxolitinib (RUX) can be effective, but only a minority of patients attain durable complete remissions. Biopsies from the gut in patients with refractory GVHD are frequently characterised by large clonal expansions of CD8+ T cells. Experimental models of GVHD have suggested that these T cell effector expansions may be sustained by progenitor-type T cells expressing the transcription factor TCF1, which possess greater inherent proliferative and self-renewal potential than effector cells. We hypothesised that a similar progenitor-type population can be found in humans and is resistant to GC treatment.
 Using clinically relevant concentrations of methylprednisolone and several independent methods for human T cell stimulation, we determined output population architecture and function with a combination of multiparameter flow cytometry, bulk and single cell transcriptional profiling. Under conditions of repetitive anti-CD3/CD28 stimulation over a three-week period, GC-treated CD8+ T cells showed greater proliferation and overall expansion than control cells. GC-treated CD8+ T cells showed greater retention of cell markers (e.g., IL-7RA, CD27) and transcriptional profiles (e.g., KLF2, LTB, BCL2) associated with a 'less-differentiated’ state. In vitro assays indicated intact cytokine-generating function and killing capacity of the GC-resistant CD8+ T cells versus controls. These GC-driven changes to T cell proliferation and phenotype were largely restricted to CD8+T cells and occurred independently of the presence of CD4+ T cells.
 To track the population architecture of GC-treated CD8+ T cells compared to controls, we performed scRNAseq of 3-week expanded cultures. The GC-treated CD8+ T cell population showed a distinct differentiation trajectory composed primarily of two IL7RA-expressing clusters: a major effector memory-like cluster expressing cytotoxic genes (e.g., PRF1) as well as known GC-regulated genes (e.g., GILZ); and a smaller cluster composed of progenitor-like cells, expressing TCF7 (encoding TCF1) and LEF1. To test how this GC-induced shift in population architecture emerged during culture, we tracked cell proliferation and cellular state according to the individual input differentiation status of CD8+ T cells (TN, TCM, and TEM(RA)) prior to activation; these experiments showed that GC-induced changes in proliferation and cell state were primarily derived from the expanding TN-origin cells. To test the clinical relevance of these findings in vivo, we interrogated patient scRNAseq data derived from n=19 biopsies of acute lower gut GVHD, treated with (n=14) or without GC (n=5) at the time of biopsy. We identified strong enrichment for our TCF-1+ progenitor-like cluster in patients with severe GVHD treated with GC (median 35.1% versus 9.5% of CD8+ T cells, p<0.05).
 To address how JAK1/2 inhibition would influence the GC-resistant phenotype, we applied RUX at clinically relevant concentrations and showed that its addition blocked proliferation in GC-treated cultures to a greater extent than control cells. However, RUX simultaneously further enriched for the TCF-1hi IL-7Rahi progenitor-like population which additionally displayed elevated expression of the anti-apoptotic molecule, BCL-2. We reasoned that BCL-2 inhibition would have the potential to separately target the progenitor population. To test this hypothesis, we treated control and GC-treated T cell cultures with clinically relevant concentrations of Venetoclax (VEN), alone or in combination with RUX. VEN treatment alone did not block proliferation but led to reduced frequencies of progenitor-like cells arising in the presence of GC. When combined, VEN and RUX led to both reduced proliferation and reduced progenitor frequency in parallel to increased activated Caspase-3 expression by CD8+ T cells, particularly in the presence of GC.
 Taken together, these data show that treatments used for GVHD including GC and RUX may select for progenitor-like CD8+ T cells with the potential to sustain tissue injury and lead to refractory disease. Strategies combining drug targets which can inhibit T cell proliferation whilst preventing the retention of multipotent and proliferative progenitor populations may be required to overcome the limitations of current GVHD treatment strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5de99b6fdb68f489811020a31ec532757463d4e2" target='_blank'>
              T cell resistance to glucocorticoids in graft-versus-host disease
              </a>
            </td>
          <td>
            Andrew McIntyre, Lisanne Schoutens, Elisa Armbrecht, Andrew Gravett, Nicolas Sanschagrin, Callum Wright, Matthew Collin, R. Chakraverty
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Purpose Cancer immunotherapy aims to enhance the immune system’s ability to recognize and eliminate cancer cells, providing a sustained and effective immune response. However, the tumor microenvironment (TME), characterized by an abundance of tumor-associated M2 macrophages and the presence of exhausted or naïve T cells (non-effector T cells), remains a major barrier to effective immunotherapy. Herein, inflammatory M1 macrophage-derived extracellular vesicles (M1EV) were surface-modified to display interleukin-2 (M1EV_IL2), aiming to develop a multifunctional cancer immunotherapeutic agent capable of modulating both innate and adaptive immune responses. Methods We engineered M1EV to label the surface with azide groups through metabolic glycoengineering and developed M1EV_IL2 that displayed IL-2 via bioorthogonal chemistry. M1EV_IL2 were purified by size-exclusion chromatography (SEC) and characterized through comprehensive analyses, including nanoparticle tracking analysis (NTA). In vitro macrophage repolarization and T cell activation were evaluated at the gene-expression level, followed by ex vivo assays assessing T-cell proliferation, cytokine secretion, and activation marker expression. Results M1EV_IL2 effectively retained the intrinsic physicochemical properties of EVs while displaying IL-2 stably on its surface. It upregulated M1 macrophage markers, IL-1β and CXCL10, while downregulating the M2 macrophage marker CD206, thereby inducing M2-to-M1 macrophage repolarization. In addition, M1EV_IL2 also activated CD4+ T cells and induced the activation of naïve CD8+ T cells to effector T cells, leading to enhanced cell proliferation and secretion of antitumor cytokines. Conclusion These results indicate that M1EV_IL2 has the potential to reshape the tumor immune landscape by simultaneously activating macrophages and T cells, thereby enhancing both innate and adaptive immune responses. Unlike conventional cancer therapies, which directly target tumor cells, M1EV_IL2 is expected to enhance immune responses, potentially mitigating adverse effects while improving therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b118249d7b0665de4875eb1da2d46b5bd10b41f" target='_blank'>
              Interleukin-2 Surface Displayed M1 Macrophage-Derived Extracellular Vesicles for Modulating the Tumor Microenvironment
              </a>
            </td>
          <td>
            Kyeong Tae Kim, Jeong Hyun Lee, S. Kang, W. Rhee
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Abstract Introduction Dendritic cells (DCs) are crucial in immune responses; however, the role of DCs in trauma patients remains poorly understood. Therefore, this study aimed to investigate the frequencies and functions of two major DC subsets in trauma patients: plasmacytoid DCs (pDCs) and conventional DCs (cDCs). Methods This study included 25 trauma patients and 40 healthy controls. Using flow cytometry, the frequencies, cytokine production (IFN-α, TNF-α, IL-12), and expression of co-stimulatory (CD86) and co-inhibitory (CD274) markers were analyzed in the DC subsets. The relationship between CD274+ pDCs and the Injury Severity Score (ISS) was also evaluated. Additionally, in vitro experiments were conducted using proinflammatory cytokine stimulation and blocking antibodies to assess their effects on DC activation markers. Results Trauma patients showed decreased percentages and absolute numbers of pDCs, while cDC levels remained unchanged. Cytokine production was impaired, with reduced IFN-α and TNF-α from pDCs and IL-12 from cDCs. CD86+ and CD274+ expressions were increased in pDCs but decreased in cDCs, with CD274+ pDCs positively correlating with ISS. In vitro studies revealed that proinflammatory cytokine exposure enhanced activation markers, peaking at 72 h; this observation was reversed by blocking antibodies. Conclusion This study demonstrates that trauma induces both numerical and functional deficiencies in circulating pDCs despite increased activation marker expression. The correlation between CD274+ pDCs and trauma severity, along with the temporal dynamics of cytokine-induced activation, suggests a complex role for pDCs in post-traumatic immune responses. These findings provide new insights for developing targeted therapies for trauma-related immune complications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c4f75945935db312fe6c6d357d32dd682ef1f079" target='_blank'>
              Circulating Plasmacytoid Dendritic Cells Are Numerically and Functionally Deficient in Trauma Patients
              </a>
            </td>
          <td>
            Ki-Jeong Park, H. Jin, Young-Nan Cho, Jung-Chul Kim, Seung-Jung Kee, Young-Goun Jo, Yong-Wook Park
          </td>
          <td>2025-10-23</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Elimination of tumors is typically dependent on T cells, which require prior or ongoing activation signals. These dependencies form the basis for our understanding of “tumor‐reactive immunity” and for the successes of immunotherapies, particularly immune checkpoint blockades. Over the years, tremendous work has been done towards understanding the biology of this reactive immunity and early investigation identified dendritic cells (DC) as key contributors. Recent advances have shed more light on dendritic cell heterogeneity in tumors, revealing specialized roles for each subtype. In addition, the network of cellular interactions surrounding DCs has grown as additional cell types have been revealed to variously influence how the immune system can become most effective at eliminating malignancies. Greater understanding of intratumoral DC biology has empowered investigators to engineer dendritic cell vaccines and consider other approaches to augment this component of reactive immunity, towards the generation of anti‐tumor immune responses de novo. In this review, we will discuss the state of the field, recent advances and suggest what the near future of scientific inquiry could entail.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77f18aefa5a339d8c7ed8fce463a8ad785b49774" target='_blank'>
              Dendritic Cells at the Center of Reactive Tumor Immunity
              </a>
            </td>
          <td>
            Lomax F. Pass, Matthew F. Krummel
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid proliferation, diffuse infiltration, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis remains dismal, with median survival rarely exceeding 15 months. The immunosuppressive and heterogeneous tumor microenvironment (TME), along with profound tumor-intrinsic resistance mechanisms, contributes significantly to treatment failure. Cardiotonic steroids (CTS), such as ouabain, have recently gained attention for their pleiotropic effects beyond Na+/K+-ATPase inhibition, including modulation of intracellular signaling, induction of cell death, and immune regulation. In GBM, ouabain has been shown to reduce tumor cell viability, impair migration, disrupt angiogenesis, and alter different signaling pathways. Although direct evidence of ouabain’s effects on the GBM immune microenvironment is limited, findings from other models suggest that it can modulate both innate and adaptive immune responses, affecting T cells, regulatory T cells, dendritic cells, monocytes, and NK cells. While previous reviews have explored the anticancer and pharmacological aspects of cardiotonic steroids, the immunological dimension of ouabain’s activity remains underrepresented. This review integrates current evidence on ouabain’s dual actions in tumor biology and immune regulation, emphasizing its emerging therapeutic potential and the need for deeper investigation within high-grade glioma models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c73049935628c7b64bd22cf222eb78736095626" target='_blank'>
              From hormonal immunomodulation to glioblastoma therapy: the emerging role of Ouabain
              </a>
            </td>
          <td>
            Arthur Gomes de Andrade, D. Carvalho, Daniel Wilson Arruda Magalhaes, A. C. de Queiroz, M. S. Alexandre-Moreira, Sandra Rodrigues-Mascarenas, L. H. A. Cavalcante-Silva
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Innate immune cells and pathways are central to shaping the tumor microenvironment (TME), where they influence tumor growth, metastasis, and responsiveness to immunotherapy. Although research on innate immunity in cancer has expanded considerably, the mechanisms driving immune dysfunction remain incompletely understood. This review summarizes current knowledge on the functional states of innate immune cells within the TME and highlights how metabolic reprogramming contributes to immune suppression and tumor progression. We further discuss recent advances in therapeutic strategies targeting innate immune pathways, emphasizing their translational potential. Importantly, we also examine unresolved controversies and knowledge gaps across innate immune cells, metabolic networks, and innate immune factors such as complement and cytokines, outlining key challenges for clinical translation. By linking mechanistic insights with emerging interventions and identifying future directions, this review provides a framework for integrating innate immunity into next-generation cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c04681fced7ce655cf3c2cb9b142258798132d57" target='_blank'>
              Innate immunity in tumors: roles and therapeutic targets
              </a>
            </td>
          <td>
            Songze Leng, Yuyue Ren, Yao Tian, Weiwei Zhao, Yue Mou, Xingyu Chen, Hong Zhou, Wei Wang
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Objective Antisynthetase syndrome-associated interstitial lung disease (ASS-ILD) exhibits clinical heterogeneity and progression, with unclear immunopathogenic mechanisms. This study aimed to define the cell type-specific interferon immune signatures and transcriptional networks underlying ASS-ILD. Methods Single-cell RNA sequencing (scRNA-seq) was performed on peripheral blood mononuclear cells (PBMCs) from three treatment-naive ASS-ILD patients and three healthy controls (67,421 cells). A comprehensive analysis was conducted in conjunction with an external cohort, encompassing 126,026 cells. The analytical pipelines included the following: AUCell for interferon-stimulated gene (ISG) activity scoring, Seurat for clustering, Monocle for trajectory inference, and CellChat for cell–cell communication. The inference of transcription factor activity was facilitated using decoupleR software. Results Monocyte-specific ISG activity was identified and validated in an integrated cohort of 126,026 cells. Among the six monocyte subsets, mono2 exhibited elevated IFNG expressions and a preferential inflammatory trajectory, marked by upregulated innate and adaptive immune pathways. Cell-cell interaction modeling revealed dysregulated type II interferon (IFN-II) and tumor necrosis factor (TNF) signaling, with mono2, NK, and CD8+ T cells as key signal transmitters. Regulatory network analysis revealed that the transcription factors ETV5, IRF5, IRF7, RORB, RORC, and SMAD1 drive inflammatory and profibrotic signatures via the IL-17, JAK-STAT, and TGF-β pathways. Conclusions This study identifies monocytes as central orchestrators of immune dysregulation in ASS-ILD, highlighting IFN/TNF signaling and associated transcriptional regulators as therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47f464fb1ee52ecdbedeb181795c17c978583c5f" target='_blank'>
              Monocyte-driven IFN and TNF programs orchestrate inflammatory networks in antisynthetase syndrome-associated interstitial lung disease
              </a>
            </td>
          <td>
            Yu Fan, Weijin Zhang, Miaotong Su, Shaoyu Zheng, Jianqun Lin, K. Zheng, Fengcai Shen, Guohong Zhang, Yukai Wang
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="


 Background: Signal-induced proliferation-associated gene 1 (Sipa1), a RAP1 GTPase-activating protein, is expressed in both hematopoietic cells and stromal cells. It negatively regulates G-protein signaling pathways involving in cell adhesion and proliferation. We have demonstrated that Sipa1loss induces bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs, CD45-TER119-CD31-CD44-CD51+SCA1+ and SCA1- subsets) alterations that drive the development of myeloproliferative neoplasm. Meanwhile, we have observed reduced Sipa1 expression in the BM MSPCs in mice with acute myeloid leukemia (AML) (Blood Adv. 2018, 2(5):534-548). However, the impact of the Sipa1 reduction on AML progression remains unclear.
 Methods: We have here explored the impact of Sipa1 expression in the host BM mesenchymal and immune cell niche by, 1) analyzing AML progression in Sipa1-/- and Sipa1+/+ recipient mice transplanted with MLL-AF9 AML cells with or without prior irradiation; 2) in vivo depletion of specific lymphoid subsets using neutralizing antibodies to determine their contributions; 3) immune and mesenchymal niche characterization using RNA sequencing and flow cytometry; 4) determining clinical correlation between Sipa1 expression in hematopoietic cells and treatment outcomes in patients with AML.
 Results: Remarkably, Sipa1 deficiency in host microenvironment led to delayed or no AML development, reflected in that 30% of the Sipa1-/- recipient mice did not develop AML while all Sipa1+/+ mice did after AML cell injection without prior irradiation. Notably, such a difference in AML development was not observed in lethally irradiated Sipa1-/- and Sipa1+/+ recipient mice where their immune cells were eliminated, indicating the critical involvement of Sipa1-/- immune cells in the AML inhibition. Further, in vivo depletion of NK cells by antibody neutralization could completely reverse the difference in AML development kinetics in the Sipa1-/- mice, suggesting that Sipa1 deficiency may boost NK cells anti-AML immune response. The enhanced anti-AML activity of Sipa1-/- NK cells was consistent with the increased maturation and activation of Sipa1-/- NK cells derived from spleen and blood. Furthermore, RNA sequencing suggested significant enrichment of the inflammatory genes associated with NK cell cytoxicity in Sipa1-/- BM MSCs (CD45-TER119-CD31-CD44-CD51+SCA1+) relative to that in Sipa1+/+ mice, providing another potential mechanism contributing to the increased anti-AML activity of Sipa1-/- NK cells, driven by the inflamed Sipa1-/- BM MSCs. Most importantly and notably, in line with these findings in mice, low SIPA1 expression in bone marrow mononuclear cells is associated with better survival and therapy responses to BET and mTOR inhibitors in AML patients (TCGA LAML dataset, and unpublished data from Prof. Caroline Heckman's lab in Helsinki University).
 Conclusions: Altogether, our study suggests that Sipa1 loss boosts anti-AML response of NK cells, possibly triggered by enhanced inflammatory host microenvironment. These findings along with the clinical correlation between low SIPA1 expression and better survival in AML patients point to the translational potential of these discoveries, meriting further investigation of therapeutic potential of Sipa1 deficient NK cells for AML and the underlying mechanisms.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f8871824fe2ad8aaef916abb388f27c2c0036c5" target='_blank'>
              Sipa1 loss in host niche boosts anti-AML immune response
              </a>
            </td>
          <td>
            Runqing Zhang, L. Sandhow, H. Cai, Hong Qian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Upon activation, B cells integrate signals from antigen and T cell help to choose between a rapid extrafollicular (EF) response and entry into the germinal center (GC). EF differentiation produces short‐lived plasmablasts that provide immediate but relatively low‐affinity antibody, whereas GC entry commits B cells to iterative selection, somatic hypermutation, and affinity maturation, ultimately yielding high‐affinity plasma cells and memory B cells. At the B–T cell border, where both responses originate, B cells also undergo class switch recombination (CSR). In this review, we examine the molecular mechanisms of CSR, highlighting the interplay between the DNA deaminase AID, transcription, and noncanonical nucleic acid structures. We further discuss the differential requirement of glycolysis between the EF versus GC response and how the cytokine IL‐21 fine‐tunes B cell entry into the GC. Together, these perspectives integrate genomic alterations, metabolic demands, and cytokine‐mediated signaling at the critical decision point between EF and GC pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ecc034aac7cb165cdbc5d307ab3c3ccca1cecfd1" target='_blank'>
              Mechanisms Promoting Stability of B Cells
              </a>
            </td>
          <td>
            Vivian L S Kuan, Jayanta Chaudhuri
          </td>
          <td>2025-10-29</td>
          <td>Immunological Reviews</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="


 Immunotherapy combinations can improve patient outcomes, yet the interactions within the tumor microenvironment (TME) that drive therapeutic synergy are poorly understood. Tumor establishment drives monocyte recruitment and differentiation into tumor-associated macrophages (TAMs), which have essential roles in coordinating immune responses and are thus attractive targets for therapeutic modulation. In a murine model of combination anti-PD-1 and anti-PD-L1 checkpoint blockade, tumor control was associated with increased infiltration of CD8+ T cells and M1-like repolarization of TAMs. Live-cell imaging of the tumor microenvironment revealed stable contacts between tumor-infiltrating CD8+ T cells and TAMs, in which the extent of the contact interfaces increased with combination immunotherapy. Treatment with anti-PD-L1 was able to increase macrophage expression of pro-inflammatory factors and phagocytic activity, suggesting a role for TAMs to reactivate CD8+ T cells in the TME. However, co-treatment with anti-PD-1 was ultimately necessary for tumor control, indicating the need for combination targeting of the TME.



 Mayo Clinic David and Margaret Grohne Cancer Immunotherapy Pilot Award



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b4b5c68bd11e510478b663ba12c5b0fe316f16" target='_blank'>
              Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 2076
              </a>
            </td>
          <td>
            Tina Kwok, Jessica N Lancaster, Haidong Dong, Ildefonso Silva
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5efa7f94822ae99000facb8bcf334e922c852364" target='_blank'>
              Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells
              </a>
            </td>
          <td>
            Lauren Sarko, David Givand, Claire Shepley, Brendan Rattin, Allen Attar, Rachel Taylor, Benjamin Kutler, Roshini M. Traynor, Anika Upadhyaya, Mackenzie Mnuk, Cavin Gehrke, Nat Murren, Tyler K. Ulland, Theresa Kotanchek, Krishanu Saha
          </td>
          <td>2025-10-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy, despite revolutionizing hematological malignancies, remains limited in solid tumors due to immunosuppressive microenvironments and systemic toxicities from combination immunotherapies. Recent engineering innovations demonstrate that physically linking anti-PD-L1 antibodies to interleukin-12 within CAR-T cells creates tumor-localized immunomodulation, concentrating therapeutic activity at PD-L1-positive sites while minimizing systemic exposure. In preclinical models, PD-L1-binding IL-12 fusion proteins achieved superior antitumor responses (100 vs. 50% complete responses) compared to non-binding controls, with significantly reduced inflammatory toxicity. Spatial proteomic analysis revealed comprehensive tumor microenvironment remodeling including enhanced CD8+ T cell infiltration and reduced immunosuppressive myeloid populations. Validation in human CAR-T cells targeting TAG72-positive ovarian cancer confirmed appropriate PD-L1 binding and enhanced cytotoxicity. This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7a6546fc7d661b815d3d60a952bbd89932e2713" target='_blank'>
              Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies
              </a>
            </td>
          <td>
            Maryam Abid, Ursula Abu Nahla, Muhammad Nabeel Saddique
          </td>
          <td>2025-11-04</td>
          <td>Annals of Medicine and Surgery</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Introduction Immunotherapy has shown clinical promise in multiple myeloma (MM), but relapse remains common, largely due to the immunosuppressive bone marrow (BM) microenvironment, characterized by T cell exhaustion and the accumulation of myeloid-derived suppressor cells (MDSCs). Recent advances highlight the therapeutic promise of 4-1BB (CD137) agonist antibodies in enhancing T cell–mediated anti-tumor responses, though their efficacy in MM remains poorly defined. Investigating 4-1BB expression dynamics in a preclinical MM model informed our rationale for targeting this pathway. Tasquinimod (TasQ), a small-molecule immunomodulatory agent, currently evaluated in a phase Ib/IIa clinical trial in MM patients (NCT04405167), offers a complementary strategy. By inhibiting the S100A9 signaling pathway, TasQ interferes with the recruitment and function of MDSCs, resulting in a less suppressive tumor microenvironment (TME) which reestablishes the anti -tumor immunity. In this study, we assessed the therapeutic potential of two distinct 4-1BB agonist antibody clones in an immunocompetent preclinical MM model. Building on these findings, we further explored the combination of the most effective 4-1BB agonist with TasQ, aiming to overcome the immunosuppressive tumor microenvironment, and strengthen anti-myeloma immune activity.
 Methods 4-1BB expression was analyzed during disease progression in 5T33MM mice using single-cell RNA sequencing of spleen and BM, 2 myeloma-infiltrating organs. These findings were validated by flow cytometry in both 5T33MM and 5TGM1 models. Therapeutic potential was assessed by treating 5TGM1 tumor-bearing mice with two 4-1BB agonist clones—LOB12.3 (IgG1κ; n=7/group) and 3H3 (IgG2a; n=5/group), using clone-specific isotype controls. Beginning on day 3 post-tumor inoculation, mice received 100µg of antibody intraperitoneally twice weekly until end stage. In a follow-up experiment, the lead 4-1BB agonist was combined with TasQ, administered at 30mg/kg in drinking water, to evaluate the impact of dual targeting the immunosuppressive TME (n=11/group). Tumor burden was assessed by determining the percentage of plasmacytosis in BM and spleen through cytospin stainings, together with M-protein measurement by serum electrophoresis. Immunomodulating effects were investigated using multi-parameter flow cytometry. Statistical significance was determined using the Mann–Whitney U test or one-way ANOVA, with p<0.05 considered significant.
 Results 4-1BB was predominantly detected on T cells and natural killer (NK) cells, with its expression further increasing as the disease progressed. Treatment of 5TGM1 mice with 4-1BB agonists significantly increased the percentage of CD4+ and CD8+ T cells in the BM and spleen. Interestingly, treatment with clone LOB12.3 resulted in a significant reduction in NK cell percentages in both the BM and spleen, while clone 3H3 selectively reduced splenic NK cells. Therapeutically, clone 3H3 significantly decreased M-protein levels and BM plasmacytosis (p<0.01), while no significant effects were observed for clone LOB12.3.
 Treatment with the IgG2a-formatted 4-1BB agonist combined with TasQ led to a significant reduction in M-protein levels and BM plasmacytosis (p<0001). Plasmacytosis was 62.50% in the isotype control group, decreased to 36.18% with 4-1BB agonist, 37.64% with TasQ, and further reduced to 14.09% in the combination therapy group, highlighting the enhanced efficacy of dual treatment. These effects were mediated by increased granzyme B–mediated T and NK-cell activation and enhanced differentiation of effector T cells (CD44⁺CD62L⁻). While this therapy did not alter the frequency of dendritic cells (DCs) in the BM, it enhanced their maturation, as evidenced by increased CD86 expression—particularly on type 1 and type 2 conventional DC subsets.
 Conclusion In conclusion, our findings demonstrate that 4-1BB activation can enhance anti-tumor immunity in MM; however, the therapeutic efficacy is dependent on the specific agonist used. Notably, the IgG2a-formatted 4-1BB agonist showed superior activity, underscoring the importance of isotype selection in achieving optimal immunotherapeutic outcomes. Moreover, co-administration with TasQ enhanced therapeutic efficacy, supporting the potential benefit of a combinatorial approach. Further investigation is warranted to elucidate the mechanisms driving these responses and to refine 4-1BB-targeted strategies for effective clinical translation.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/588054f9d7bef7f7dc4607713845e8f0a14c731a" target='_blank'>
              IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
              </a>
            </td>
          <td>
            Hatice Satilmis, Adrien Denis, Emma Verheye, E. De Bruyne, E. Menu, M. Törngren, H. Eriksson, K. Vanderkerken, K. De Veirman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="


 Long-lived plasma cells (LLPCs) sustain lifelong antibody secretion, forming the foundation of durable immune memory. However, the molecular mechanisms underpinning LLPC survival within the bone marrow (BM) remain incompletely understood. Using single-nucleus RNA-seq and ATAC-seq (10X Multiome) from matched blood and BM antibody-secreting cells (ASCs) of healthy adults, we profiled 8,059 nuclei, generating an integrated transcriptional and epigenetic map of ASCs across their developmental continuum with unparalleled resolution. In the BM LLPC cluster, Gene Set Enrichment Analysis (GSEA) validated the enrichment of the TNF/NF-κB signaling pathway and TLR cascades, emphasizing their anti-apoptotic roles. These clusters also demonstrate increased chromatin accessibility at key loci such as RELA, TLR1, TLR6, TLR10, NFKBIA, and TAB1, underscoring the central roles of TLR and TNF-α signaling pathways in activating the NF-κB pathway. Upregulated genes such as BCL2, NFKBIZ, TNFAIP3, and BIRC3 highlighted key survival mechanisms, while motif enrichment analysis revealed significant enrichment for REL and NF-κB binding motifs, supporting chromatin-level regulation of LLPC longevity. Together, these findings advance our understanding of LLPC survival and resilience and provide a framework for improving vaccine strategies and targeted immunotherapies.



 Computational and Systems Immunology (COMP)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86cf15dec942c9c651d1f78f13be792e4e03baf" target='_blank'>
              Dissecting the transcriptional and epigenetic landscape of human antibody-secreting cells in blood and bone marrow long-lived plasma cells 4589
              </a>
            </td>
          <td>
            Hira Anis, Monica Cabrera-Mora, Christopher Scharer, Ignacio Sanz, Greg Gibson, F. Eun‐Hyung Lee
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Osteosarcoma (OS) is the most common primary malignant bone tumor, predominantly affecting adolescents and young adults. Despite decades of research, survival rates for metastatic or recurrent disease remain dismal, underscoring the urgent need for therapeutic innovation. This malignancy frequently exhibits refractory responses to immunotherapy, a limitation increasingly attributed to dysregulated immunometabolic crosstalk. Growing evidence supports cellular metabolism as a master regulator of both neoplastic progression and immune cell functionality. To meet heightened biosynthetic demands, OS cells undergo metabolic reprogramming, adopting distinct programs divergent from normal counterparts. These changes reshape the tumor microenvironment (TME) into an immunosuppressive milieu, restricting immune cell infiltration and effector activity. Consequently, targeting these immunometabolic pathways offers a promising strategy to overcome therapeutic resistance. Here, we critically analyze the current understanding of OS immunometabolism, systematically delineating OS-specific evidence from extrapolated concepts. We dissect the key metabolic barriers to successful immunotherapy and propose a forward-looking roadmap to guide the development of more effective, biomarker-driven therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/34801467c697468afaea47ccfec61a47f910f893" target='_blank'>
              Osteosarcoma immunometabolism: emerging mechanisms and clinical implications
              </a>
            </td>
          <td>
            Bowen Tan, Jingyuan Ning
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background: Cerebral malaria (CM) is a severe and often fatal complication of Plasmodium falciparum infection that causes devastating brain injury largely through immune-mediated mechanisms. Pathogenic brain-infiltrating CD8+ T cells are key drivers of CM pathology, yet the intracellular signals enabling their harmful autoimmune-like activity remain poorly defined. Here, we identify protein kinase C θ (PKCθ), a central antigen receptor-signalling mediator, as a critical contributor to experimental cerebral malaria (ECM). Methods/Results: Using a PKCθ null allele mouse strain on a C57BL/6N background, we demonstrate that PKCθ deficiency significantly improves survival in Plasmodium berghei ANKA (PbA)-infected mice without altering parasite burdens in the blood or brain. Mechanistically, loss of PKCθ skews T cell differentiation towards central memory (Tcm) rather than effector memory (Tem) phenotypes, thereby reducing effector differentiation and sequestration of CD8+ T cells in the cerebral microvasculature. This prevents extensive neurovascular damage, preserves neural tissue integrity, and alleviates neurological signs and symptoms. Our findings provide genetic evidence that PKCθ drives CD8+ T cell-mediated brain injury in ECM. Conclusions: These results underscore the potential for repurposing clinically PKCθ inhibitors as host-targeted interventions to protect against cerebral injury and improve outcomes in patients with CM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f72ad9681b0a4fb1435cab237ed155e8996cc887" target='_blank'>
              Inhibition of PKCθ Abrogates CD8+ T Cell-Mediated Neurotoxicity in Murine Cerebral Malaria
              </a>
            </td>
          <td>
            Karin Albrecht-Schgör, Victoria E. Stefan, Martina Steinlechner, Dominik Humer, K. Siegmund, Sebastian Peer, Thomas Gruber, Maja Überegger, Stephanie zur Nedden, Gabriele Baier-Bitterlich, Peter Lackner, Erich Schmutzhard, Nikolaus Thuille, V. Klepsch, G. Baier
          </td>
          <td>2025-10-22</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="


 Systemic lupus erythematosus (SLE) is an autoimmune disease involving immune and non-immune cells, with complex pathogenesis and limited therapies. Dysregulated B cells, particularly double-negative 2 (DN2) B cells (CD19?, CD27?, IgD?, CD21?, CD11c?), are central to SLE by driving autoimmune processes. However, the origins and development of DN2 B cells remain poorly understood. B lymphopoiesis occurs in the bone marrow and is strongly regulated by mesenchymal stromal cells (MSCs). MSCs are non-hematopoietic immunosuppressive cells, which regulate immunity, including promoting regulatory B cells over plasma cells. In SLE, MSCs fail to suppress B cell activation into plasma blasts, but their immunomodulatory properties remain underexplored. We hypothesize that pathogenic DN2 B cells partly originate from a dysregulated bone marrow niche due to impaired stromal cell function. Single-cell transcriptomics and proteomics of healthy bone marrow identified resident DN B cells (∼30% of total B cells), with a small percentage being DN2. SLE plasma-primed MSCs while maintaining their phenotype, showed reduced PGE2 and TGF-β production and promoted naïve B cell differentiation into DN2 B cells, unlike healthy plasma-primed MSCs. These findings suggest that SLE MSCs exhibit impaired immunomodulatory capacity, contributing to the expansion of pathogenic DN2 B cells. This study provides new insights into DN2 biology and MSC dysfunction, highlighting potential therapeutic targets for SLE.



 LRA and Boston Children’s Hospital Cell Discovery Network



 Hematopoiesis and Immune System Development (HEM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5523d5b604cb369018cf0d5d4d7bd4c741b26f91" target='_blank'>
              Functional genomics deciphers pathogenic B cell dynamics in lupus bone marrow 3662
              </a>
            </td>
          <td>
            Mariasilvia Colantuoni, Nada Abdel Aziz, Marcos Chiñas, Holly Wobma, P. Nigrovic, Lauren A. Henderson, Diana Gomez Martin, Maria Gutierrez-Arcelus
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Tumor necrosis factor receptor 2-positive regulatory T (TNFR2+ Treg) cells, the most suppressive subset of Treg cells, are enriched in malignant pleural effusion (MPE), contributing to disease progression. However, the underlying mechanisms responsible for their accumulation remain unclear. Here we demonstrate that the C–X–C motif chemokine ligand 16 (CXCL16)/C–X–C chemokine receptor type 6 (CXCR6) axis plays a critical role in recruiting TNFR2+ Treg cells to MPE, with cancer-associated fibroblasts serving as the primary source of CXCL16. Mechanistically, under the hypoxic conditions prevailing in the pleural cavity, cancer-associated fibroblasts in MPE undergo glycolysis, which in turn leads to an increase in the production of endogenous lactate. This elevated lactate induces histone H3 lysine 18 lactylation (H3K18la) at the promoter regions of both the CXCL16 gene and its transcription factor forkhead box O3 (FOXO3), which may contribute to CXCL16 transcription. TNFR2+ Treg cells that express high levels of CXCR6, the only receptor for CXCL16, are subsequently recruited into MPE. The infiltration of TNFR2+ Treg cells may reinforce the immunosuppressive milieu of MPE, facilitating disease progression. Collectively, these findings uncover a novel mechanism governing immunosuppression in MPE, providing new insights into potential therapeutic strategies to disrupt this process. Malignant pleural effusion (MPE) is a severe condition often seen in advanced lung cancer, characterized by the accumulation of fluid around the lungs due to the presence of cancer cells. Researchers explored why the immune system struggles to fight MPE. They focused on a type of immune cell known as TNFR2+ Treg cells, which suppress the body’s ability to attack cancer. The study involved analyzing samples from patients and mice to understand how these cells are drawn to MPE. The researchers found that cancer-associated fibroblasts in MPE produce a protein called CXCL16, which attracts TNFR2+ Treg cells. This process is driven by lactate, which regulates genes expression in a way that increases CXCL16 production. Blocking CXCL16 reduced the recruitment of these suppressive cells and slowed disease progression. The study suggests that targeting lactate production or CXCL16 could improve treatment outcomes for MPE. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/91a71b2ab5cf300257fc0c85581cf1150ec21a51" target='_blank'>
              H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2+ Treg recruitment
              </a>
            </td>
          <td>
            L. Ye, Xuan Xiang, Zi-Hao Wang, Siyu Zhang, Q. Xue, Xiao-Shan Wei, Yao Liu, Haolei Wang, Jiaqi Ai, Bohan Yang, Long Chen, Yiran Niu, W. Peng, Qiong Zhou
          </td>
          <td>2025-11-01</td>
          <td>Experimental & Molecular Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="
 Despite responses in other malignancies, immune checkpoint inhibitor immunotherapy does not significantly improve outcomes for most glioblastoma (GBM) patients. Our group previously showed that anti-PD-1 therapy extended survival in CD8-knockout (CD8-KO) mice, implicating that another immune population may mediate the therapeutic effect. Now, depleting the CD4 T-cell in the CD8-KO mice significantly extended survival (medOS=66) in syngeneic gliomas compared to CD8-WT mice treated with IgG (med OS=39.5, p-val=0.0256) or anti-CD4 alone (medOS=35.5, p-val=0.0008). Immune-enriched single-cell RNA sequencing from the gliomas during the therapeutic window (P45) revealed a previously underappreciated CD3⁺CD4⁻CD8⁻ double-negative T-cell (DNTs) population expanded in the tumor of the CD4-depleted CD8-KO mice. These DNTs exhibited upregulation of pro-inflammatory cytokines (Tnf, Ccl12), activation markers (Cd40lg, Il7r, Cd69, Cd226), and reduced expression of exhaustion markers (Pdcd1, Ctla4, Tox), distinguishing them transcriptionally from conventional T-cells. The DNT population lacks markers consistent with NK-cells, NK T-cells, or gamma-delta T-cells. In vitro, DNTs secrete TNF-α at baseline and in response to glioma stem cells (GSCs). DNT–GSC co-culture suppresses GSC proliferation by 20-36%. The DNTs co-cultured with M0 macrophages increased macrophage phagocytosis by 44%, as assessed by fluorescent E. coli uptake assays. Glioma-associated myeloid cells from DNT-enriched mice showed upregulated gene ontologies related to inflammation, antigen presentation, and phagocytic activation, contrasting with the immune tolerance signatures in the CD8-WT background mice. Moreover, anti-PD-1 treatment in the CD4-depleted CD8-WT background and the CD8-KO only mice blunted the survival difference, suggesting that global T-cell elimination is a prerequisite for the emergence of antitumor DNT function. In summary, our findings identify a novel immunoregulatory and antitumor role for DNTs in glioma, characterized by TNFα-driven inflammatory signaling and myeloid activation. These data uncover a previously unrecognized immune axis that may be leveraged to overcome immunotherapy resistance in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928ff08c6367893a7a75add253009e2dfc2d8104" target='_blank'>
              IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma
              </a>
            </td>
          <td>
            Malcolm F. McDonald, Yuhui Yang, Ashley Puentes, H. Najem, Khatri Latha, Eric A. Goethe, Yeunjung Ko, A. Heimberger, A. Harmanci, Ganesh Rao
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non-AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8+ T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8+ T cell-dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1+PD-1+Tim-3- stem-like memory CD8+ T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8+ T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8+ T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8+ T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c80f585d4308a75bf3227e6815a7fdd66bafcb" target='_blank'>
              Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infection.
              </a>
            </td>
          <td>
            Guangming Li, Yaoxian Lou, Jianping Ma, Liang Cheng, Haisheng Yu, Ourania Tsahouridis, Xiu-yuan He, Masaya Funaki, James Ahodantin, Wenwen Bi, Jianwen Chen, Xiaoxuan Fan, Salma Sharaf, N. Goonetilleke, R. B. Jones, Shyamasundaran Kottilil, Poonam Mathur, Lishan Su
          </td>
          <td>2025-11-05</td>
          <td>Science translational medicine</td>
          <td>1</td>
          <td>40</td>
        </tr>

        <tr id="Natural killer (NK) cells serve as pivotal effector cells within the innate immune system, playing an indispensable role against infections and tumors. Individuals with diminished NK cell activity or NK cell deficiency are at a higher risk of developing cancers and experiencing severe viral infections. With global demographic shifts toward aging populations, elucidating the mechanisms of immunosenescence becomes increasingly critical for developing targeted therapeutic interventions against age-related disorders. This review provides a comprehensive summary of the phenotypic characteristics, functional changes, and mechanisms of NK cells in aging and diseases. By synthesizing current research, it highlights key pathways contributing to NK cell immunosenescence in the elderly and explores potential strategies to preserve or restore their cytotoxic and immunoregulatory functions. The review provides novel insights into NK cell immunosenescence and proposes innovative approaches to enhance NK cell activity in aging individuals, offering potential therapeutic avenues for mitigating age-related immune decline.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6176129feabcadd207bec7b9a7e512c4a503122e" target='_blank'>
              Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence
              </a>
            </td>
          <td>
            Zixuan Guo, Feng-tian Wu, Yao Chen, Jia Xu, Zhi Chen
          </td>
          <td>2025-10-21</td>
          <td>Immunity & Ageing : I & A</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the microenvironment (TME) underlying these resistances remain unclear. In this study, we used a cohort of melanoma patients (n = 61) treated with ICB, pre-treatment (n = 33) and post-progression (n = 28), for whole-exome sequencing, single-nucleus RNA sequencing and high-resolution spatial imaging. We developed a framework to analyze response and resistance (intrinsic and acquired) via tumor-intrinsic programs, immune features, and tumor-stromal-immune interactions. Patients with low immune infiltration exhibited enrichment of macrophages associated with hypoxia and angiogenesis phenotypes. Samples with high immune infiltrates displayed an enrichment in lymphocytes, particularly TCF7+ CD8+ T cells. Pre-treatment samples from patients experiencing durable clinical benefit are encriched in memory B cells and plasmablast-like B cells.The presence of Bcells and of follicular dendritic cells in non-lymph node biopsies support the presence of tertiary lymphoid structures within the TME. Lastly, the presence of a TIMD4-expressing macrophage subset correlates with lymphocyte infiltration, indicating its potential role in promoting anti-tumor immunity. Our work defines TME immune profile interaction with tumor-stromal cells associated with clinical outcomes in melanoma.



 NCI HTAN



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2a8d3010e6c8bda33a8b18473b82b46e0a2ceaea" target='_blank'>
              Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
              </a>
            </td>
          <td>
            Giuseppe Tarantino, Yiwen He, Priyanka Solanky, Xinyu Cui, K. Pfaff, A.R. Thorner, Timothy R. Blosser, Elliot Boblitt, Allison Frangieh, Tyler J. Aprati, Boyang Zhang, Jiajia Chen, H. Faulkner, Aleigha R Lawless, M. Manos, K. Helvie, T. Sharova, Dennie T. Frederick, Sachi Krishna, Chanell Mangum, Domenic Abbondanza, Cai McCann, Bruce Johnson, Alex K. Shalek, Eliezer M. Van Allen, Xiaowei Zhuang, Ryan J. Sullivan, Barbara Engelhardt, Sami Farhi, S. Rodig, F. S. Hodi, Genevieve M. Boland, David R. Liu
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Introduction Glioblastoma (GBM) is a highly invasive brain tumor with limited treatment options and poor prognosis. Natural killer (NK) cells are key effectors of antitumor immunity, capable of eliminating cancer stem-like cells. However, GBM creates an immunosuppressive microenvironment that limits NK cell function. Here, we identify cystatin F as an immunosuppressive factor involved in regulating NK cell granule-mediated cytotoxicity. Methods We analyzed cystatin F expression in GBM and its correlation with immune exhaustion markers. NK cell activity was compared between GBM patients and healthy donors. In vitro co-cultures of cystatin F-expressing microglial cells and glioblastoma stem-like cells were used to assess NK cell function. To block cystatin F activation from dimeric to active monomeric form, a small-molecule inhibitor of cathepsin V, the activating protease, was applied. Results Cystatin F expression correlated with immune exhaustion and suppression markers in GBM. NK cells from patients showed reduced cytotoxicity compared to healthy donors. Co-cultures confirmed that cystatin F-expressing microglia impaired NK cell cytotoxicity, while inhibition of cathepsin V restored NK cell function in standard cytotoxicity assays, 3D spheroids, and microfluidic perfused models. Discussion These results indicate that cystatin F mediates NK cell suppression in GBM. Targeting its activation enhances NK cell cytotoxicity, offering a potential strategy to improve NK-based immunotherapy for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3bb3c49f85522c7de4609841eca5e88d65fb2178" target='_blank'>
              Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models
              </a>
            </td>
          <td>
            E. Senjor, A. Habič, U. Švajger, Ana Mitrović, M. Proj, A. Porčnik, Borut Prestor, Miha Jerala, Matic Bošnjak, Stanislav Gobec, B. Breznik, Janko Kos, Milica Perišić Nanut
          </td>
          <td>2025-10-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c454ed40c54564b7e7bad898b56913f7bebc36e6" target='_blank'>
              Multicellular Calcium Waves in Cancer-Associated Fibroblasts Regulate Neuronal Mimicry and Anisotropy Leading to Immune Exclusion
              </a>
            </td>
          <td>
            Giovanni Giangreco, Zoe Ramsden, Antonio Rullan, S. Hooper, David Novo, Joana Leitão Castro, Probir Chakravarty, Marta Milan, Hamid Mohammadi, Sandra Llop, Marc Juarez, Deborah Schneider-Luftman, M. Oliva, Laia Alemany, Mihaela Angelova, A. Olow, Xin Yu, Philip S Hobson, K. Harrington, E. Sahai
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a349f447081e148334ada4b0e5ec3e64399cf656" target='_blank'>
              Trophoblast stem cells and syncytiotrophoblasts lack inflammatory responses to LPS but retain robust interferon-mediated antiviral immunity
              </a>
            </td>
          <td>
            Cristine R. Camp, Joshua Baskaran, Matthew Brown, Carly Parker, Paige Drotos, Rachel C. West
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Recent advancements in the treatment of multiple myeloma (MM), including immunomodulatory agents, monoclonal antibodies, and T cell-redirecting therapies, have significantly improved patient outcomes. However, MM remains incurable. The interaction between MM cells and non-malignant cells within the immunosuppressive tumor immune microenvironment (TiME) plays a critical role in disease progression, but it has not been fully elucidated.
 Our previous study reported that myeloid-derived suppressor cells (MDSCs), dysfunctional dendritic cells (DCs), and tumor-promoting osteoclasts (OCs) are enriched in the bone marrow of myeloma patients and play critical roles in T cell dysfunction. However, the underlying mechanisms remain incompletely understood (Front Immunol. 2022). A myeloid inhibitory receptor, LILRB4, was identified as highly expressed in a super high-risk subgroup of MM cells by single-cell RNA sequencing of patient samples. LILRB4 expression facilitated the generation of monocytic MDSCs and was associated with poor outcomes in MM patients (Haematologica 2024 & 2025). These findings suggest a potential mechanism by which LILRB4 drives an immunosuppressive microenvironment through the induction of immunosuppressive myeloid cells.
 Here, we further observed a significant reduction in erythroid-lineage commitment in MM patients with high LILRB4 expression, and we explored its molecular and cellular impact on the interaction between myeloma cells and the tumor microenvironment (TME). We report that LILRB4 is highly expressed in MM and activates the SHP2/ERK/AP-1 signaling cascade, thereby enhancing the expression of AP-1-associated chemokines and promoting the transdifferentiation of erythroid cells into immunosuppressive erythroid-derived myeloid cells (EDMCs). Through in vivo and in vitro analyses, we demonstrate that CD45⁺ erythroid progenitor cells (EPCs) in the MM microenvironment lose their erythroid differentiation potential and instead transdifferentiate into EDMCs. This reprogramming is driven by elevated levels of CCL3 secreted by LILRB4⁺ MM cells. Compared with the control group, deletion of CCL3 significantly inhibited myeloma cell growth, increased peripheral blood hemoglobin levels, reduced EDMC proportions in the bone marrow, enhanced IFN-γ secretion by CD8⁺ T cells, decreased the frequency of regulatory T cells (Tregs), and reduced the proportion of macrophages. Additionally, the ratio of monocytic MDSCs (M-MDSCs), which preferentially differentiate into tumor-associated macrophages (TAMs), to granulocytic MDSCs (G-MDSCs) was also decreased. EDMCs emerged as another major source of tumor-associated myeloid cells, further contributing to the suppressive TiME.
 These results provide a novel model of hematopoietic diversion in which myeloma “hijacks” CD45⁺ erythroid progenitor cells, redirecting them toward a myeloid fate to evade immune surveillance. EDMCs, as potent immunosuppressive players, strongly inhibit CD8⁺ T cell function and accelerate disease progression. Additionally, our findings establish a mechanistic link between LILRB4 and MM-associated anemia, a well-known poor prognostic factor.Our study therefore suggests that LILRB4 overexpression induces key molecular changes that enable macrophage inflammatory protein-1 alpha (MIP-1α/CCL3)-mediated formation of an immunosuppressive myeloid tumor microenvironment, thereby promoting MM cell growth and survival.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1316f08649414674d11974365803ce69ba88ff10" target='_blank'>
              LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells
              </a>
            </td>
          <td>
            Lanting Liu, Hao Sun, Yijie Wang, Xiyue Sun, Gang An, Lugui Qiu, Mu Hao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Objective Regulatory T cells (Tregs) play a pivotal role in tumor immune evasion, and strategies to overcome their immunosuppressive activity are urgently needed. This study investigates the immunomodulatory effects of microwave ablation (MWA) on TNFRSF4+ Tregs, focusing on the OX40L/TNFRSF4 signaling axis as a potential therapeutic target. Methods TNFRSF4+ Tregs were isolated from C57BL/6 mice and subjected to MWA-mimetic thermal stress. In vitro functional assays and in vivo LLC xenograft models were employed, with OX40 agonist intervention. Molecular mechanisms were analyzed via RT-qPCR, Western blot, and immunohistochemistry. The balance of tumor-infiltrating immune cells was quantified by multi-color flow cytometry. Results MWA induced three key effects: (1) Phenotypic shift: decreased CTLA-4+ (P<0.0001) Treg subsets, but increased OX40L+ (P<0.01) in LLC cells; (2) Functional impairment: reduced Treg-mediated support for LLC proliferation, migration, and invasion; (3) Enhanced CD8+ T cell cytotoxicity. In vivo, MWA reshaped the tumor microenvironment by significantly increasing the intratumoral CD8+/Treg ratio (P<0.001), indicating a shift toward an anti-tumor inflammatory state. Mechanistically, MWA suppressed NF-κB/IκBα/TRAF6 signaling, and these effects were amplified by an OX40 agonist, suggesting the pathway is potentially OX40L-dependent. Conclusion This study demonstrates that MWA disrupts Treg immunosuppression, likely by activating OX40L/TNFRSF4 signaling, and favorably alters the balance of effector to suppressor cells, providing a novel rationale for combining thermal ablation with OX40-targeted immunotherapies in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f38c9a306dd490d7b2909de55961bc75bf9d4ebe" target='_blank'>
              Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity
              </a>
            </td>
          <td>
            Runqi Guo, Yufeng Wang, Jie Sun, Yuanming Li, Zhixin Bie, Xiaoguang Li
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Introduction: Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulations. Venetoclax (Ven), a selective BCL-2 protein inhibitor, has shown robust clinical activity in both treatment-naïve and relapsed/refractory (R/R) CLL. In Ven-treated patients with CLL, a reduction in the number of non-malignant lymphocytes and a decline in tumor-supportive T-cell subsets were reported. However, the effects of Ven treatment on the patients' immunological profile remain incompletely characterized.
 Aims: This study aims to characterize the immunological effects of Ven-based therapies in CLL by tracking longitudinal changes in T-cell and NK-cell phenotypic and functional profiles.
 Methods:In this multicenter, observational study 68 patients with R/R CLL, eligible for therapy with Ven-based regimens, were enrolled. Forty-six patients received Ven + rituximab and 22 Ven monotherapy. Peripheral blood (PB) samples were collected at the time of treatment start (n=68), and after 1 (n=60), 6 (n=56) and 12 (n=57) months of therapy. The percentage and the phenotype of T and NK cells were assessed by multicolor flow cytometry.
 Results: Data of 58 enrolled patients have been analyzed to date. In parallel with the reduction of circulating leukemic cells, Ven treatment induced a significant decline in absolute CD3⁺, CD4⁺ and CD8⁺ T-cell counts, which was already evident after one month and persisted at the 6- and 12-month timepoints. During treatment, in the CD4⁺ T-cell compartment, the frequency of naïve (TN) and central memory (TCM) subsets remained stable over time, while within the cytotoxic subsets we observed a decrease in the effector memory (TEM) T cells and a parallel, significant increase of the terminally differentiated (TEMRA) T cells compared to the pre-treatment distribution. In the CD8+ T-cell compartment we observed a similar rise in the proportion of TEMRA, which was paralleled by a decrease in the proportion of TCM and TEM subsets. The evaluation of immune checkpoint expression on CD4⁺ T cells revealed a downmodulation of PD-1 that was already evident after one month of treatment and a reduction of BTLA, TIM-3 and LAG-3 levels that became evident at the later 6- and 12-month timings. Interestingly, a more detailed analysis performed in a subgroup of patients showed that the observed reduction in immune checkpoint expression was mostly restricted to the less differentiated (i.e. TN, TCM) CD4+ subpopulations. Concerning the CD8⁺ T-cell compartment, Ven treatment significantly lowered BTLA expression - particularly within the TN and TCM subsets - across all timepoints, whereas the levels of the other immune checkpoints remained largely unaltered. Of note, an expansion of the immunosenescent CD57⁺PD-1⁻ subset was persistently detected within the CD8⁺ TEMRA subset already after one month of treatment and within the CD4⁺ TEM and TEMRA subsets at the later 12-month timepoint. T-cell homing capacity was also evaluated, based on CXCR3 and CD62L expression. Interestingly, both CD4⁺ and CD8⁺ T cells showed increased CD62L expression after 12 months of treatment, indicating enhanced migration capacity to lymph nodes. In the context of innate immunity, Ven administration resulted in an overall decrease in the absolute number of NK cells, detectable as early as one month after treatment initiation. Notably, the frequency of the CD56dimCD16⁺ NK-cell subset, mostly responsible for cytotoxic activity and ADCC, increased significantly at the 6- and 12-month timepoints. By contrast, the proportion of the less represented CD56bright NK-cell subset remained stable in the PB of Ven-treated patients. We did not detect any relevant difference in the modulation of T-cell and NK-cell phenotype between patients treated with Ven plus rituximab and those receiving Ven monotherapy.
 Conclusion: This study provides a longitudinal evaluation of the immunomodulatory effects of Ven treatment in the largest cohort of patients with CLL analyzed to date. Our results indicate that Ven therapy reshapes both the T-cell and NK-cell compartments by alleviating features of exhaustion, enhancing lymph node homing potential and promoting the expansion of cytotoxic subsets. At the time of data presentation, conclusive results from additional phenotypic analyses and functional assays will be available. These immunological modulations may be harnessed to elucidate Ven off-tumor effects and to refine optimal therapeutic sequencing strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ba4e66f3d5a0eec4a163635c182e19c61aaa3c7e" target='_blank'>
              Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Giorgia Mancin, V. Griggio, Rebecca Jones, Giulia Bondielli, A. Visentin, R. Moia, A. Frustaci, A. Bosi, M. Varettoni, Francesca Perutelli, M. C. Montalbano, G. Catania, P. Sportoletti, L. Laurenti, F. Mauro, L. Orsucci, Luca Arcaini, Francesco Passamonti, M. Deodato, G. Gaidano, L. Trentin, B. Bruno, C. Vitale, M. Coscia
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="


 Immunosenescence leads to impaired immunity against infections in the elderly. As a key component of adaptive immunity, T cells are crucial for immunity against infection and cancer and exhibit distinct phenotypic changes with age. Characterizing these age-related alterations in T cells is essential for developing strategies to address immune dysregulation in the elderly. In vitro activation model showed that aged mice have a higher frequency of PD1+ exhausted-like CD8 T cells at baseline and higher TCR-induced cell death upon activation. Inhibiting both apoptosis and necrosis rescues TCR activation-induced cell death. Using a murine hepatitis virus (MHV) intranasal infection model, we observed that aged mice had greater weight loss, higher mortality, and impaired CD8 T cell responses during MHV infection. Infected aged mice exhibited increased expression of inhibitory receptors on antiviral CD8 T cells and a decrease in the population of CD8 T cells producing IFN-γ. Single-cell RNA sequencing showed that aging altered the transcriptional profile of antiviral CD8 T cells and reduced T-Bet and ZEB2 expression, key factors for effector CD8 T cell differentiation. Aging also upregulated T cell exhaustion gene signature mediated by the transcription factor TOX. Overall, our findings demonstrate that aging reshapes the molecular program of antiviral CD8 T cells and compromised antiviral T cell immunity in the aged.



 Supported by NIH/ NIA AG-083398; NIAID AI-158294



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80e47c0f1fb034ad0cc56d0aad4b1018f719c06e" target='_blank'>
              Aging compromises effector differentiation and induces exhaustion-like phenotype in CD8 T cells 2511
              </a>
            </td>
          <td>
            Ziang Zhu, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e-4). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e08f1dd96dd018add58f7a79b8066098738fcfe" target='_blank'>
              Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
              </a>
            </td>
          <td>
            Denis J Ohlstrom, William C. Pilcher, Marina E. Michaud, Chaitanya R. Acharya, Sarthak Satpathy, Edgar Gonzalez-Kozlova, R. Jayasinghe, Katherine E. Ferguson, Hope L. Mumme, Shivani Nanda, Yizhe Song, Sowmitri Mantrala, Dimitra Karagkouni, Jessica Schulman, Nick Pabustan, Junia Vieira Dos Santos, Daniel W. Sherbenou, J. Keats, Alex Gout, Steven Foltz, A. Laganà, T. Kourelis, Ravi Vij, M. Dhodapkar, D. Avigan, H. Cho, L. Baughn, Ajay K Nooka, S. Lonial, Shaji Kumar, Mehmet K Samur, Ioannis S Vlachos, Li Ding, Sacha Gnjatic, George Mulligan, Manoj K. Bhasin
          </td>
          <td>2025-12-09</td>
          <td>Blood cancer discovery</td>
          <td>0</td>
          <td>110</td>
        </tr>

        <tr id="Recently, we observed that pars planitis (PP) patients present alterations in peripheral blood (PB) Th17/Treg associated with dysregulation in the Th1 response. Yet, little is known about the systemic distribution of myeloid cells, which drive the recruitment and differentiation of the adaptive effectors toward pathogenic inflammatory Th1 and Th17 as well as regulatory lymphocytes in PP. Although myeloid populations in patients with uveitis have previously been addressed, the data did not provide an exact description of PP patients. Using flow cytometry, we evaluated monocyte and IDO-expressing monocyte-like myeloid-derived suppressor cell (MDSC) subpopulations in PB samples from 15 patients with different courses of PP (cystoid macular edema and non-macular edema subgroups; CME and nCME, respectively) and 17 healthy controls (HCs) in relation to the Th1, Th17, and immunoregulatory subsets. We observed that only PP patients from the CME subgroup presented a significantly higher fraction of CD16+ IDO-expressing MDSCs and intermediate CD14highCD16+ monocytes compared to the HCs; this corresponded with relative up-regulation of Th1 and Th17, and down-regulation of Treg. In addition, alongside the increased percentage of IDO-expressing CD16+ MDSCs, the MDSC compartment displayed an inappropriate level of IDO (more pronounced in the CD16− subset) only in CME patients. At the same time, the fraction of CD16− myeloid cells did not differ significantly among the patient cohorts and healthy participants. Our study is the first to evaluate subpopulations of circulating myeloid cells in PP patients and indicates that an increased fraction of CD16+ myeloid cells might reflect the immunological and clinical severity of PP.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cd1fd2d076c43e8bd265181bbac902c87dc1f38" target='_blank'>
              Circulating CD16-Positive Monocyte-like Myeloid-Derived Suppressor Cells and Intermediate Monocytes Associated with Clinical and Immunological Complications in Pars Planitis Patients
              </a>
            </td>
          <td>
            A. Kosmaczewska, Joanna Przeździecka-Dołyk, L. Ciszak, Zofia Rojek-Gajda, I. Frydecka, A. Turno-Kręcicka, Marta Misiuk-Hojło, Edyta Pawlak
          </td>
          <td>2025-10-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b6398ddc5edaa94a066851abec2558753a9728" target='_blank'>
              NLRP1 Shapes Immune and Inflammatory Signatures in Human Melanoma but Not in Mouse Models
              </a>
            </td>
          <td>
            V. P. Targhetta, Raquel de Souza Vieira, Hedden Ranfley, C. N. de Souza Breda, N. O. Câmara
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="ABSTRACT The immune system is tasked with mounting effective responses to pathogens while preventing inflammation triggered by innocuous antigens, including those derived from self, food, and commensal microbes. This balance is especially critical in the intestine, where dietary and microbial antigens are constantly encountered. Peripherally induced regulatory T cells (pTreg or iTreg) play a key role in suppressing inappropriate immune activation and maintaining gut homeostasis. Elucidating how pTreg cells are generated along the gastrointestinal tract is therefore critical to understanding peripheral tolerance. Recent studies have revealed that intestinal antigen‐specific pTreg cell differentiation is induced by a distinct lineage of antigen‐presenting cells (APCs) requiring expression of the transcription factors RORγt and PRDM16. Genetic perturbation of these APCs results not only in microbiota‐specific proinflammatory T cell responses but also in the breakdown of oral tolerance, which in turn predisposes to allergic inflammation. In this review, we summarize the discovery of these tolerance‐inducing APCs, highlight their role in instructing pTreg cell differentiation in response to microbiota and dietary antigens, and discuss the regulatory networks that support their function during intestinal immune tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3da30c377152a2f5e064e9a65d6e95246713e092" target='_blank'>
              Specialized Dendritic Cells Mediating Peripheral Tolerance to Intestinal Antigens
              </a>
            </td>
          <td>
            Liuhui Fu, Dan R. Littman
          </td>
          <td>2025-12-02</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Multiple myeloma (MM), the second most common hematologic malignancy, presents significant clinical challenges due to its relapsing/refractory nature and incurability, primarily attributed to the high complexity of the bone marrow (BM) microenvironment. Emerging evidence suggests that metabolic reprogramming within the tumor microenvironment (TME) plays a pivotal role in tumor progression and the anti-tumor function of CD8+ T cells. However, the limited understanding of the metabolic landscape of the MM BM microenvironment has hindered the identification of potential therapeutic targets. In this study, we demonstrate that although CD8+ T cells from MM patients exhibit elevated expression of immune checkpoint molecules, they do not enter a canonical exhausted state. Instead, their dysfunction is reversibly suppressed by microenvironmental alterations. Metabolomic profiling revealed a significant remodeling of the tryptophan metabolic pathway in the MM BM microenvironment, characterized by the accumulation of nitrogen-containing metabolites and indole derivatives, which directly impair CD8+ T cell-mediated anti-tumor activity. Further investigation identified indole-related metabolites as key metabolic regulators in the MM BM niche, promoting immune evasion by functionally suppressing CD8+ T cells. These findings not only uncover a novel mechanism of immune suppression in MM but also provide potential therapeutic targets for developing metabolism-focused immunomodulatory strategies.
 In multiple myeloma (MM) patients, bone marrow CD8+ T cells exhibit elevated PD-1 expression but comparable TIM-3 levels to non-myeloma controls. Notably, no significant differences were observed in cytokine secretion capacity or exhaustion-related transcription factor expression between PD-1+/TIM-3+ and PD-1-/TIM-3- T cell subsets. Thus, while a substantial population of CD8+ T cells persists in the MM microenvironment, they do not exhibit the canonical exhausted phenotype traditionally defined in chronic viral infections or other malignancies.
 Unexpectedly, fresh myeloma BM CD8+ T cells show blunted cytokine responses, reversible by overnight culture but inhibited by autologous BM supernatant. This suppression is BM-specific, as peripheral T cells remain unaffected by plasma.
 The <3 kDa hydrophilic fraction of bone marrow (BM) supernatant significantly impaired the cytotoxic capacity of BCMA CAR T cells. Untargeted metabolomic profiling revealed that the inhibitory BM supernatant exhibited distinct metabolic alterations, primarily enriched in the following pathways：Amino acid metabolism; Energy metabolism ; Nucleotide metabolism. Notably, multiple indole derivatives were upregulated in the tryptophan metabolic pathway.
 Metabolomic analysis revealed significant upregulation of indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and kynurenine in the inhibitory bone marrow supernatant. Functional validation demonstrated that indole, indoleacrylic acid, IPA, and IAA all exhibited dose-dependent suppression of CAR T cell-mediated tumor cytotoxicity. Notably, IAA displayed potent immunosuppressive activity even at low concentrations, suggesting enhanced immunomodulatory potential. Mechanistically, both IAA and IPA significantly upregulated aryl hydrocarbon receptor (AHR) expression， indicating that indole-related metabolites may impair antitumor T cell function through AHR-mediated signaling pathways.
 Overall, we have come to the following conclusions：flow cytometric and transcriptional analyses revealed that CD8+ T cells in the multiple myeloma (MM) bone marrow microenvironment exhibit an activated phenotype rather than classical exhaustion markers, despite their functional impairment. Ultrafiltration and functional assays demonstrated that the <3 kDa hydrophilic fraction of MM bone marrow supernatant significantly inhibits CD8+ T cell effector functions. Indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) are significantly elevated in the bone marrow of a subset of multiple myeloma (MM) patients, where they potently inhibit the anti-tumor function of CD8+ T cells, likely through activation of the aryl hydrocarbon receptor (AhR) signaling pathway on T cell surfaces.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1c2fdacb0730e5456a357462f821514cc752968" target='_blank'>
              Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma
              </a>
            </td>
          <td>
            Yueyi An, Huixing Zhou, Xiaoyun Jin, Shengdian Wang, Wen Gao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="
 Besides its robust antiviral activity, type I interferon (IFN-I) also exerts immunomodulatory effects and can even drive pathology during chronic viral infections. Mechanisms that regulate IFN-I induction during virus infection, thus strongly affecting the outcome of disease, remain to be defined. Here, using the lymphocytic choriomeningitis virus (LCMV) Docile strain, we identified acid ceramidase (aCDase,
 Asah1
 ) as a critical lipid-metabolic regulator of endosomal, nucleic acid-driven IFN-I responses and disease outcome during chronic virus infection. aCDase is highly expressed in plasmacytoid dendritic cells (pDCs) and required for robust early IFN-I production. aCDase deficiency resulted in ceramide accumulation, blunting IFN-α/β induction, impairing IFN-I-dependent upregulation of programmed death-ligand 1 (PD-L1) on antigen-presenting cells and preventing the exhaustion of virus-specific CD8
 +
 T cells, leading to severe immunopathology. This pathology is abrogated by CD8
 +
 T-cell depletion or by adoptive transfer of IFN-I-induced PD-L1-expressing macrophages. Conversely, limiting ceramide production in acid sphingomyelinase (Asm)-deficient mice prevented ceramide accumulation, and pDCs showed accelerated IFN-I induction. Mechanistically, ceramide abundance regulated IFN-I production by altering endosomal signaling microdomains. Collectively, our findings reveal ceramide homeostasis as a key determinant of IFN-I-driven CD8
 +
 T-cell exhaustion and immunopathology during chronic viral infection and highlight aCDase as a potential therapeutic target.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3347a83451be199ba4cf611d6ba58e4cec09e11d" target='_blank'>
              Acid ceramidase regulates CD8+ T-cell exhaustion via type I interferon-mediated upregulation of PD-L1
              </a>
            </td>
          <td>
            Zhongwen Hu, Hossam Abdelrahman, Abdelrahman Elwy, F. Kuang, Swati Dhiman, Shafaqat Ali, Marcel Marson, Lisa Holnsteiner, Thamer A Hamdan, Justa Friebus-Kardash, Elisa Wiebeck, Wiebke Hansen, S. Scheu, Erich Gulbins, P. Lang, K. Lang, Judith Lang
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Regulatory T cells (Tregs) are a distinctive subset of CD4+ T cells critical in self-tolerance maintenance to prevent the development of autoimmunity. The mechanisms by which these cells provide immune regulation are numerous and, consequently, deeply involved in the pathogenesis of many autoimmune disorders. Treg-based adoptive cell transfer (ACT) therapy has generated interest as a novel, promising strategy to restore self-tolerance in autoimmunity. Polyclonal Treg-based ACT therapy was first implemented in clinical trials, presenting adequate safety profiles. Subsequent preclinical studies have shown antigen-specific Tregs to be safer and more effective than polyclonal approaches, so research has recently moved in this direction. Antigen-specificity can be conferred to Tregs by viral transduction of genes coding for engineered T cell receptors (eTCRs) or chimeric antigen receptors (CARs), with encouraging outcomes in different animal models of autoimmunity. This review focuses on the biology of Tregs, as well as on current preclinical and clinical data for Treg-based ACT in the field of autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/245990f7801c19be0c77d295d5bb4e3aed2c7143" target='_blank'>
              Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity
              </a>
            </td>
          <td>
            Eduardo Gozálvez, Adrián Lario, Guillermo Muñoz-Sánchez, Francisco Lozano
          </td>
          <td>2025-10-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Background:
 Autoimmune phenomena occur in 20-50% of patients with myelodysplastic syndromes (MDS), exacerbating hematopoietic suppression and increasing cardiovascular/infection/bleeding risks. Recent data from our group suggest that the canonical model of stem cell intrinsic failure in MDS is incomplete in that a major fraction of MDS patients present with a large-granular-lymphocyte (LGL) phenotype, comprised of clonal-like expansions of CD57+ T-cells and NK cells in the bone marrow (BM) that strongly correlate with autoimmune cytopenias in lower-risk (LR)-MDS. We hypothesized that CD57+LGLs contribute to BM failure (BMF) through three key mechanisms: (i) enhanced expression of the Fc receptor, CD16A and associated reactivity in response to IgG1 and IgG3 autoantibodies; (ii) ability to recognize loss of HLA class I expression on hematopoietic progenitors; and (iii) activation and proliferation in response to cytokines and chemokines. Targeting these cells has the potential to restore effective hematopoiesis.
 Methods:
 Clinical flow cytometry was used to profile presence and abundance of cells across >20 immune subsets in matching BM and blood samples (N=279 MDS). We then performed scRNA-seq, including matched TCR as well as single-nucleotide ATAC seq on BM mononuclear cells (BMMCs) from a separate cohort of six LR-MDS pts and three healthy individuals. Further, we performed mass cytometry (CyTOF) for ex-vivo profiling of BM from 19 MDS patients (N=10 LR/IR-MDS, N=9 high-risk-MDS) and age-matched controls. From this same cohort, we also performed in vitro killing assays by incucyte using isolated BM-derived LGLs. Retrospective analysis of 22 MDS patients treated with intravenous immunoglobulin (IVIG) for autoimmune cytopenias and LGL expansion was performed. TCR clonality was assessed via TCR-seq in a subset.
 Results:
 Clinical flow analysis reveal a strong association with BMF with expanded BM NK cells (>20% of lymphocytes) and/or circulating NK-LGL or CD8-LGLs (p<0.00001). Strikingly, their abundance was inversely correlated with myeloblast burden (p<0.05). In parallel, we show a major fraction of MDS patients have high abundance of BM-derived CD57+CD8 T cells and NK cells by CyTOF analysis. Further characterization by scRNA-seq and TCR-seq reveal expansion of conventional T cells or CD57+LGLs that bear a profound phenotypic relation to innate-like cells (e.g., expression of NKG2A and/or KIR receptors, CD16A, NKG2D, etc). We compared innate-like CD8 T cells between age-matched controls and LR-MDS patients, and observed a clear qualitative difference in their functional status, where LGL CD8 T cells from LR-MDS patients were strongly activated and expressed significantly higher levels of perforin, granzymes, cytokines and chemokines compared to the same subsets of cells from controls (p<0.0001). Finally, we co-cultured patient BM-derived LGLs with autologous BM cells and demonstrated in vitro killing uniquely in the presence of autologous BM-derived IgG, revealing antibody-dependent cellular cytotoxicity (ADCC) reactivity and an unappreciated axis of autoantibodies engaging LGLs as a clear mechanism of BMF.
 To test the hypothesis that LGL-mediated ADCC might drive BMF, we conducted a retrospective clinical study of IVIG treated MDS patients with severe BMF and abundance of LGLs (N=22) and observed an ORR=73% (16/22). In a subset of nine patients (n=7 with lower-risk MDS) who had serial blood samples available for TCR-Seq, those with confirmed clonality via TCR-Seq had an 80% hematologic and 60% hemolytic response, whereas patients without detectable clonality had only 25% response.
 Conclusion:
 Although the dataset is small and retrospective, it strongly suggests a beneficial effect of IVIG on BMF in patients with expanded NK cells and T cell clones. This clinical response to IVIG is further evidence of the importance of ADCC reactivity and underlying autoimmune signatures in driving BMF, where BM LGLs, comprised of terminally mature CD57+ NK and CD8 T cells, have capacity to kill autologous developing hematopoietic cells. Based on all of our preclinical data, we predict IVIG has a ‘diluting’ effect on the overall abundance of endogenous autoantibodies and their ability to bind antigen and induce ADCC. This strategy to target these cells has the potential to improve peripheral blood counts, patients' quality of life and improved capacity for response to immunotherapies targeting the MDS clone(s).
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/487a001efb78fcaad4458104694c8d2635056e0b" target='_blank'>
              Bone marrow CD57+ LGL cells comprised of NK and CD8 T cells drive bone marrow failure in Myelodysplastic Syndromes
              </a>
            </td>
          <td>
            J. Feld, R. Rai, Kyle Wiatrowski, Richard Sheppard, Haocheng Yu, E. Demakos, Diego Chowell, Jane Houldsworth, Shafinaz Hussein, A. Horowitz, Lewis R Silverman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Dendritic cells (DCs) are essential regulators of adaptive immunity, functioning as professional antigen‐presenting cells that bridge innate sensing with the induction of adaptive immunity and immune memory. The DC population is heterogeneous, encompassing numerous phenotypic subsets depending on the tissue, pathophysiological condition and species studied, which historically complicated their classification. Advances in bulk or single‐cell transcriptomics and ontogenetic studies have clarified DC heterogeneity and highlighted type 1 conventional DCs (cDC1s) for their unique ability to induce protective CD8+ T cell responses against cancer and intracellular pathogens. Beyond immunity, DCs also maintain tolerance to self and harmless antigens. Contrary to earlier assumptions that tolerogenic DCs are simply immature, recent evidence shows that both immunogenic and tolerogenic maturation involve an extensive and convergent reprogramming of cDC1s during the activation process licensing them for shaping T cell responses, a process referred to as DC maturation. This evolving understanding is reshaping how we study DCs, including the necessity to integrate the timing of DC maturation and their microanatomical redistribution during this process. The novel insights these studies are bringing carry significant implications for vaccines or immunotherapies against intracellular pathogens or cancers, and treatments against allergy or autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f0236bce193fec556b42698afce4c36c4c5719f" target='_blank'>
              Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells
              </a>
            </td>
          <td>
            Ramazan Akyol, Marc Dalod
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Neutrophils foster a pro-tumorigenic microenvironment in multiple myeloma (MM) by releasing inflammatory cytokines, immunosuppressive factors, and reactive oxygen species (ROS), contributing to immune evasion and disease progression. Elevated neutrophil-to-lymphocyte ratio serves as a poor prognostic marker, yet neutrophil-targeted therapies remain underexplored. Our prior work identified three novel drug combinations that disrupt both epigenetic regulation and cell cycle control—particularly effective in transcriptionally active, treatment-resistant MM. These combinations also upregulate Smad signaling, indicating potential to reprogram the immune microenvironment and enhance anti-myeloma immunity.
 The CDKi/HDACi combination of dinaciclib and entinostat was identified as a potent combinatorial therapy, as it showed the greatest synergy in treatment-resistant myeloma subtypes and presented higher survival in a murine Vk*MYC; Nras LSL Q61R/+; IgG1-Cre (VQ) allograft mouse model. We investigated the CDKi/HDACi combination for further preclinical development. We explored the targets, mechanism of action, and efficacy of combined CDK/HDAC inhibition in vitro (cell lines) and in vivo (NSG xenografts and Bcl-xL transgenic spontaneous tumors) and confirmed that the combination leads to MYC suppression, upregulation of tumor suppressors like p16, anddelayed tumor progression. Freshly obtained smoldering myeloma patient bone marrow biopsy cells were utilized to evaluate the efficacy of the combination compared to single-agent treatment. The CDKi/HDACi combination was effective at selectively reducing the viability of human CD138+ MM cells ex vivo.Finally, a genetic signature of combined CDK/HDAC inhibition emerged for MM cells. RNA-seq and gene set enrichment analysis revealed downregulation of DNA replication, protein folding, and, importantly,immune pathways, including those related to leukocyte migration and pro-inflammatory chemokines (e.g., CXCL1, CXCL2, IL1A, IL23A). These changes align with the suppression of inflammatory and neutrophil-recruiting signals, suggesting that CDK/HDAC inhibition may indirectly suppress neutrophil activation and trafficking in the MM microenvironment.
 To overcome translational barriers associated with dinaciclib and entinostat, we evaluated next-generation agents: KB0742, a selective and orally bioavailable CDK9 inhibitor, in combination with quisinostat or zabadinostat, two potent HDAC inhibitors with more favorable pharmacokinetic and safety profiles. We validated their synergistic action in limiting proliferation and alteration of biomarker expression. Our next steps are to use co-culture conditions of MM cells with neutrophils, to observe the effects of CDKi/HDAi combination treatment by monitoring neutrophil activation markers, including CD11b and ROS production, compared to single agents. We will further investigate pro-inflammatory cytokines and chemokines involved in neutrophil recruitment and activation (e.g., CXCL1, CXCL2, CXCL8, IL1A, IL23A). These transcriptional changes, accompanied by increased re-expression of tumor suppressors (e.g.,p16) and TGFβ/SMAD signaling components, would predict reprogramming of an anti-inflammatory microenvironment by these combination treatments in myeloma.
 These findings point to a promising but underdeveloped therapeutic avenue whereby suppressing neutrophil-driven inflammation enhances anti-myeloma immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9784fe983e1a8413d51f126d5fbd75b2e2cf4b86" target='_blank'>
              HDAC and CDK inhibitor combinations suppress neutrophil activation in myeloma
              </a>
            </td>
          <td>
            Snehal M Gaikwad, Tyler J. Peat, Wendy Du Bois, Shuling Zhang, Nana Gyabaah-Kessie, Jing Zhang, Dickran Kazandijian, Aleksandra Michalowska, Beverly Mock
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ff39811b58af3141f8b13471490c1f390abe0d9" target='_blank'>
              Non-canonical inflammasome drives intrinsic anti-microbial responses in human Natural Killer cells
              </a>
            </td>
          <td>
            N. G. Leborgne, Jadie Acklam, Alexander J. Hogg, Zarema Albakova, Karen Hogg, K. Robinson, Grant Calder, Arnel Villamin, Callum Robson, Freya Pealing, Matthew A. Care, Monika Gonka, James M. Fox, James Iremonger, J. Hewitson, David G. Kent, Alison M. Layton, Frances E. Pearson, Max E. Noble, W. Grey, Jillian L. Barlow, Dave Boucher
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Central tolerance in the thymus ensures that the developing T cell repertoire is safe yet effective against infections. This process relies greatly on antigen presentation by both stromal and hematopoietic antigen‐presenting cells (APCs), with dendritic cells (DCs) playing a particularly critical role. Thymic DCs acquire a broad spectrum of self‐antigens, including tissue‐restricted antigens (TRAs), inflammation‐associated antigens (ISAs), and peripheral antigens imported via circulation or immigrating DCs. These diverse inputs allow DCs to mediate clonal deletion, regulatory T cell (Treg) induction, and other agonist selection outcomes. In this review, we revisit thymic DCs, outlining their ontogeny, transcriptional control, and functional specialization. We compare thymic DC1 and DC2 subsets with their peripheral counterparts, highlighting their distinct localizations, maturation cues, and division of labor: DC1 excel in cross‐presentation and Treg generation, while DC2 preferentially drive clonal deletion. We also highlight the heterogeneity of DC2s, which consist of four distinct subsets based on their transcriptional and phenotypic programs. We further examine plasmacytoid DCs, transitional DCs, monocytes, and macrophages, which contribute to tolerance through apoptotic cell clearance, antigen transfer, and lineage diversion of thymocytes. Finally, we discuss the role of homeostatic maturation, sterile inflammatory cues, and thymic immigration in shaping APC diversity. Together, these insights underscore the heterogeneity of thymic APCs, the complexity of thymic DC biology, and its vital importance in enforcing immune self‐tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1473206cc1c86ff765811adea927b31445fec7e" target='_blank'>
              Thymic Dendritic Cells Revisited
              </a>
            </td>
          <td>
            Matouš Vobořil, Shuya Xuan, Kristin A Hogquist
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Background: Immunotherapy has transformed cancer care, inducing durable responses in both hematologic and solid tumors. Despite these advances, many patients derive limited benefit, potentially secondary to an immunosuppressive tumor microenvironment (TME), defined by defective antigen presentation, immunosuppressive cell infiltration, and stromal barriers that restrict T-cell trafficking.
 Our group has established the use of mesenchymal stem cells (MSCs) as modifiers of the tumor microenvironment (TME) (Studeny M…Andreeff, Cancer Res 2002; JNCI 2004). We demonstrated in solid tumors that intravenously injected MSCs have the innate capacity to migrate into the TME and contribute to the generation of tumor-associated fibroblasts at the invasive edge of the tumor and their metastases. While MSCs are believed to be immunosuppressive, we hypothesized that they could be modified into immunostimulatory cells and convert a “cold” TME into a pro-inflammatoryTME. In a clinical pilot trial, we demonstrated proof-of-concept that IFNβ-secreting MSCs homed to ovarian tumors and mediated intratumoral IFNβ delivery (NCT02530047)(Andreeff M et al. Cancer Res (2018)78:75).
 Results: We developed an immunotherapeutic strategy using induced pluripotent stem cell–derived mesenchymal stem cells (iMSCs) engineered to secrete IL-7 and IL-15, two potent cytokines selected for their robust immunostimulatory properties. iMSCs, clonally derived from iPSCs, offer superior expansion and scalable production compared to BM-MSCs. These iMSCs retained classical MSC morphology and proteogenomic profiles, supporting their identity and functionality. Telomere length and CyTOF-based cell cycle analysis revealed high proliferative capacity, far superior to BM-MSCs. Stable transgene expression was validated using GFP-tracked clones throughout differentiation and expansion. These iMSCs enhanced bone marrow regeneration following radiation therapy (Okeleji, O et al ASH2025).
 Proprietary gene editing ensured efficient and consistent integration of IL7 and IL15 transgenes, providing a robust platform for cytokine delivery. IL-7/IL-15-iMSCs produced supraphysiological cytokine levels (2,000–4,000 pg/mL), representing a nearly 20-fold increase over levels seen in previously engineered T cells. This enhanced cytokine output drove proliferation of resting and CD3/CD28-activated T cells, as confirmed via CFSE assays. CyTOF profiling revealed robust downstream STAT5 phosphorylation, pS6 activation, and BCL2 upregulation, indicative of efficient IL-7/IL-15 receptor downstream signaling. Hence, immunosuppressive iMSCs were modified to be potent immunostimulatory cells. We applied this concept to high-grade serous ovarian carcinomas (HGSOC). PBMCs conditioned with IL-7/IL-15-iMSCs significantly reduced the number of both platinum-sensitive and platinum-resistant ovarian cancer cells in vitro. To evaluate therapeutic efficacy in vivo, we administered IL-7/IL-15-iMSCs i.p. into the ID8 murine ovarian cancer model in immunocompetent mice. Multiplex immunofluorescence demonstrated that iMSCs home to tumors, secrete cytokines locally, and promote intratumoral T-cell, NK-cell, and macrophage infiltration, collectively leading to prolonged survival. This outcome was associated with a shift from an immune-excluded to an inflamed, immune-infiltrated TME. The ovarian TME was enriched in CD163⁺Arg1⁺PD-L1⁺M2-like macrophages, which exhibited a phenotypic shift toward an M1-like state, marked by Arginase-1 downregulation, in the IL-7/IL-15 treatment group. Experiments investigating activity of IL-7/IL-15-iMSCs in carboplatin-resistant ID8 models are ongoing and will be reported. Results in triple-negative breast cancer will be reported separately (Singh, S et al. ASH2025).
 Conclusion: We demonstrate that IL-7/IL-15-iMSCs display potent in vitro immunostimulatory activity, inducing robust T cell proliferation and activation. IL-7/IL-15-secreting iMSCs convert an immunosuppressive TME into a “hot” milieu, defined by massive T-cell and macrophage infiltration, M1 polarization, and restoration of T-cell functionality. Gene-modified iMSC-induced reprogramming of ovarian TME resulted in reduced tumor burden and improved survival in a murine ovarian cancer model. Results support the potential of IL-7/IL-15-iMSCs as a novel immunotherapeutic platform for overcoming immune resistance in cancer, including hematological malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9ab550875609985f12d7a0a7eb4312645f47adc" target='_blank'>
              Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes
              </a>
            </td>
          <td>
            M. Muftuoglu, Sandeep Singh, Andrea D Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren B. Ostermann, Ivo Veletic, Christopher D. Pacheco, Poo Yee Mak, Edward Ayoub, Taeyun Kim, Kyle M. Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher B. Rohde, M. Andreeff
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="


 Introduction: The bone marrow (BM) microenvironment supports survival of the malignant multiple myeloma (MM) cells and is composed of cellular components that foster MM development and progression by suppression of immune responses. Despite major progresses in understanding the MM biology and pathophysiology, it is still incurable. Myeloid cells are well-described to suppress antitumor immunity (Barry et al., 2023; De Sanctis et al., 2023). However, the molecular mechanisms to achieve immunosuppressive myeloid cell states are unknown. Cytokine IL-4 is the primary driver of tumor infiltrating monocyte-derived macrophage (MO-MAC) phenotype as reported by LaMarche that deletion of IL-4Rα alone within early myeloid progenitors in BM reduced tumor burden; while deletion in downstream mature myeloid cells had no effect (LaMarche et al., 2024). Mechanistically, IL-4 derived from BM basophils and eosinophils acted on granulocyte-monocyte progenitors (GMPs) to transcriptionally program the development of immunosuppressive tumor-promoting myeloid cell.Hematopoietic Adaptor-Containing SH3 and SAM domains (HACS1) maps to a region on chromosome 21 that is frequently disrupted in hematopoietic malignancies, suggesting its involvement in these diseases (Claudio et al., 2001). Previously, we showed that Hacs1 is involved in MM development through changes of its microenvironment. It regulates IL4 signaling in B cell, T cell, macrophages and dendritic cells and affects their function (Wang et al., 2010). Hacs1-/- bone marrow derived macrophages (BMDMs) are hyper-responsive to IL-4 stimulation and display an alternative activation M2 phenotype. We found CD11b+/Gr-1+/ CD31+/Siglec F myeloid progenitors as well as immature myeloid progenitors and eosinophils were significantly increased in Hacs1-/- mouse bone marrow.
 Method: In the current study, we investigated the role of Hacs1 in MM immunosuppressive microenvironment utilizing Hacs1-/-mouse BM-myeloid derived suppressor cells (MDSCs) as well as MM tumor-bearing mice to study MM progression and therapeutic resistance.
 Results: Our results showed Hacs1-/-mouse bone marrow in MM tumor-bearing mice has upregulated PD-L1 expression in MDSCs, suppressing T cell function. Overexpression of Hacs1 or stimulation Hacs1 reduces MDSC accumulation, resulting in elevated T cell activity and reduced tumor load. Our data suggest that Hacs1 plays a key role in regulation of the immunosuppressive microenvironment in MM. Furthermore, myeloid cells from Hacs1-/-mouse BM have increased expression of MS4A3 gene, a key gene regulating cell differentiation to monocytic/granulocytic-myeloid-derived suppressor cells (M-MDSCs and G-MDSCs, respectively) (Liu et al., 2019). At the mechanistic level, MS4A3 enhances IL-3 and GM-CSF signaling in Hacs1-/-BM CD34+ cells, compared to Hacs1+/+cells.Conclusion: These data suggest that Hacs1 negatively regulate IL-4 signalling axis in bone marrow and drives pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling. Hacs1 is a key player in cellular signaling within the immune system with roles in immune regulation, cancer development, and potential serves as a MM therapeutic target.
 Keywords: Hacs1-/-, Multiple Myeloma, myeloid derived suppressor cells (MDSCs), bone marrow microenvironment, chemo resistance
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f2d0467e47b26436ae5260ef710bda44c102442" target='_blank'>
              Title: Hacs1 is a myeloma immunosuppressor driving pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling
              </a>
            </td>
          <td>
            Dingyan Wang, Xiao-Yan Wen, Jamie Li, Raymond Qu, Wiiliam JiaYi Wu, Xinmiao Andrew Yang, Derek Shiqi Xu, Jingdong Wu, Leqi Shen, Jeremy Dai, Yuan Gao, Jinyi Zhang, Anthony Gramolini Gramolini, Xiaoyuan Liu, K. Siminovitch, Keith Stewart
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Monocyte derived macrophages (MDMs) comprise a major cellular fraction of the brain metastatic breast cancer (BMBC) tumor microenvironment (TME), however, their role in BMBC growth and response to therapeutics remains elusive. We developed heterotypic three-dimensional (3D) co-culture spheroid platform of triple negative BMBC cell line MDA-MB-231Br or BMBC patient xenograft derived cell line F2-7 and THP1 monocytes and assessed the impact of monocytes/MDMs on BMBC proliferation, immune modulation, and response to paclitaxel. BMBC cell and monocyte interactions enhanced BMBC cell proliferation and upregulated markers pertaining to M2 macrophage, immune suppression and evasion. Additionally, F2-7 and monocyte co-culture upregulated M1 macrophage and both pro- and anti-inflammatory markers. Co-culture spheroids exhibited higher resistance to paclitaxel as compared to monoculture BMBC spheroids. Our 3D co-culture platform successfully recapitulated to an extent the pro-tumorigenic, immunosuppressive, therapy resistant TME, and tumor immune heterogeneity of BMBC and could contribute towards understanding tumor immune interactions in BMBC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0cfa4d858167de2fc2fe4156990547cb6f78eb42" target='_blank'>
              Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer
              </a>
            </td>
          <td>
            S. Gurung, Kyra Berger, Shreyas S Rao
          </td>
          <td>2025-12-01</td>
          <td>NPJ Breast Cancer</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Atherosclerosis remains the primary driver of cardiovascular and cerebrovascular morbidity and mortality. A pivotal event in its pathogenesis is the phenotypic conversion of vascular smooth muscle cells (VSMCs), particularly the transition from a contractile to a macrophage‐like state. Using a murine model of atherosclerosis, we demonstrate that this process is orchestrated by a progressively disrupted perivascular immune milieu characterized by an expansion of CD44⁺ memory CD4⁺ T cells at the expense of CD44− naive CD4⁺ T cells. Within this niche, CD44⁺ natural regulatory T cells (nTregs) actively promote VSMCs macrophage‐like reprogramming, whereas their CD44− counterparts exert an opposing, protective effect. Reciprocally, macrophage‐like VSMCs foster the trans‐differentiation of nTregs into pathogenic Th17 cells, amplifying vascular inflammation. In contrast, induced Treg cells (iTregs) display phenotypic stability and potently inhibit VSMCs macrophage‐like switching, restrict pathological VSMCs migration, and curtail VSMCs survival. Systemic infusion of iTregs selectively remodels the perivascular immune microenvironment toward an antiatherogenic profile. Adoptive transfer of iTregs at early disease stages decreased the abundance of macrophage‐like VSMCs, attenuated plaque burden, and these benefits were partially mediated by transforming growth factor β signaling. Collectively, iTreg‐based cellular therapy represents a promising strategy to intercept VSMCs macrophage‐like transformation and limit atherosclerotic progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f53dac592bfbe7181b6731e2e832bb43126fb9b5" target='_blank'>
              Infusion of Induced Regulatory T Cells Alleviates Atherosclerosis by Reducing Pathological Macrophage‐Like Vascular Smooth Muscle Cells
              </a>
            </td>
          <td>
            Ximei Zhang, Ye Chen, Yesheng Ling, Lin Wu, Ding-hui Liu, Linli Wang, Yong Liu, Guang-yao Shi, Bin Zhou, Bao-shun Hao, Zhenda Zheng, Shujie Yu, Min Wang, Jun Zhao, Donglan Zeng, Julie Wang, Yan Lu, Jun Tao, Wenhao Xia, Song Guo Zheng, Xiaoxian Qian
          </td>
          <td>2025-10-22</td>
          <td>MedComm</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Inflammatory bowel diseases (IBD), including Crohn´s disease (CD) and ulcerative colitis (UC) remain highly prevalent and are associated with a reduced quality of life in affected patients. The pathophysiology of IBD is multifactorial since genetic predisposition, altered immune function, changes in intestinal microbiota, environmental factors, and loss of intestinal barrier function together induce disease manifestation. A critical key factor is the dysregulation of the immune system which explains that all medical therapeutic approaches target the immune response. However, the success of these therapies is limited and associated with severe side effects which demonstrates the need for novel therapeutic approaches. Previous research demonstrated that CD4+ regulatory T (Treg) cells are important regulators of intestinal homeostasis but are reduced in number and function relative to effector T cells in IBD. This led to the concept that genetically engineered, antigen-specific Tregs may represent a promising strategy to address immune dysregulation in IBD. Due to their antigen specificity, chimeric antigen receptors (CARs) enable additional target-dependent activation and migration of Tregs at disease sites. While CARs are increasingly established for the generation of antigen-specificity for T cell therapies in cancer, the implementation of CARs for IBD is in a preliminary state. Nonetheless, CAR constructs specific to circulating carcinoembryonic antigen (CEA), flagellin, or IL23R have been developed recently for potential application in IBD. Based on these novel developments, this review will discuss the role of Tregs in IBD disorders and present the current state of CAR Treg models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ca608e891981776bd2aa9079f1b66c12af72c13e" target='_blank'>
              Opportunities and challenges harnessing antigen-specific CD4+ regulatory T cells in inflammatory bowel disease
              </a>
            </td>
          <td>
            Jessica Kümmel, Nicolas Schlegel, Johanna C. Wagner
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="
 Chordomas are malignant notochordal remnant tumors resistant to standard therapies. Using single-cell RNA-sequencing and spatial transcriptomics, we identified that the chordoma immune landscape is marked by macrophage-rich infiltrates and T-cell dysfunction. Furthermore, we reconstructed a differentiation pathway showing that naïve and memory T-cells in the blood transition into cytotoxic and eventually exhausted T-cells within the tumor, suggesting that immunotherapies may offer benefit despite clinical responses thus far being limited. Profiling chordomas with multiplex immunofluorescence (n=34), we found that immune cells were not randomly distributed but rather accumulated in fibrous septa, and inter-immune cell distances were much closer in fibrous septa versus tumor-resident regions. Using patient-matched (n=2) surgical chordoma specimens obtained before and after nivolumab treatment, a programmed death-1 (PD-1) blocker, we used multiplex imaging to investigate how the tumor microenvironment (TME) shapes immune suppression and therapy resistance through spatial sequestering of immune cells in fibrous septa. All patients had disease progression after PD-1 blockade, and spatial analysis revealed that although there was increased density coverage of CD4+ and CD8+ T-cells around tumor cells, only the proportion of CD8+ T-cells increased minimally from 0.001 to 0.003 (p=0.0010) as a function of nivolumab treatment. Additionally, while the distance between immune cells decreased after treatment, the distance between immune cells and tumor cells increased, reflecting physical confinement of immune cells in fibrous septa. Using treatment-naïve chordoma specimens (n=3), we then characterized the single-cell composition of fibrous septa. Correlating immunofluorescence staining of extracellular matrix (ECM) markers with histological architecture, we identified Type I collagen as a reproducible marker for fibrous septa. Multiplex imaging showed close spatial interactions between fibroblasts and CD8+ T-cells and sequestering of immune cells in collagen-rich tumor stroma. Overall, these data suggest that the intra-tumoral fibrous septa of chordomas are not passive structural elements, but dynamic immune microenvironments shaping T-cell dysfunction.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/97fb56885d0283f35f7ba09b907fdd2e2c7d8e5d" target='_blank'>
              IMMU-50. Spatial Immunophenotypic Characterization of Immune Exclusion and Dysfunction via Collagen-Rich Fibrous Septa in Chordomas
              </a>
            </td>
          <td>
            Rebecca Du, V. Arrieta, Jasim K Benotbatme, Sachin Govind, K. Habashy, H. Najem, G. Vázquez-Cervantes, Si Wang, Joshua Katz, Hanxiao Wan, Alina R Murphy, Pouya Jamshidi, C. Horbinski, A. Sonabend, A. Heimberger, James P Chandler, J. Wolinsky, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified four bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across four activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 hours. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune Checkpoint Expression in Mucosal-Associated Invariant T (MAIT) Cells is Stimulus-Dependent.
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of leukocyte biology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="
 The tumor microenvironment of glioblastoma is dominated by immunosuppressive microglia/macrophages that dampen anti-tumor immunity, comprising a major barrier to effective immunotherapy. Developing strategies to reprogram these macrophages is essential to overcome treatment resistance. Bacterial extracellular vesicles (bEVs) are secreted nano-sized (~25–100 nm) particles that modulate myeloid cell activity in a species-dependent manner. We developed a scalable strategy to purify bEVs from the human commensal Escherichia coli Nissle strain consisting of: tangential-flow filtration, Benzonase depletion of free nucleic acids, and size-exclusion chromatography, yielding ~3.5 mg of bEV-associated protein per liter of culture. E. coli Nissle bEVs activated NF-κB and IRF pathways in THP-1 dual-reporter monocyte-derived cells in a dose-dependent manner, with an ED50 approximately seven-fold lower than that of purified LPS or heat-killed bacteria, indicating a distinctly higher potency. We further depleted free LPS that may co-isolate with bEVs, and noted a ~3000-fold reduction in LPS content, with less than 10% protein loss. LPS-depleted bEV bioactivity surpassed LPS amount-matched crude bEVs, supporting that bEV, not residual copurifying LPS, drove the observed in vitro bioactivity. bEVs activated peripheral-blood mononuclear cell-derived CD11b⁺CD68⁺ macrophage-like cells at concentrations as low as 1 ng/mL, while lymphocyte populations experienced minimal effects, in line with bEVs acting primarily on myeloid cells. We next treated M-CSF, IFNγ, and IL-4 polarized human monocyte-derived macrophages with bEVs. In IL-4 polarized (M2-like) macrophages, bEVs induced a more pronounced M1-like reprogramming compared to IFN-γ treatment, increasing CD38, CD80, and CD86 while decreasing CD47 and CD206. This reprogramming persisted even at sub-ED50 concentrations, as low as 0.6 ng/mL. Collectively, this workflow consistently yielded bioactive bEVs that robustly reprogram macrophages. Future work will test the ability of bEVs to reprogram GBM-associated microglia/macrophages, with the ultimate goal of combination with immunotherapies to overcome treatment resistance in the immunosuppressive GBM microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/314efedf3ab7696248eb4216de5020641b87b2b2" target='_blank'>
              IMMU-16. Development of high-purity bacterial extracellular vesicles for suppressive myeloid cell reprogramming in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Irem Karaman, Justin Ruiz, O. T. Pumar, Asmita Pathak, Jonathan Mitchell, B. León, Selma Maacha, Wael El-Rifai, Defne Bayik, Dionysios C. Watson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet resistance and immune-related adverse events (irAEs) remain significant challenges. γδ T cells and B cells are recognized as critical players in the tumor microenvironment (TME), but their roles in shaping T cell phenotypes and contributing to ICI resistance are not fully understood. Using syngeneic tumor models in autoimmune-prone NOD mice, which enable simultaneous profiling of tumor immunity and autoimmunity, we investigated mechanisms underlying ICI sensitivity and resistance. In the resistant tumor model, CD8+ T cells exhibit a naïve phenotype, with elevated TCF-1 expression and reduced activation markers such as PD-1 and CTLA-4. In contrast, activated CD8+ T cells dominate the sensitive tumor model, highlighting T cell phenotypes as key drivers of ICI responses. Further analyses implicated γδ T cells and B cells in these divergent responses. Depleting γδ T cells in the resistant model significantly improved tumor control, underscoring their role in mediating resistance. Conversely, CD8+ T cell activation was enhanced in B cell-deficient mice, suggesting B cells may restrict antitumor immunity. Together, these findings provide critical insights into the interplay between T cells, γδ T cells, and B cells within the TME and highlight potential therapeutic strategies to overcome ICI resistance without inducing irAEs.



 National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number: T32AI138945



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a88c64fd65f389029580f6961ad4a61916ee0e46" target='_blank'>
              The Interplay Between γδ T cells and B cells Contributes to Immune Checkpoint Inhibitor Resistance 3426
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Persistent antigen exposure, a hallmark of chronic infections and tumors, drives the formation of a distinct population of CD8+ T cells, known as exhausted CD8+ T (TEX) cells, with increased expression of immune checkpoint molecules and reduced effector function. Immune checkpoint inhibition (ICI) therapy has emerged as a powerful tool to reinvigorate the function of TEX cells. However, despite the immunostimulatory effects of radiotherapy (RT), combining RT with ICI has yielded modest clinical benefits in cancer patients. While the success of ICI therapy largely depends on the presence of progenitor TEX cells, the impact of high-dose ionizing radiation (IR) on the TEX population, particularly enriched within the treatment field, remains understudied. Here, we show that chronically infected mice with LCMV-Clone 13 subjected to sublethal whole-body irradiation (WBI) exhibited a lasting numerical decline and impaired antigen-specific function in their TEX cells. Using single-cell RNA sequencing and multiparameter flow cytometry, we observed that WBI gradually altered the subset composition of surviving TEX cells, highlighted by the loss of progenitor and effector-like TEX cells while terminally-exhausted TEX cells were enriched. Lastly, WBI rendered ICI therapy less effective in rescuing TEX cells and decreasing viral burden. These findings provide important insights into how high-dose IR alters the fate of TEX cells, potentially impairing their responsiveness to ICI therapy.



 Supported by NIH Grants GM134880, AI114543



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ef55b305a83cb203c9064f70e6ab8c59e03b2320" target='_blank'>
              Ionizing radiation impairs the efficacy of immune checkpoint inhibition by driving terminal exhaustion of progenitor exhausted CD8+ T cells 4054
              </a>
            </td>
          <td>
            Mohammad Heidarian, S. Kannan, Xin Zhao, M. Mix, Hai-Hui (Howard) Xue, John T. Harty, V. Badovinac
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>53</td>
        </tr>

        <tr id="Decades of experimental work have helped define the heterogeneity of the various cell types that compose the immune system. The different cell types arise from distinct hematopoietic stem and progenitor cells in a coordinated fashion during ontogeny, providing a set of diverse cells that contribute to host defense. Cells can also differentiate into different subsets in response to the cytokine and tissue environment, creating a level of cellular heterogeneity that helps direct the nature and magnitude of the immune response. Here we are discussing a variation whereby cellular heterogeneity arises due to the expression of X‐linked immune genes that escape X chromosome inactivation, giving an advantage to a subset of cells more prone to respond to stimulation by external (pathogens) but also internal signals (i.e., mechanosensing). Interestingly, these inflammatory subsets are much more likely to be differentially enriched in patients with autoimmunity or inflammatory diseases which are well known to be predominant in females. We are using plasmacytoid dendritic cells (pDCs) as a model cell type, as these cells are a rare but critical subset of innate immune cells, with a rapid and massive capacity to produce type I IFNs (IFN‐I) upon sensing of nucleic acids from pathogens, but also from the self, and these cells have been linked to the pathogenesis of many autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98b5143104584df960a1c460b9d9fe7799416cad" target='_blank'>
              Escape From X Chromosome Inactivation as a Driver of Plasmacytoid DC Heterogeneity in Health and Disease
              </a>
            </td>
          <td>
            Franck J. Barrat, J. Guéry
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="


 Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting can be detrimental, as recent evidence shows that inflammatory macrophages are essential to support CAR T-cell activity. We therefore identified CD123 as selectively expressed on immunosuppressive TAMs, making it a promising target to remodel the TME. Meanwhile, B7-H3 is a tumor-associated antigen that is broadly expressed in pHGGs, making it an ideal target for CAR T-cell therapy. We now hypothesize that dual targeting of CD123+ TAMs and B7-H3+ tumor cells would synergistically deplete suppressive myeloid populations, restore T-cell function, and enhance anti-tumor efficacy.



 To evaluate the therapeutic potential of CD123 and B7-H3 dual CAR T-cell therapy in modulating the TME, preserving supportive myeloid subsets, and enhancing anti-tumor efficacy in pHGG.



 Using immunocompetent pHGG models, we tested CD123 and B7-H3 CAR T-cells through in vitro cytotoxicity, antigen stimulation, and co-cultures with bone marrow–derived M1 or M2 macrophages. In vivo, CD123 CAR T-cells were administered intratumorally as monotherapy or in combination with B7-H3 CAR T-cells. Endpoints included TAM depletion, phenotypic and transcriptomic TME remodeling, tumor progression, and survival.



 CD123 CAR T-cells exhibited minimal cytotoxicity against B7-H3+ glioma cells but selectively depleted M2-like TAMs in vitro and in vivo. M2 macrophages suppressed B7-H3 CAR T-cell persistence in vitro; this suppression was reversed by co-treatment with CD123 CAR T-cells. Dual CAR T-cell therapy significantly enhanced anti-tumor activity, reduced myeloid and microglial infiltration, and extended survival in vivo.



 Targeted depletion of CD123+ TAMs enhances B7-H3 CAR T-cell efficacy by mitigating immunosuppressive signaling while preserving beneficial myeloid support. This dual-targeting strategy offers a mechanistically guided approach to overcoming TME-driven resistance in DIPG and other pHGG.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43e9945f878d4e3f16528ee181777513363175aa" target='_blank'>
              EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Paulina Velsquez, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Introduction: Relapsed and refractory hematologic malignancies remain a significant clinical challenge despite integration of newer therapeutic strategies engaging the immune system as standard of care. As such, identifying and characterizing specific defects in the anti-tumor immune response will be key to the development of newer therapies that improve survival. We have previously reported that the immune checkpoint Siglec-15, a member of the sialic acid binding immunoglobulin-like lectin family of proteins, is overexpressed in hematologic malignancies and circulates at high levels in the plasma of children in leukemia. Importantly, inhibition of Siglec-15 restored local anti-tumor immune responses and abrogated tumor progression highlighting a crucial role for Siglec-15 in immune evasion in murine models of leukemia and lymphoma. However, the mechanism(s) by which Siglec-15 promotes immune escape and leukemogenesis has not yet been defined. Here we investigate how Siglec-15 creates an immunosuppressive immune microenvironment through aberrant hematopoiesis in a murine model of leukemia.
 Methods: Using a well-established model of murine B-cell acute lymphoblastic leukemia (B-ALL), control (Cas9) or CRISPR knockout Siglec-15 BCR-ABL1+cells wereinjected into un-irradiated, immune competent (wild type, WT) or immune deficient (Rag1-/-) C57BL/6 mice and single cell RNA sequencing (scRNA seq) performed on paired bone marrow (N=4/group) and spleen (N=4/group) samples. To validate scRNA findings, multiparameter flow cytometry was performed to determine impact of knockout of Siglec-15 on hematopoiesis and innate immune subsets.
 Results: scRNA seq suggests that knockout of Siglec-15 in B-ALL restores circulation of mature neutrophils that are associated with an anti-tumoral, pro-inflammatory phenotype as compared to control where there are predominantly more immature neutrophils that have a pro-tumoral and immunosuppressive gene signature. With Siglec-15 KO, there is increased expression of genes such as Egr1, Ccl6, Klf6 that are known to promote neutrophil differentiation, pro-inflammatory cytokine production and recruitment to tumor sites. By flow cytometry, there is an increase in pluripotent stem cells in the bone marrow of Siglec-15 knockout mice (p<0.01, one-way ANOVA, n=10 mice/group) compared to control. Further, there is increased skewing to myeloid primed multipotent progenitors, MPP2/3 and FCyR+ MPP3, with Siglec-15 knockout (p<0.01, one-way ANOVA, n=10 mice/group). Interestingly, there is no expansion of the immediate myeloid precursors, common myeloid precursors and granulocyte -monocyte precursors, in control mice, there is a significant decrease with knockout of Siglec-15 (p<0.001). However, we observe an increase in innate and adaptive effector immune cells, including neutrophils, B and T cells, in the bone marrow and spleen of knockout mice.
 Conclusions: We have found that there are significant Siglec-15 dependent changes in the bone marrow and spleen in B-ALL by scRNA sequencing. Preliminary data suggests that Siglec-15 may promote aberrant myelopoiesis in murine model of B-ALL at early time points. Ongoing experiments aim to examine the extent to which B-ALL promotes aberrant myelopoiesis in children. Together, these data implicate Sig-15 as an immune checkpoint that may be inhibited therapeutically to promote an immune response to leukemia cells.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/da7888656dfb2e3a70892bf153bf689cc4183854" target='_blank'>
              Siglec-15 dependent alteration of the leukemia immune microenvironment
              </a>
            </td>
          <td>
            Dailia B. Francis, Marina E. Michaud, Jodi Dougan, Miyoung Lee, Manoj K. Bhasin, Christopher Porter
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="
 Introduction:
 Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate immune cells against tumor cells but can cause immune related adverse events such as myocarditis, a serious side effect with up to 40% case fatality rate. We hypothesize that cardiac fibroblasts and cytotoxic T-Cells work in tandem to direct inflammation in the setting of ICI treatment, resulting in myocarditis.


 Methods:
 To study the role of CFBs in ICIM, we first examined fibroblast behavior
 in vivo
 through picrosirius red staining for cardiac fibrosis. We then cultured C57BL/6 murine CFBs and treated them with cardiac serum acquired from a genetic mouse model of ICIM and analyzed
 Cxcl9
 expression by qPCR. Additionally, we stimulated CFBs with media or IFNγ for 24 hours (uCFBs and sCFBs respectively) before co-culturing them with CD8 CXCR3hi T-Cells for 6 hours, after which we analyzed
 Cxcl9
 and
 Cxcl10
 CFB expression by qPCR (Fig 1C) and T-Cell cytotoxicity by flow cytometry (Fig 1D/E). We next examined CD8 T-Cells harvested from C57BL/6 mice treated with combination immunotherapy to induce ICIM via single-cell sequencing to investigate potential axes of T-Cell/CFB crosstalk
 in vivo
 .


 Results:
 Our picrosirius red staining revealed a significant increase in cardiac interstitial and perivascular fibrosis, suggesting that CFBs are inflammatorily active and fibrotic in the context of ICIM (Fig 1A). We demonstrated that treating CFBs with ICIM cardiac serum results in a significant upregulation of CXCL9 by qPCR (Fig 1B). Utilizing our co-culture system, we demonstrated that the presence of CD8 CXCR3hi cytotoxic T-cells significantly increases CXCL9/10 expression compared to both control and IFNγ stimulation, underscoring the importance of T-cell presence in CFB activation (Fig 1C). We also used flow cytometry to confirm the cytotoxic quality of the T-Cells used in our co-culture system (Fig 1D/E). Using single-cell sequencing, we identified a cluster of CXCR3hiVLA4hi CD8 T-Cells from ICI-treated myocarditis mice (Fig 1F.) which are highly cytotoxic compared to other clusters (Fig 1G.), demonstrating that VLA-4:VCAM-1 signaling between T-cells and CFBs may act as a critical driver of cytotoxicity in the heart.


 Conclusions:
 Our findings position cardiac fibroblasts as potentially critical drivers of T-Cell migration and increased cytotoxicity in the context of ICIM, rendering this crosstalk an important direction of study in future of understanding and treating ICIM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f55ccb863bc3d94fa9ccdf7c648353cb039d3ca" target='_blank'>
              Abstract 4369397:
 Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis
              </a>
            </td>
          <td>
            Noah Wagner, Maria Rosaria Vitale, Yin Sun, Maria Zambrano, Abraham L. Bayer, Pilar Alcaide, Javid Moslehi, Han Zhu
          </td>
          <td>2025-11-04</td>
          <td>Circulation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="
 Glioblastoma (GB) is recalcitrant to immunotherapy due to severe CD8⁺ T cell exclusion and abundance of immunosuppressive tumor-associated macrophages (TAMs). Defining the mechanisms of immune evasion in GB is essential for identifying therapeutic vulnerabilities. Here, we unveil dural nociceptors—pain-sensing sensory neurons—as critical, noncanonical drivers of immune evasion in GB. We demonstrate that dural nociceptors are activated and reprogrammed by soluble factors present in GB-associated cerebrospinal fluid. In syngeneic orthotopic GB murine models, ablation of nociceptors significantly improves survival, enhances anti-tumor immune responses, and sensitizes otherwise unresponsive tumors to immune checkpoint blockade therapy (ICBT). Mechanistically, GB-associated dural nociceptors secrete elevated levels of the immunomodulatory neuropeptide calcitonin gene-related peptide (CGRP). Single-cell RNA-sequencing analyses of human GB samples show that RAMP1, the receptor subunit for CGRP, is selectively expressed on TAM subsets with pronounced immunosuppressive features. Using macrophage-specific RAMP1 conditional knockout (cKO) mice, we found that RAMP1 deletion in TAMs significantly prolongs survival of GB-bearing mice, reduces TAM immunosuppression, and enhances CD8⁺ T cell infiltration and effector function while limiting exhaustion. This survival benefit is lost with CD8⁺ T cell depletion, highlighting the key role of CGRP-driven TAM–T cell crosstalk in shaping anti-tumor immunity. Importantly, GB-bearing cKO mice exhibit markedly improved responsiveness to ICBT. At the molecular level, we uncover a strong reciprocal antagonism between CGRP and interferon-gamma (IFN-γ) signaling that dictates TAM fate. CGRP inhibits IFN-γ–induced STAT1 activation, while IFN-γ blocks CGRP-driven cAMP levels and downregulates RAMP1 expression. CGRP acts as a neural cue that imprints immunosuppressive features in TAMs by blocking their sensitivity to IFN-γ, a critical pro-inflammatory cytokine required for anti-tumor immunity, at transcriptional and epigenetic levels. Thus, the CGRP–RAMP1 axis represents a hijacked neural circuit driving immune evasion in GB and offers a translatable strategy to restore immunotherapy response by repurposing FDA-approved CGRP antagonists.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9270ae1ee1b759973548b67c05e73c8236d6b169" target='_blank'>
              IMMU-68. Glioblastoma co-opts dural nociceptors to drive immune evasion and immunotherapy resistance
              </a>
            </td>
          <td>
            Suman Asalla, Omar Santiagonunez Ahumada, Jordan E. Krull, Yan Wang, Disha Patel, Tom Liu, Samiksha Prasanna, Andrew Jerome, Shuo Chen, Andreas Wieland, Pierre Giglio, Benjamin M. Segal, Qin Ma, Nandini Acharya
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 During a recall immune response, memory B cells differentiate into plasma cells (PCs), which are indispensable for antibody production and humoral immunity. Furthermore, memory B cells proliferate sooner and require less stimulation to differentiate into PCs relative to naïve B cells and can thus be considered ‘poised’. The exact mechanisms explaining this discrepancy remain incompletely understood. Our lab has previously observed that mouse Marginal Zone (MZ) B cells are analogously ‘poised’ to become PCs relative to Follicular (FO) B cells. Transcriptomic analyses have shown that MZ B cells are enriched for hallmark mTORC1 signaling, unfolded protein response (UPR) pathway, and Myc target gene signatures compared to FO B cells, which are all required for PC differentiation. We hypothesized that these same gene signatures would be enriched in human memory B cells. From a cohort of healthy human donors, RNA-sequencing was performed on splenocytes. Indeed, we observe these same hallmark gene signatures enriched in memory B cells along with others involved in the synthesis of ribosomal proteins and translation. These results suggest that human memory B cells are better equipped to produce massive amounts of proteins that involve mTORC1 and Myc activity along with the UPR pathway, all of which are needed for antibody production by PCs. The better we understand PC differentiation mechanisms, the higher potential they can be manipulated for clinically relevant purposes.



 5RO1AI175185-02 - Biochemical Mechanisms for Sustained Humoral Immunity



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dd3d5c1fdc51b8e4993b6ad53828921baab12d6d" target='_blank'>
              Are human memory B cells ‘poised’ to become plasma cells? 4156
              </a>
            </td>
          <td>
            Isaiah Rozich, Brian T. Gaudette, Jennifer Londregan, David Allman
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Activation of the stimulator of interferon genes (STING) modulates cellular responses in a cell-context-dependent manner. Intrinsic IFN-stimulated gene (ISG) expression enhances cellular responses to STING activation. We previously demonstrated that chronic myelomonocytic leukemia (CMML) is characterized by cell-intrinsic ISG upregulation. While STING-activation can mediate hematopoietic stem-cell (HSC) self-renewal or exhaustion and CD14+-monocyte depletion, the distinct effects of acute, short-term and long-term STING activation in distinct clonal hematopoietic populations remains unclear.
 Therefore, we sought to evaluate the effects of STING activation dynamics in normal and CMML HSC and monocyte populations. To do so we first treated BM mononuclear cells (MNCs) from patients (pts) with CMML (n=11) or healthy donors (HDs, n=6) in co-culture with mesenchymal stromal cells with a STING agonist (dazostinag). Given that monocytic lineage is characterized by high expression of cysteine-cysteine chemokine receptor 2 (CCR2), MNCs were also treated with TAK-500, an IgG1 anti-CCR2 antibody linked to a STING agonist payload, to evaluate the specific effects of STING activation in monocyte populations. Dazostinag or TAK-500 depleted total and CCR2+ MNCs from CMML pts but not from HDs Accordingly, STING activation with dazostinag or TAK-500 induced a dose-dependent depletion of monocytic cell lines (MOLM13, THP1) through IRF3 phosphorylation and caspase 3 cleavage. To evaluate if acute STING activation impairs CMML's HSPCs repopulation potential we performed colony-formation studies in BM CD34+ cells from CMML pts (n=8) and observed that TAK-500 and dazostinag impaired myeloid, but not erythroid, colony-formation.
 We previously reported that Vav-KDM6B/Tet2f/f/Vav-Cre (KDM6B/Tet2)mice recapitulate features of CMML. Single-cell RNA-sequencing (scRNA-seq) of MNCs from these mice and control (Vav-cre) mice confirmed myeloid bias and expansion of CCR2+ monocytes that upregulate IFN response genes and inflammatory signals in KDM6B/Tet2 mice. BM CCR2+ monocyte expansion in KDM6B/Tet2 mice was confirmed by flow cytometry. Therefore, to evaluate the effects of acute STING activation in vivo, we treated KDM6B/Tet2 mice with a single dose of TAK-500. TAK-500 enhanced CCR2+ BM cell apoptosis and reduced LSK colony formation capacity. In vivo depletion of MOLM-13 and human CD45+ cells was also observed after acute TAK-500 treatment in xenograft models and in a CMML patient-derived xenograft model, respectively.
 To dissect the effects of short-term STING activation, we then treated KDM6B/Tet2 mice with vehicle or TAK-500 weekly for 3 consecutive weeks. Therapy was associated with peripheral blood monocyte depletion, BM CCR2+ cell depletion, and apoptosis. TAK-500 also induced LSK expansion and depletion of granulomonocytic, common-myeloid, and megakaryocytic/erythroid progenitors. LSK expansion with reduced colony-forming capacity and CD14+ monocyte differentiation was sustained in colony-formation assays. Bulk RNA-sequencing of sorted LSKs demonstrated downregulation of genes involved in RNA metabolism and translation, G1/S transition and neutrophil degranulation, suggesting reduced cell activity and differentiation. scRNA-seq of BM MNCs after 3 weeks of therapy confirmed depletion of CCR2+ cells, myelomonocytic precursors and monocyte populations with TAK-500 but not with vehicle. STING activation induced type I IFN gene expression (e.g Irf7) in monocytes and splenic extramedullary hematopoiesis. Analysis of cell-cell communication networks revealed increased number of interactions involved in cell migration, inflammation and immune interactions between monocyte and other cell types.
 To compare the effects of short vs long-term STING activation, we treated control and KDM6B/Tet2 mice with TAK-500 over a period of 14 weeks. In contrast to short-term STING activation, long-term TAK-500 exposure was not associated with CCR2+ cell depletion, changes in LSK or progenitor populations or transformation in KDM6B/Tet2 mice. scRNA-seq of MNCs revealed decreased expression of inflammatory genes on monocyte and progenitor populations compared to short-term exposure which suggests cell-adaptive responses to overcome inflammatory and cell death programs associated with acute STING activation.Together, these data highlight the complex effects of STING activation dynamics in distinct hematopoietic populations and their role in CMML pathophysiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d404567ac411e598fe7813e54939096a5ebec9" target='_blank'>
              Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
              </a>
            </td>
          <td>
            Yue Wei, Xiaoping Su, Ziyi Li, S. Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alexander Parent, N. Lineberry, Siddha Kasar, G. Garcia-Manero, G. Montalban-Bravo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>141</td>
        </tr>

        <tr id="The tumor microenvironment (TME) plays a critical role at all stages of tumor progression. Cancer-associated fibroblasts (CAFs), as the main components of this environment, display diversities in origin, phenotype, and function, which contribute to cancer progression by regulating the tumor cell biology via cell–cell contact, releasing numerous regulatory elements such as growth factors (GFs), cytokines, and chemokines, and even remodeling the extracellular matrix (ECM). In this Review, we discuss the current understanding of CAFs’ pro- or anti-tumor functions in various hematological malignancies, including acute and chronic leukemia, lymphoma, and multiple myeloma (MM). The accumulating evidence highlighted that CAFs not only are implicated in these neoplasms’ initiation, development, and metastasis but also are involved in chemoresistance to various chemotherapy drugs such as daunorubicin and bortezomib. Intriguingly, cell culture-based methods’ results outlined that targeting signaling pathways that are used by CAFs to exert their pro-tumorigenic effects could be exploited in favor of tumor inhibition, which requires more investigation. Therefore, this therapeutic approach should be considered in future studies to develop a novel targeted therapy in hematological malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9c626fb73b1c7437edf3b7ee6bad0590c30c6a7c" target='_blank'>
              The emerging role of cancer-associated fibroblasts in hematological malignancies: from their influence on tumor progression and drug resistance to novel therapeutic opportunities
              </a>
            </td>
          <td>
            Sahar Jalilivand, Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Mehrdad Izadirad, Fatemeh Mikanik, Ahmad Gharehbaghian
          </td>
          <td>2025-11-11</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 CD8 T cells are a critical component of the immune response to infections as well as in prevention and restriction of cancer growth. Across multiple solid cancer types, tumor infiltration of CD8 T cells is associated with improved patient survival. CD8 T cell cytotoxicity and cytokine production have been characterized as the primary mechanisms by which these cells execute their immune function. However, basal cell motility, defined as random walk and exploratory spread, is an essential and underappreciated aspect of the CD8 T cell-mediated antitumor response. Cell motility enables effector CD8 T cells to search for and reach their cell targets within a solid tumor microenvironment. Here, we investigate the impact of IL-21 on effector CD8 T cell motility. We show that compared to effector CD8 T cells expanded in the presence of IL-2 alone, those expanded in IL-2 and IL-21 exhibit increased cell motility in vitro and in vivo. We also show that IL-21 enhances mitochondrial respiration and mitochondrial calcium in effector CD8 T cells. Our data suggests that increased mitochondrial calcium and mitochondrial ATP promote CD8 T cell motility through IL-21-mediated STAT3 activity. Therefore, IL-21 plays an important role in effector CD8 T cell mitochondrial fitness, cytoskeleton stiffness, and cell motility, which can be leveraged in the design of adoptive T cell therapies for the treatment of solid tumors.



 Supported by NIH R01 CA260909; T32AI007405.



 Cytokines and Chemokines and Their Receptors (CCR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c85e17d7c962d1daada79818491cc536bfb732e9" target='_blank'>
              Enhancement of effector CD8 T cell motility by IL-21 through STAT3 4131
              </a>
            </td>
          <td>
            Maureen Hoen Rauhut, Fahiima Abdullahi, Felipe Valença-Pereira, Mercedes Rincon
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 The treatment landscape of diffuse large B-cell lymphoma (DLBCL) has progressed with the emergence of immune-cell therapies (ICTs), such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. However, many patients still remain incurable despite these innovative options. Treatment resistance in DLBCL is associated with the immunosuppressive tumor microenvironment (TME), and myeloid-derived suppressor cells (MDSCs) play a crucial role in contributing to it. Furthermore, an increase in MDSCs has been linked to disease progression, poor prognosis, and reduced effectiveness of ICTs. Therefore, understanding how DLBCL cells promote MDSC development is essential for overcoming treatment resistance to ICTs. To address this issue, in this study, we investigated how DLBCL cells induce monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs) using an indirect co-culture system and traced the molecular changes involved. Four human DLBCL-derived cell lines (HDBCLs), including two double-expressor HDBCLs (KPUM-UH1 and KPUM-MS3) (Sasaki N, Exp Hematol 2011) and two activated B-cell-like HDBCLs (HBL1 and DLBCL2), were used. PBMCs from healthy donors were indirectly co-cultured with HDBCLs for 96 hours, and flow cytometry was used to analyze PBMCs for the induction of M-MDSCs displaying the CD14+/HLA-DR-/low phenotype. Total RNA was extracted from the CD33+ myeloid fraction of PBMCs after co-culture, and gene expression profiles (GEP) were analyzed using microarray analysis. Consequently, we first demonstrated that all four HDBCLs tested were effective in inducing CD14+/HLA-DR-/low myeloid cells from normal PBMCs within 96 hours of co-culture. The induced CD14+/HLA-DR-/low myeloid cells were also shown to be potent in inhibiting T cell proliferation, confirming these cells as M-MDSCs both phenotypically and functionally. The ability to induce M-MDSCs was highest in DLBCL2, followed by HBL1, while KPUM-UH1 and KPUM-MS3 showed modest M-MDSC-inducing capabilities. Based on the finding that M-MDSCs were induced through indirect co-culture with HDBCLs, we screened soluble factors in the conditioned medium (CM) of HDBCLs secreted by these cells using cytokine arrays, and found that all four HDBCLs secreted MIF. Additionally, the results showed that DLBCL2 cells produced high levels of interleukin-10 (IL-10), while HBL1 cells secreted IL-10 at low levels, and KPUM-UH1 and KPUM-MS3 cells did not produce detectable IL-10. We then examined the functional roles of MIF and IL-10 in the induction of M-MDSCs by HDBCLs. Interestingly, the MIF inhibitor 4-IPP greatly reduced M-MDSC induction by all four HDBCLs, and exposure to recombinant (r) MIF alone had minimal ability to induce M-MDSCs from normal PBMCs, indicating that MIF plays an essential but preparatory role in M-MDSC induction. Conversely, blocking IL-10 with a neutralizing antibody significantly decreased M-MDSC induction from PBMCs by IL-10-secreting HDBCLs, and adding rIL-10 increased the M-MDSC-inducing effect of IL-10-non-secreting HDBCLs, indicating that IL-10 plays a more facilitative role in inducing M-MDSCs. To understand the molecular regulation in PBMCs during the induction of M-MDSC by the co-existence with HDBCLs, we examined gene expression changes in CD33+ myeloid cells at 24, 48, and 96 hours after co-culturing with HDBCLs. We also examined the molecular dynamics in co-culture with non-IL-10-secreting cell lines that occurred after 96 hours of rIL-10 treatment. Results from gene set enrichment analysis revealed that gene sets associated with inflammatory response and tumor necrosis factor-alpha (TNF-α) signaling, as well as inflammatory molecules such as IL-1α, were upregulated 24 hours after co-culture. However, these upregulated gene sets became less expressed after 48 hours and eventually were downregulated after 96 hours. Additionally, the downregulation of inflammatory response and TNF-α signaling was further amplified by rIL-10. In conclusion, our study demonstrated that the multistep process of M-MDSC induction from PBMCs, triggered by HDBCLs, begins with an initial transient hyper-inflammatory phase induced by MIF and transitions into a post-inflammatory immunosuppressive phase accelerated by IL-10. Our findings suggest that targeting phase-specific cytokines and related molecules could reduce the induction, maturation, and proliferation of M-MDSCs, ultimately enhancing therapeutic outcomes, especially in ICTs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ebe1659b4ff0741b0dd9144d5311758dfae1768" target='_blank'>
              Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells
              </a>
            </td>
          <td>
            Yu Inoue, Y. Shimura, Yui Niiyama-Uchibori, Shotaro Chinen, Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Immune Aplastic Anemia (AA) is an autoimmune disease where hematopoietic stem and progenitor cells (HSPC) are destroyed by cytotoxic CD8+ T cells, resulting in peripheral cytopenias, i.e. anemia, thrombocytopenia and neutropenia. Most compelling evidence that HSPC destruction is immune-mediated is that two-thirds of severe AA patients demonstrate hematologic improvement in response to immunosuppressive therapy consisting of anti-thymocyte globulin and cyclosporin A. Interferon γ (IFNγ) and tumor necrosis factor α (TNFα) have both been implicated as critical effector molecules involved in the destruction of bone marrow HSPCs in AA. Furthermore, mRNA expression of the inflammatory chemokine receptor CXCR3 and the chemokine CCL20, a ligand of CCR6, has been shown to be elevated in peripheral blood and bone marrow mononuclear cells, suggesting a role for T helper/cytotoxic (Th/c) 1 and Th/c17 cells in the pathobiology of AA.



 To further elucidate the pathobiology of AA, we conducted a comprehensive multiproteomic analysis of adult AA patients eligible for bone marrow transplant ([BMT]; n=20; samples pre-BMT) and matched healthy controls (n=20). We performed plasma proteomic analyses using Olink and conducted high-dimensional immunophenotyping by flow cytometry using peripheral blood mononuclear cells (PBMCs).



 Using Olink proteomic analysis, we observed that, relative to healthy controls, plasma from AA patients exhibited significantly higher levels of several hematopoietic growth factors, including thrombopoietin (TPO), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and Fms-like tyrosine kinase 3 ligand (FLT3LG), indicating that an AA disease signature is reflected in circulation. Furthermore, we observed that AA patients had significant (Bonferroni corrected) elevations in interleukin 15 (IL15), a cytokine that plays a crucial role in T cell activation and effector functions. Thus, we looked at other T cell-associated molecules and observed trends towards elevations in several other cytokines in plasma of AA patients, including IFNγ, IL17A, IL17F, and interleukin 2 receptor α (IL2Rα). Interestingly, there was also a trend towards an increase in plasma CCL20 in AA patients, as previously reported.
 Using high-dimensional flow cytometry immunophenotyping on PBMCs, we observed an increase in the percentage of circulating T cells, both CD4+ and CD8+ T cells, in PBMCs from AA patients. These T cells exhibited an activated phenotype with increased surface expression of the costimulatory receptor 4-1BB. Profiling of both CD4+ and CD8+ T cell subsets revealed a T helper 17 (Th17) and T cytotoxic 1 (Tc1) cell enrichment with increased proportions in overall Th17 (both Th1.17 and Th17.22 cells) and Tc1 cells (both Tc1 and Tc1.17 cells).
 While antigen presentation plays a critical role in initiating immune responses in autoimmune diseases, little is known about the role of antigen presenting cells (APCs) in AA pathobiology. Here, we showed that, while the percentage of professional APCs, i.e., B cells, monocytes and dendritic cells, was reduced in blood of AA patients, these cells presented an activated phenotype characterized by significant upregulation of the costimulatory receptor 4-1BB at their surface. In addition, B cells from AA patients exhibited higher surface expression of the inflammatory chemokine receptor CCR6 and the antigen presentation molecule HLA-DR, while monocytes expressed higher level of CCR7, a chemokine receptor essential for cell migration to lymph nodes.Conclusion: In this study, we confirmed that AA is characterized by significant increases in several hematopoietic growth factors in the periphery, which may reflect compensatory mechanisms that counterbalance the lack of blood cell production in the bone marrow. Furthermore, we demonstrated that AA is an autoimmune disease characterized by an inflammatory phenotype biased towards a Th/c1.17 immune response and increased circulating Th1 and Th17 cytokines (e.g. IFNγ and IL17A/F). Finally, we showed that multiple APCs may participate in antigen presentation in AA, as both B cells and monocytes/DCs exhibit an activated phenotype with increased expression of chemokine receptors and major histocompatibility complex class II molecules. Overall, our data suggest that broad APC activation and pathogenic Th/c1.17 immune responses contribute to AA pathobiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc62d3214c4189d70d8471303aff50affc5b9a9f" target='_blank'>
              Comprehensive multiproteomic analysis reveals an inflammatory phenotype in immune aplastic anemia characterized by broad activation of antigen presenting cells and t helper/cytotoxic 1.17 immune responses
              </a>
            </td>
          <td>
            audrey le floch-ramondou, Julie Horowitz, Kirsten Nagashima, Maria Matthaiakaki Panagiotaki, Erica Chio, Shane McCarthy, Kerry Casey, S. Hamon, Thomas Norton, L. Perlee, Andrea T Hooper, J. Orengo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 We are witnessing a significant increase in complex T cell-mediated immune disorders, such as food allergies and autoimmune disease. This trend suggests that the activation threshold for T cells may be altered, and understanding how to modulate this threshold has profound implications for disease treatment. In this study, we demonstrate that the effector program of CD8? T cells (including naïve, circulating memory, and tissue-resident cells) induced by TCR and cytokine stimulation is regulated by the class II histone deacetylase, HDAC5. HDAC5 exhibits little to no deacetylase activity against histone tails, but can function in the cytoplasm as a scaffolding protein or to directly deacetylate protein targets. Using small interfering RNA (siRNA) in cell lines of primary human CD8+ cytotoxic intraepithelial lymphocytes (IE-CTLs), we show that the loss of HDAC5 decreases their activation. Furthermore, inhibiting HDAC5 activity with the HDAC4/5 inhibitor LMK235 reduces the activation potential of ex vivo isolated human intestinal IE-CTLs following stimulation, suggesting that HDAC5 enzymatic activity is required for this effect. Finally, our data indicate that HDAC5 inhibition broadly impacts CD8? T cell activation, including in circulating memory and naïve subsets. This work identifies HDAC5 as a critical enzyme regulating the activation of CD8? T cells and highlights the potential of targeting HDAC5 to modulate CD8? T cell activation thresholds in inflammatory disorders.



 Supported by NIH BIBIB 2 T32 EB 9412; NSF Graduate Research Fellowship Program; University of Chicago Celiac Disease Research Center.



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3f63a425ec70d967412fb047c150bfd3ab601d0" target='_blank'>
              HDAC5 regulates the activation of cytotoxic CD8+ T cells 4190
              </a>
            </td>
          <td>
            Megan Borregard, C. Ciszewski, Yandong Zhang, Hening Lin, B. Jabri
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="


 T cell-engaging bispecific antibodies (TCBs) depleting B cell subsets are promising therapeutics for cancer and autoimmune diseases, with several approved or in development. However, an unavoidable consequence is immunosuppression in already vulnerable patients. Depleting B cells compromises the ability to fight infections and vaccine efficacy. These risks vary with underlying disease, effects on off-target cell populations and the TCB target. Differentiating drug candidates’ secondary TCB effects is key in drug development, but preclinical models may not fully capture complex B cell biology. We employed a multimodal systems immunology approach of two human in-vitro systems: immune organoids capturing productive germinal center responses, and an immunocompetent bone marrow model with B precursor- and differentiated plasma cells. We integrated data from high-dimensional flow cytometry, single cell RNA- and CITE-sequencing, to assess the consequences of TCB-mediated immune responses across different tissues. This allowed us to capture a differential off-tumor B cell subset toxicity of TCBs directed against two therapeutically validated TCB targets, in line with the reported clinical infection risk and B cell depletion that diverge between both. Overall, this translational work shows the value of human in-vitro approaches as a preclinical evaluation for immunosuppression, by accurately capturing complex human immune biology and therapeutic activity of candidate molecules.



 Translational and Interventional Immunology (TI)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ab71e60522c5a275a95f316de0a2c67184842200" target='_blank'>
              Translating immunosuppressive risks of T-cell bispecifics using human in vitro models and systems immunology 9247
              </a>
            </td>
          <td>
            Lea Schroer, Jenna M. Kastenschmidt, Michael Bscheider, Nick Corr, Susanne Fischer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB). Several alterations in the BM microenvironment have been linked to AML onset and progression, some of which affect the immune system and promote tumor evasion. Genetic alterations also contribute to these processes, including overexpression of the MN1 gene, which is addressed in this study. MN1 overexpression is associated with a more aggressive leukemic phenotype and therapeutic resistance. Among the pathological findings in the leukemic BM microenvironment, the relative increase in AML-associated macrophages (AAMs) appears to support AML progression. AAMs display a phenotype similar to that of healthy M2-like macrophages and are thus linked to anti-inflammatory and immunosuppressive activity. In this context, therapeutic approaches aimed at reprogramming AAMs toward a more inflammatory and antitumoral profile, resembling M1-like macrophages, have been investigated. This study aimed to evaluate the immunomodulatory effects of BPI-2358, a tubulin polymerization inhibitor and JNK pathway activator, on AAMs in AML models driven by MN1 overexpression. Human PB-derived M2 macrophages were treated with BPI-2358 (0.125–0.5 µM) for 48 hours. Immunophenotyping (CD80, CD86, CD206, CD163) and cytokine analysis (TNF-α, IL-1β, TGF-β) revealed a shift toward a pro-inflammatory profile. Our findings showed that BPI-2358 treatment had a significant impact on marker expression, leading to an upregulation of CD86 and a downregulation of CD163 in human samples. Additionally, we detected elevated levels of pro-inflammatory cytokines, including IL-1β and TNF-α, along with a reduction in TGF-β secretion. Similarly, murine BM-derived M2 macrophages treated under the same conditions showed increased expression of M1-related genes (Cd80, Tnf-α, Nos2) and downregulation of Arg1, a classical M2 marker, by qRT-PCR. A phagocytosis assay was performed using M2-polarized murine macrophages treated with BPI-2358 (0.5 μM) and MN1-GFP⁺ murine AML cells. Treated macrophages exhibited an increased phagocytic capacity compared to untreated controls. A cell proliferation assay was performed by co-culturing BM-derived M2 murine macrophages, pre-treated with BPI-2358 (0.5 μM), with MN1-GFP⁺ murine AML cells at a 1:1 ratio. Cell growth was monitored over a 10-day period by performing regular cell counts. Notably, a significant decrease in MN1 cell proliferation was observed on days 3 and 4 in co-cultures with BPI-2358-treated macrophages, indicating that the treatment impaired leukemic cell expansion. Moreover, exposure to an AML-conditioned microenvironment induced a tolerogenic macrophage profile in vitro, which was partially reversed by treatment, highlighting the functional plasticity of these cells. Transcriptomic analysis by RNA-seq revealed differential gene expression and pathway enrichment consistent with macrophage reprogramming. Transcriptomic analysis showed that BPI-2358 upregulated 4,829 genes, including those involved in tissue damage response, tissue remodelling, and the pro-inflammatory cytokine Il1b. The treatment also significantly suppressed the IL-6/JAK/STAT3 pathway, a key driver of the immunosuppressive M2 phenotype and tumor immune evasion. Ex vivo cytotoxicity was assessed in a panel of primary AML samples (n=25) treated with BPI-2358 (0.125–0.5 µM) for 72 hours. Flow cytometry was used to evaluate viability of leukemic blasts (CD34⁺ or CD117⁺ for CD34⁻ AMLs) and macrophages (CD34⁻ or CD117⁻ HLA-DR⁺ CD14⁺) using Annexin V/DAPI staining and TMRE for mitochondrial membrane potential. Finally, the in vivo efficacy of BPI-2358 was assessed in an MN1-driven AML mouse model (MN1-GFP⁺). Mice received BPI-2358 (7.5 mg/kg IP, daily), and flow cytometry analysis of the BM showed a reduction in leukemic engraftment. The treatment did not impact the animals' body weight, suggesting minimal systemic toxicity. A significant decrease in the frequency of circulating MN1⁺ cells was observed, along with a marked reduction in MN1⁺ cell infiltration in the spleen. This was further supported by a significant decrease in spleen weight in the BPI-2358-treated group. These findings reinforce the potential of macrophage reprogramming as a complementary strategy in AML treatment, especially in molecularly high-risk subtypes such as those associated with MN1 overexpression.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7341436505bbad9e3856fea1f022bb194207dcdb" target='_blank'>
              BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo
              </a>
            </td>
          <td>
            L. Pinheiro, I. Weinhäuser, D. Pereira-Martins, Katherine Hampton, Annalisa Altera, D. Fowler-Shorten, Matthew Markham, A. Polski-Delve, Tabitha Bartlett, C. Hellmich, Luíse A A Simões, Cleide Lúcia Araujo, Rita De Cássia Cavaglieri Medeiros, L. Quek, G. Huls, J. Schuringa, S. Rushworth, E. Rego
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="
 Brain metastases (BM) from lung adenocarcinoma represent a formidable clinical challenge due to limited therapeutic efficacy. To gain insight into complex tumor microenvironment (TME) of BM, we analyzed single-cell RNA-sequencing data comprising 66,769 cells from primary tumors (PTs; 44,355 cells) and matched BM lesions (22,414 cells). Our analysis revealed a profound shift in cellular composition during metastasis: while T cells predominated PT (44.12%), tumor cells became the most abundant population in BM (55.17%), with corresponding reductions in T cells (27.57%) and macrophages (19.3%). Cell–cell communication analysis identified fibroblasts as central mediators in both PT and BM, with a transition from collagen signaling in PT to thrombospondin signaling in BM, facilitating interactions with tumor cells, B cells, and oligodendrocytes. Ingenuity Pathway Analysis revealed enrichment of collagen-related genes in fibroblasts (MFAP4, COL15A1, FBLN1, FBLN2) and Th1/Th2 pathway genes in T cells (IKZF1, SH2D1A, RASGRP1, SKAP1). Subclustering uncovered seven distinct fibroblasts subpopulations and a notable shift from PT-enriched C0 to BM-enriched C1, suggesting dynamic phenotypic adaptation. Pseudotime trajectory analysis further clarified fibroblasts differentiation states. T-cell subclustering revealed a significant increase in immunosuppressive regulatory T cells (84.1%) and proliferating CD4+ T cells (10.5%) in BM, highlighting mechanisms of immune evasion. COL15A1 expression correlated with poor patient survival and emerged as a promising therapeutic candidate, showing increased sensitivity to Dabrafenib, Trametinib, Piperlongumine, Cabozantinib, Staurosporine, and Vemurafenib. Additional gene drug associations were observed, with FBLN1, RASGRP1, MFAP4, SH2D1A, and IKZF1 linked to potential sensitivity to Erlotinib, Afatinib, Fluorouracil, and Brefeldin A. These findings provide a high-resolution map of the BM TME and highlight COL15A1 and related pathways as potential targets for precision therapy in patients with BM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc3a5b204d80d9cd5d66d31480f9cf9dd3274795" target='_blank'>
              TMIC-44. Fibroblast reprogramming and immune evasion define the tumor niche in brain metastases
              </a>
            </td>
          <td>
            Sanskriti Dey, J. Chuang, Chih-Yang Wang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune evasion is a hallmark of cancer development and poses an important impediment to the effectiveness of immune checkpoint inhibitors (ICIs). Cancer cells take advantage of heterogeneous intrinsic and extrinsic pathways to circumvent immune detection, such as metabolic remodeling (e.g., increased glycolysis, activation of IDO1), genomic mutation (e.g., JAK/STAT, β-catenin), and epigenetic suppression of immune-regulatory genes. Concurrently, TME promotes immune suppression through Tregs, MDSCs, TAMs, and fibroblast-mediated extracellular matrix remodeling. Hypoxia and cytokine dysregulation also undermine antigen presentation and T-cell functionality. These immunoevasion strategies form the foundation of both native (innate) and adaptive resistance to ICIs, while recent evidence places emphasis on microbiota composition being able to modify therapeutic response. The PD-1/PD-L1 pathway remains the focus of ICI therapy, but PD-L1 expression is limited by spatial, temporal, and technical heterogeneity. Beyond PD-L1, integrated biomarker approaches including tumor mutational burden (TMB), microsatellite instability (MSI), IFN-γ gene signatures, and circulating tumor DNA (ctDNA) have arisen to further inform patient stratification. Emerging therapeutic technologies—e.g., dual checkpoint blockade, engineered cytokines, personalized neoantigen vaccines, and adoptive T cell therapy (CAR-T, TCR-T)—are designed to overcome resistance and maximize clinical efficacy. Integration of multi-omics and AI-based models provides additional precision in the tailoring of immunotherapy. This review integrates existing knowledge of immune escape and resistance, highlighting dynamic biomarker development and combinatorial approaches for next-generation personalized cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ea6fa22f99aea24aa51b0cd66f7e9b27adb85e90" target='_blank'>
              Immune Evasion and Resistance in Cancer Progression: Overcoming Checkpoint Inhibition Challenges with Personalized Immunotherapy Guided by PD-L1 Expression
              </a>
            </td>
          <td>
            Archana Venkatesan, Karthick Sivanatham
          </td>
          <td>2025-10-21</td>
          <td>Journal of Analytical Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exhausted T cells, marked by sustained expression of inhibitory receptors such as PD-1 and impaired effector function. These exhausted T cells represent a major barrier to durable anti-tumor immunity and effective immunotherapeutic intervention. To address this, we explored PD1-IL2v, an engineered immunocytokine designed to selectively stimulate PD-1⁺ cells with IL-2 signaling while minimizing activation of regulatory T cells. Using both the immunogenic GL261 and the immune checkpoint-resistant SB28 murine models of GBM, we administered PD1-IL2v either systemically or directly into the tumor. Flow cytometry was employed to assess changes in tumor-infiltrating lymphocytes, with particular focus on exhaustion and effector phenotypes. Notably, local administration of PD1-IL2v, but not systemic delivery, effectively reactivated CD8⁺ T cells within the tumor microenvironment. PD1-IL2v treated mice exhibited enhanced cytokine production, increased proliferation, and restoration of cytotoxic activity in T cells. Phenotypic profiling of tumor infiltrating lymphocytes (TILs) revealed an expansion of a stem-like subset of exhausted T cells (PD-1⁺TCF1⁺), alongside the emergence of a novel, differentiated population with superior effector functions, termed “better-effector” T cells. Therapeutic intervention with PD1-IL2v led to complete tumor rejection in a subset of animals, and increased infiltration of functional T cells into the tumor core. Our findings underscore T cell exhaustion as an untapped reservoir of tumor-reactive T cells that can be therapeutically reinvigorated using PD1-IL2v. This approach not only restores anti-tumor immunity but also induces superior effector populations capable of driving tumor regression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d2a360e4ecb23a3988292b555a7155b5788a697" target='_blank'>
              IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
              </a>
            </td>
          <td>
            U. Salazar, B. Taskoparan, Sereina Deplazes, V. Nicolini, Laura Codarri-Deak, H. Okada, C. Klein, Johannes vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="
 Leptomeningeal metastasis (LM) occurs when tumor cells spread into the cerebrospinal fluid (CSF)-filled leptomeninges. 5-10% of solid tumor patients develop LM. Survival is generally less than a year, and therapeutic options are limited. Several aspects of the LM immune microenvironment remain unexplored, and their understanding will be key in the development of novel immunotherapies targeting LM. We investigated the immune microenvironment and characterized T cell responses in the CSF of patients with confirmed LM (n = 16) and tumor patients without LM (n = 5). The LM cohort comprised patients with diverse primary tumors, including carcinomas, hematological, and glial tumors. By combined single-cell RNA and T cell receptor (TCR) sequencing, we generated a transcriptomic immune landscape from LM CSF samples. We identified different myeloid and lymphoid immune cell populations, including various subtypes of CD4 and CD8 T cells. The majority of CD8 T cells displayed an effector cytotoxic phenotype characterized by the expression of genes such as GZMA, NKG7 and PRF1. Analysis of the distribution of the most clonally expanded TCRs revealed an enrichment in effector cytotoxic CD8 T cells, indicating a CD8-mediated anti-tumor response. Furthermore, differential gene expression analysis of effector cytotoxic CD8 T cells and effector CD4 T cells in LM vs. control samples revealed upregulation of genes related to interferon response (ISG15, MX1, IFI6, STAT1) and antigen presentation (TAP1, HLA-C, CD74). Overall, this data demonstrates that T cells in the CSF exhibit cytotoxic activity, supporting the rationale for exploring immunotherapeutic strategies to treat LM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fabbabf1d83b95bbc52eda4e118d97e09dc5b004" target='_blank'>
              IMMU-65. Single-cell analysis of the immune microenvironment of cerebrospinal fluid in leptomeningeal metastasis
              </a>
            </td>
          <td>
            David Palmero-Canton, A. Dietsch, P. Koopmann, Clara Tejido, Alina Paul, Anna Kocharyan, N. Grassl, I. Mildenberger, M. Platten, L. Bunse
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="


 Clonal hematopoiesis (CH), defined as an expanded hematopoietic stem cell (HSC) clone with somatic mutations in the absence of blood malignancy, is common in aging and associated with increased severity of inflammatory non-hematologic disorders. The co-occurrence of CH in patients with solid tumors correlates with poor prognosis and a more aggressive phenotype of the malignancy. This leads to the notion that CH mutations alter anti-cancer immunity, and that CH-derived monocytes and macrophages may contribute to a proinflammatory tissue microenvironment. Being innate immune cells, monocytes and macrophages can mount a heightened inflammatory and defense responses to secondary challenges (“trained immunity”) that are known to accentuate tumor control. On the other hand, excessive or prolonged stress stimulus may lead to its suppression (“immune tolerance”). The effect of DNMT3A mutations found in CH on innate immune responses has not been explored.
 Using colitis-associated colon cancer (CAC) as a model, we previously reported that CH driven by heterozygous loss of Dnmt3a, mimicking the most common genetic alteration in human CH, promoted initiation and progression of solid tumors in the context of severe chronic inflammation. We hypothesized that Dnmt3a-CH tilts myeloid responses toward immune tolerance rather than trained immunity, compromising tumor control.
 To assess the impact of Dnmt3a-CH to tumor immune microenvironment (TME), we created a mouse model with 10% test BM cells (Dnmt3a+/– or WT control) marked with CD45.2 mixed with 90% CD45.1+CD45.2+ WT competitor and engrafted into pre-conditioned CD45.1+ recipients prior to CAC induction by the azoxymethane (AOM)/dextran sulfate sodium (DSS) method. Mice with Dnmt3a+/– BM developed more numerous, larger CAC tumors, solidifying the prooncogenic role of Dnmt3a-CH. Flow cytometry revealed preferential infiltration of Dnmt3a+/– BM-derived cells in the TME, particularly immune-suppressive M2-like macrophages. Increased abundance of Dnmt3a+/– anti-inflammatory M2-like macrophages was confirmed by scRNA-seq on FACS-sorted tumor-infiltrating donor-derived CD45.2 cells from mice non-competitively transplanted with Dnmt3a+/– compared to WT control BM. Cytokine profiling in whole tumor lysates revealed reduced pro-inflammatory IL-1β and TNF-α indicating a switch to a tolerogenic immune state in Dnmt3a+/– BM chimerae.
 Repeated inflammatory insults can cause a switch to immune tolerance. To test this, mice transplanted with Dnmt3a+/– and WT control BM were subjected to 3 bouts of DSS-induced bacterial colitis or kept untreated. Despite developing more pronounced colitis as evidenced by greater shortening of the colon and increased weight loss, Dnmt3a+/–-engrafted recipients showed decreased pro-inflammatory cytokine levels in serum and elevated levels of immunosuppressive IL-10. Strikingly, although in vitro differentiated BM-derived macrophages (BMDMs) from untreated Dnmt3a+/– mice showed higher phagocytic activity compared to WT controls, this function was dramatically impaired after DSS challenge in alignment with an immune tolerance phenotype. Similar results were observed in human THP-1 cells CRISPR-edited to disrupt one DNMT3A allele. After stimulation with high-dose lipopolysaccharide (LPS) to mimic an inflammatory challenge associated with endotoxemia secondary to colitis, DNMT3A-disrupted THP-1 macrophages exhibited significantly dampened phagocytosis compared to WT controls. RNA-seq analysis revealed the DNMT3A+/- THP-1 showed reduced expression of gene sets and pathways related to inflammation and innate immune defense.
 These observations demonstrate that tolerogenic reprogramming of Dnmt3a-CH macrophages after an inflammatory insult establishes a tumor-permissive immune microenvironment in CAC. Indeed, myeloid-specific heterozygous Dnmt3a loss (by LysM-Cre) was sufficient to promote tumor initiation, while depletion of phagocytes in vivo using clodronate liposomes during CAC induction reversed Dnmt3a-CH-induced increase in colon tumor burden.
 In conclusion, DNMT3A-driven CH enables colitis-associated tumorigenesis by priming myelopoiesis towards innate immune tolerance under excessive inflammation, creating an immunosuppressive TME and corrupting tumor control. Targeting innate immune tolerance in individuals with DNMT3A-CH may represent a strategy to mitigate the risk of inflammation-associated cancers.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e59f93632128a080292d7ca72e60726d86ccb977" target='_blank'>
              DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance
              </a>
            </td>
          <td>
            Qingchen Yuan, Yang Feng, Christopher Thai, Andrey Smirnov, Eric Helm, Bowen Yan, Prabhjot Kaur, Annalisse R. Mckee, Cassandra Berntsen, Daniil E. Shabashvili, Jixiu Shan, Jason Brant, Dorina Avram, Hossein Khiabanian, Jonathan Licht, Olga A. Guryanova
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Background Cellular immunotherapy has revolutionized cancer treatment. Yet its efficacy in acute myeloid leukemia (AML) remains limited due to an immunosuppressive tumor microenvironment (TME) often characterized by deficient immune-stimulatory cytokines and elevated immunosuppressive metabolites. Adenosine (Ado), a key inhibitor is degraded by the non-redundant enzyme adenosine deaminase (ADA), which converts Ado into the immune-stimulatory inosine (Ino). IL-12 is a potent cytokine that strongly boosts immune cells, but its systemic toxicity limits clinical use. To address this, we engineered tumor-homing, non-pathogenic Escherichia coli (E. coli) to co-display surface-tethered IL-12 and ADA, enabling localized cytokine delivery and metabolic reprogramming. We hypothesized that this dual strategy efficiently reprograms the immunosuppressive niche in AML, thereby unlocking robust local NK (and T cell) anti-leukemic immunity.
 Method Non-pathogenic E. coli K12 DH5α were engineered to surface-display murine and human IL-12, ADA, or IL-12+ADA fusion using optimized outer membrane scaffolds with FLAG tags using an approach in our recently published paper (Yang et al, Nature Biotechnology 2024). Expression was induced with rhamnose and confirmed by flow cytometry. IL-12 bioactivity was validated via HEK-Blue reporter assay. ADA kinetics and activity were assessed via LC-MS and colorimetric assays. NK cells were co-cultured for 24h with E. coli displaying ADA, IL-12, ADA+IL-12, or scaffold control followed by multicolor flow cytometry to assess Ado-signaling (A2AR, CD73, CD39, CD26), surface markers (i.e., CD25, NKG2D, NKp30), and AML-directed cytotoxicity (Zombie-NIR, IFNg, TNFα) against the AML targets NOMO1 and OCI-AML3. To model TME metabolism, cells were treated with 1mM Ado, Ino or PBS. In-vivo efficacy was tested in a immunocompetent B16-F10 melanoma model and BALB/c mice bearing GFP⁺/NanoLuc⁺ WEHI-3 AML cells. Leukemic burden (bioluminescence imaging, blood), weight, and survival were monitored. Bacterial distribution was assessed by CFU assays in relevant organs.
 Results Engineered E. coli co-displaying IL-12 and ADA showed robust FLAG-tagged surface expression (>80%) with significant IL-12 bioactivity (OD650, 0.9 vs. 0.2, p<.001). Murine ADA displayed by YiaT181 showed highest enzymatic activity (Km=0.05, Vmax=53µmol/min), fully converting Ado to Ino within 4h. NK cells cocultured with IL-12 displaying E. coli showed strong upregulation of key activation markers compared to scaffold control (CD25, 56 vs. 25% and NKp30, 68 vs. 35%, p<.001), leading to a ≥3.4-fold greater AML-directed cytotoxicity and IFNγ production. Importantly, rhIL-12 (50ng/ml) increased expression of the Ado-generating metabolic checkpoint CD73 (2 to 9%, p=.003) and Ado receptor A2AR on NK cells (31 to 51%, p=.001), indicating increased Ado susceptibility. Ado exposure reduced AML-directed killing by ~50% (p<.001) and NK cell activation (NKp30 expression was 33 vs. 18%, p=.003). ADA-expressing E. coli restored NK cell immunity and AML lysis in-vitro (55 vs. 15%, p<.001). Co-display of IL-12 and murine ADA maintained full NK effector function under Ado-rich conditions and enhanced AML-targeted lysis (15 vs. 56%, p<0.01). In-vivo, i.v. delivery of E. coli expressing ADA, IL-12, or ADA+IL12 fusion was well-tolerated and demonstrated potent antileukemic activity in immunocompetent WEHI-3 AML models. Substantial tumor control led to prolonged survival in the IL-12+ADA group (2 of 3 alive at d29, median survival not reached) vs a median of 10 days in control mice. Robust tumor control was reached in the IL-12 (26d) and ADA (17d) group. Post-mortem analysis of mice revealed unprecedented tumor-guided bacterial migration to the bone marrow, a phenomenon not previously reported. ADA-engineered bacteria accumulated up to 4x105 CFU and IL-12 displaying bacteria up to 3x104 CFU in the bone marrow. Intratumoral delivery of IL12+ADA-engineered E. coli induced complete tumor regression and 100% survival in a B16-F10 melanoma model, with tumor rechallenge confirming durable antitumor immunity, suggesting immune memory and long-term immune protection.
 Conclusion Engineered nonpathogenic E. coli co-displaying IL-12 and ADA effectively reprogram the AML TME, enhance NK cell activation, and drive sustained anti-tumor responses. This live microbial platform offers a safe, localized, and versatile immunotherapy strategy applicable to both hematologic and solid tumors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04c11cfcf5a3539fa2c39d0839134cb7fc2116bd" target='_blank'>
              Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
              </a>
            </td>
          <td>
            Stephanie Sendker, Shaobo Yang, Anna Clara Bader, Alice Chen, Eden Bobilev, Ashley Hu, Xingyu Deng, Fuguo Liu, Veronica Hui, Maily Nguyen, Andreia Maia, Sara Piccinelli, Kerim Berkay Aslan, Fabian Göllner, A. Ali, Rémy Duléry, Hetal Nath, Daniel Chen, Mounica Vallurupalli, Andrew Lu, Stephanie Chamberlain, Tereza Kochs, Nathalie Javidi-Sharifi, Michal Sheffer, Roman Shapiro, Andrew Lane, Robert J. Soiffer, Mubin Tarannum, Jerome Ritz, R. Romee
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) express features of parental cells and are fundamental in modulating the crosstalk between cancer cells and their environment. Increasing evidence suggests that EVs have a pivotal role in tumorigenesis, cancer development, and drug resistance. EVs are also involved in controlling the communication between hematopoietic stem cells and the surrounding microenvironment in the bone marrow (BM), during several processes such as self-renewal, mobilization, and lineage differentiation. Proteins expressed in cancer cell-derived EVs can be useful to further understand the regulation of hematopoietic stem cell fate, a fundamental mechanism in acute myeloid leukemia (AML). Furthermore, EVs are implicated in transmitting drug-resistance mechanisms in solid and not-solid cancer types. Here, using a proteomic approach, we analyze and validate the protein profile of EVs from three AML cell lines with different genotypes, namely OCI-AML-2, OCI-AML-3, and HL-60. The majority of the identified proteins were significantly enriched in the Gene Ontology category ‘Extracellular Exosome’. Network model analysis of EV proteins revealed several significantly modulated pathways, including inflammation activation and metastatic processes in AML cell-derived EVs. The EVs proteomic profiling allows us to identify the EVs-associated molecules and pathways that could impact cancer progression and drug resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/849ae2dd1616d0c72e1ed7ba719a71d6a8bb6984" target='_blank'>
              Extracellular Vesicles Profiling in Acute Myeloid Leukemia Cell Lines: A Proteomic Characterization
              </a>
            </td>
          <td>
            B. Dufrusine, M. Cufaro, Alice Di Sebastiano, Erika Pizzinato, Pina Nardinocchi, I. Cicalini, S. Pilato, Antonella Fontana, D. Pieragostino, Enrico Dainese, Luca Federici
          </td>
          <td>2025-10-22</td>
          <td>Cells</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 Despite significant advancements in targeted therapies and immunotherapies, a substantial proportion of non-small cell lung cancer (NSCLC) patients remain unresponsive to treatment. One contributing factor is tumor-induced immunosuppression, which impairs effective T cell responses. Natural killer (NK) cells, while playing a pivotal role in antitumor immunity, have been shown to negatively regulate adaptive immune responses in various contexts. In this study, we characterized the phenotype of NK cells within the NSCLC microenvironment and investigated their potential contribution to immune suppression. CD3- CD56+ NK cells were isolated from tumor resection specimens and profiled using single-cell RNA sequencing and CITE-seq. Identified NK cell clusters were subsequently quantified in tumor-infiltrating lymphocyte (TIL) cultures exhibiting different expansion rates. Our analyses identified a tumor-specific NK cell subset associated with reduced recurrence-free survival (RFS). This subset was preferentially enriched in TIL cultures with low expansion rates compared to those with high expansion rates, suggesting a potential role in limiting T cell proliferation. Future investigations will focus on confirming the regulatory role of this NK cell subset and elucidating the mechanisms underlying its suppressive function.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96876b361473daba1aa036fd63568ae3002f5c55" target='_blank'>
              Immunoregulatory NK cells in non small cell lung cancer (NSCLC) 3221
              </a>
            </td>
          <td>
            Jules Sotty, D. Chung, Nicolas Jacquelot, Jehan Vakharia, Azin Sayad, Ben X Wang, P. Ohashi
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Acute graft-versus-host disease (aGVHD) is one of the most severe complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily caused by donor-derived alloreactive T cells that attack recipient tissues, leading to systemic inflammation and multi-organ damage. While the effector role of donor T cells is well recognized, their developmental origin, activation dynamics, and persistence remain poorly understood. The thymus is the central organ for T-cell development and immune tolerance, yet its role in aGVHD pathogenesis remains underexplored.
 In preliminary experiments using a murine aGVHD model, we observed marked thymic atrophy, along with a significant reduction in total thymocyte numbers. Flow cytometric analysis revealed a near-complete absence of CD4⁺CD8⁺ double-positive (DP) thymocytes, with only a small population of single-positive (SP) CD4⁺ and CD8⁺ cells remaining. These findings suggest that thymic architecture and function are severely compromised during aGVHD, potentially interfering with both positive and negative selection processes. This impairment may lead to the premature release of incompletely developed T cells into the peripheral circulation.
 Unexpectedly, we identified a substantial accumulation of DP T cells in peripheral target organs, including the colon, liver, and skin, in aGVHD mice. These cells were virtually absent in bone marrow–transplanted, T cell–depleted (BM-TCD) controls. Given that DP cells are typically restricted to the thymus and are rarely found in the periphery under normal conditions, their presence in peripheral tissues suggests a pathological process of premature egress from the thymus due to structural and functional failure. This observation raised the hypothesis that these peripheral DP cells may be developmentally abnormal and functionally involved in mediating tissue injury.
 To investigate the biological properties of these DP cells, we performed both single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic profiling of three representative tissues in aGVHD mice: the colon (a representative target organ), the thymus (the central lymphoid organ), and the spleen (a peripheral lymphoid organ). The aGVHD model was established using GFP-labeled C57BL/6 donor cells transplanted into lethally irradiated BALB/c recipients. The BM-TCD group served as the negative control.
 scRNA-seq analysis revealed that peripheral DP cells in the aGVHD colon expressed high levels of cell cycle–related genes such as Birc5, Cdca8, Pclaf, and Mki67, indicating strong proliferative potential. In contrast, expression of lineage-defining transcription factors and effector molecules typically associated with SP T cells, including Cd83, Tnfsf8, and Gata3, was minimal. These data suggest that the peripheral DP cells are in a non-canonical, undifferentiated state distinct from conventional effector T cells. Spatial transcriptomic data confirmed that these DP cells were enriched in subepithelial regions of the colon, which colocalized with areas of epithelial disruption and immune infiltration, implicating them in direct tissue damage.
 We further compared DP cells from the thymus of BM-TCD mice with splenic DP cells from aGVHD mice. Thymic DP cells exhibited high expression of normal developmental markers including Rag1, Rag2, Rorc, Ccr9, and Sox4, consistent with ongoing T-cell maturation within a healthy thymic environment. In contrast, splenic DP cells from aGVHD mice expressed elevated levels of activation and cytotoxicity-associated genes such as Gzmb, Il2rb, and Cd38, suggesting that they had transitioned into an activated and potentially pathogenic state. This phenotypic shift supports the concept that the inflammatory milieu of aGVHD promotes extrathymic activation and reprogramming of aberrantly exported DP cells.
 Our findings reveal that thymic dysfunction in aGVHD permits the release of immature DP T cells into the periphery, where they acquire pathogenic features and accumulate in target tissues. This thymus–periphery axis may be a key driver of ongoing inflammation and damage in aGVHD. Therapeutic strategies that restore thymic function or eliminate pathogenic DP cells may provide novel avenues to alleviate disease severity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4d45448d48e53c36fcb43dee5871db163da2fc50" target='_blank'>
              Thymic dysfunction promotes the emergence of pathogenic peripheral CD4⁺CD8⁺ T cells and induces tissue injury in acute gvhd
              </a>
            </td>
          <td>
            Meng Zhang, Hengwei Wu, Xinyi Lai, Xiangjun Zeng, Mengmeng Huang, Yingru Jiang, Yanjuan Liu, Yanmin Zhao, Fang Ye, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="


 Post-Acute Sequelae of COVID-19 (PASC) are rapidly evolving into a major public health concern. However, the link between acute infection and chronic disease remains unclear. With insights from 3 PASC patient cohorts, we established a clinically relevant mouse model and identified an aberrant immune-epithelial progenitor niche unique to the fibroproliferation in respiratory PASC. Using spatial transcriptomics and imaging, we found that lung-resident CD8+ T-cell (TRM)-derived IFN-γ and TNF stimulated local macrophages to chronically release IL-1β, promoting the accumulation of dysplastic epithelial progenitors to drive fibrosis. Neutralization of IFN-γ and TNF, or IL-1β activity improved alveolar regeneration and pulmonary function, presenting a therapeutic strategy to rescue post-viral disease in the aftermath of infection. We believe that the accumulation of CD8+ TRMs occurs due to an evolutionary need of the epithelium to maintain memory of injury and ensure rapid protection at these vulnerable sites in case of subsequent viral exposures. Dysregulation of this immune-epithelial crosstalk however, results in pathological remodelling of the lungs as observed in PASC. Thus, we are exploring the role of epithelium and the molecular basis of this crosstalk to identify key mediators to ultimately uncouple the protective and pathological functions of CD8+ TRMs post-infection to promote functional lung recovery without compromising immunity to future infections.



 Harish Narasimhan: F31HL170746 and T32AI007496 Jie Sun: AI147394, AG069264, AI112844, HL170961, AI176171 and AI154598



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/543188223d45038e3c98aeb834d328a6cf25d7e3" target='_blank'>
              An aberrant immune-epithelial progenitor niche drives post-viral sequelae 3466
              </a>
            </td>
          <td>
            H. Narasimhan, Jie Sun
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="ZC3H12A is a key RNA-binding protein and ribonuclease that plays a central role in negatively regulating inflammation and maintaining immune homeostasis. It does this by degrading the mRNA of multiple inflammatory mediators (such as IL-6 and IL-1β), as well as through its deubiquitinating enzyme activity. Not only does it limit excessive immune activation by regulating innate and adaptive immune cells (e.g., macrophages and T cells), but it also exerts bidirectional effects in tumors, acting as an anti-tumor factor to inhibit angiogenesis and oncogenic signal pathways, while promoting tumor progression under specific conditions. In recent years, ZC3H12A has emerged as a critical target for tumor immunotherapy, particularly CAR-T cell therapy. Its knockout significantly enhances T-cell persistence and anti-tumor efficacy, demonstrating broad translational potential. Furthermore, ZC3H12A plays a crucial role in systemic metabolic–immune crosstalk and infectious diseases. This review systematically summarizes the multifunctional roles of ZC3H12A in immune regulation, tumor therapy, metabolic disorders and inflammation-related diseases, with the aim of providing new insights into its potential application in the treatment of human diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc13cdb1ebd2857c2a777fb57d5c257b10ab212f" target='_blank'>
              ZC3H12A: A Critical Mediator of Inflammation, Tumor Immunotherapy, and Metabolic–Immune Crosstalk—Implications for Disease Treatment
              </a>
            </td>
          <td>
            Mingjun Lu, Jingwei Guo, Chenyang Wang, Bingbing Wan, Teng Ma
          </td>
          <td>2025-10-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Immune checkpoint inhibition (ICI) has dramatically advanced cancer treatment but is associated with adverse outcomes including ICI-induced myocarditis. Recent work demonstrated that T cells restricted to cardiac antigens are indispensable, yet how these cells provoke fatal cardiac damage remains poorly defined. To interrogate the mechanisms underlying myocarditis, we derived a transgenic mouse line with cardiomyocyte-restricted ovalbumin expression. Transfer of naïve OTI T cells into transgenic recipients did not induce pathology, but the addition of ICI led to myocarditis. Critically, PD-1 blockade alone proved sufficient. Our findings suggest that PD-1 blockade facilitates de novo CD8 T cell priming, independent of conventional microbial stimuli. Current work aims to determine if ICI obviates the need for classical 2nd and 3rd priming signals. Additionally, we characterized diseased hearts following CD8 T cell priming and subsequent cardiac infiltration. T cells constitute half of the infiltrating immune cells, while inflammatory monocytes/macrophages and DCs dominate the non-lymphocyte population. Elevations in innate cytokines IL-1β and IL-6 were also identified. We then targeted T cell-mediated innate inflammation to ameliorate disease. Thus, these studies use a novel mouse model to 1) underscore the role for CD8 T cells, 2) reveal a noncanonical activation pathway of CD8 T cells during PD-1 blockade, and 3) posit a role for innate inflammation as a driver of pathology.



 Supported by AHA predoctoral fellowship (24PRE1198808); NIH/NIAID AI123176; NIH/NHLBI HL156852



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3a81d81333df1541d1c40b6e6fdc183b42d1e5e" target='_blank'>
              Immune checkpoint blockade induces de novo CD8 T cell priming and innate inflammation leading to myocarditis 3714
              </a>
            </td>
          <td>
            Kathrynne A. Warrick, Jeffery D. Molkentin, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Tumor-immune infiltration is an important predictor of immunotherapy response in undifferentiated pleomorphic sarcoma (UPS). However, most patients respond poorly to immunotherapy due to a lack of tumor infiltrating T cells and an enrichment of tumor-promoting macrophages. Increasing tumor-immune infiltration is therefore critical to improve survival and treatment response in UPS patients. Our goal is to determine why some tumors recruit more immune cells than others. We are investigating how Vgll3, a frequently overexpressed gene in UPS, regulates tumor immune infiltration. In a mouse model of UPS, recent work showed increased immune infiltration into Vgll3-overexpressing tumors (Vgll3+) and a robust response to chemotherapy compared to immune-excluded sarcomas. We are now defining the cellular and molecular mechanisms by which Vgll3 drives immune infiltration to identify pathways that could potentially be targeted therapeutically in genetically distinct, immune-excluded tumors. We observed stronger type I IFN production by Vgll3+ sarcoma cells than sarcoma cells with normal levels of Vgll3, and that Vgll3+ tumors are enriched in a subset of immunostimulatory IFN-responsive classical monocytes. Our studies will reveal new insights into the mechanisms of sarcoma-immune cell infiltration, highlight differential responses of immune subsets to tumor-derived factors, and uncover therapeutic targets to enhance treatment response and survival outcome in UPS patients.



 Supported by funds from the Board of Governors Regenerative Medicine Institute at Cedars-Sinai (to HSG).



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20e44e54d02e13d3da3880c3c66228daf1821c74" target='_blank'>
              Role of Vgll3-driven Type I IFN in Shaping the Sarcoma Immune Landscape 9365
              </a>
            </td>
          <td>
            Basia Gala, E. Ko, Karina Nance, Helen S. Goodridge, Jlenia Guarnerio
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="


 Cancer immunotherapies have shown significant promise in multiple myeloma (MM). However, their long-term efficacy is limited by immune evasion, and MM remains incurable. A key evasion strategy involves upregulating inhibitory phagocytosis checkpoints (IPCs), which prevent antigen-presenting cells (APCs) from phagocytosing cancer cells. This pathway is critical for the immune effects of standard anti-MM agents, including bortezomib (BTZ), an inducer of immunogenic cell death (ICD), and the monoclonal antibody daratumumab (DARA). Yet, the mechanisms regulating IPCs in MM remain poorly understood.
 To address this gap, we screened IPC axes in MM cells and APCs using bone marrow (BM) aspirates from MM patients (n=39) and healthy donors (n=5) via multiparametric flow cytometry. Immunophenotyping included 9 parameters for MM cells and 16 for APCs, covering IPC and lineage markers. We identified the B2 microglobulin (B2M) / leukocyte immunoglobulin-like receptor B1 (LILRB1) axis as the dominantly expressed IPC in MM. B2M, expressed on MM cells, binds LILRB1 on APCs. Notably, B2M is a known adverse prognostic factor in MM.
 Computational analysis of flow-cytometry data using a semi-automated pipeline allowed us to define 8 distinct myeloid cell clusters, with consistently high LILRB1 abundance, especially in conventional type 1 dendritic cells (DCs). Single-cell RNA-seq data from 90 MM BM samples confirmed LILRB1 expression in DCs, monocytes (Mo) and macrophages (MΦ). qRT-PCR of BM Mo-derived DCs found that LILRB1 mRNA levels increased from healthy donor to smoldering MM to overt MM, suggesting a link to disease progression.
 To functionally assess the B2M/LILRB1 axis, we knocked out B2M in MM cell lines (n=3) and re-expressed a chimeric B2M mutant (B2MMUT) lacking functional LILRB1-binding site by introducing 16 missense mutations. B2M functions as an MHC-I subunit, so this mutant allowed us to isolate its checkpoint role without the confounding effects from complete B2M loss. Yeast 2-hybrid assays confirmed a direct interaction between B2M and LILRB1, but not for B2MMUT. Phagocytosis assays found that B2MKO and B2MMUT cells were more susceptible (more than 2-fold) than WT to phagocytosis by DCs and MΦ after BTZ or DARA treatment (p<0.01). LILRB1 knockdown (KD) in APCs, using an antisense oligonucleotide, similarly enhanced the phagocytic potential after BTZ treatment (p<0.05).
 Since MM cells actively secrete B2M (s-B2M), we analyzed the media from MM cell lines with different B2M statuses: B2M WT, B2MKO, and B2MMUT. We found s-B2M in the media from B2M WT cells, but no B2M in the KO cells and s-B2MMUT in the B2MMUT. Exposure of DCs to the conditioned media of WT s-B2M, but not s-B2MMUT, reduced phagocytosis after BTZ or DARA (p<0.05) of B2MKO cells, suggesting that s-B2M impairs APC function in a LILRB1-dependent manner. Treatment of APCs with His-tagged recombinant B2M (rB2M) confirmed activation of downstream LILRB1 signaling, assessed by modulation of p-SHP1.
 Interestingly, APCs internalized rB2M in a LILRB1-dependent manner, as both LILRB1 KD and treatment with rB2MMUT resulted in reduced internalization. Correlative light and electron microscopy (CLEM) and TEM revealed that internalized rB2M localized to perinuclear vesicles near the microtubule-organizing center (MTOC). Confocal imaging found that rB2M uptake increased microtubule stability, as assessed by a higher acetylated-to-tyrosinated tubulin ratio. Functionally, this correlated with impaired APC maturation following lipopolysaccharide stimulation (assessed by phalloidin staining) and a reduced ability to activate T cells after ICD, as measured shown by reduced T cell-mediated MM cell lysis.
 To evaluate the in vivo relevance, we generated a murine MM cell line (5TGM1) expressing a chimeric B2M (B2Mmut), which cannot bind the murine LILRB1 ortholog. Mice injected with B2Mmut cells exhibited reduced tumor engraftment and growth compared to those injected with WT cells, accompanied by increased infiltration of CD3⁺ and CD8⁺ T cells.Ongoing studies are assessing the effect of the B2M/LILRB1 axis on BTZ or DARA efficacy in vivo and will be presented at the meeting.
 This work provides fundamental insight into the immune role of B2M in MM, revealing the B2M/LILRB1 axis as a novel immune checkpoint in MM driven by impaired APC function. Targeting this axis represents a new therapeutic vulnerability to restore immune competence and improve MM outcomes.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92134e520cb60136119f8590dc507a1192c1b610" target='_blank'>
              The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
              </a>
            </td>
          <td>
            M. Turi, Pietro Folino, Francesca Barello, Tallya Maciel, Selma Cifric, Paola Rampa, Mehmet K Samur, Giovanni de Nola, Rita Starace, Vanessa Favasuli, Alessandro Salatino, Sofia Pasparaki, Carlo Campa, Delaney Vinaixa, Cole Clericuzio, Priya Thurman, Megan E Johnstone, F. Bonello, Abigail Lytton-Jean, Cirino Botta, Eugenio Morelli, Nikhil C Munshi, Kenneth Anderson, Annamaria Gullà
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Background Myeloid-derived suppressor cells (MDSCs), which include polymorphonuclear-MDSCs and monocytic MDSCs (M-MDSCs), play key roles in disease progression, resistance to immune-cell therapies, and poor clinical outcomes in multiple myeloma (MM). Among them, M-MDSCs are especially potent in suppressing anti-tumor immune responses, making them an attractive therapeutic target. Previous studies have shown that certain human myeloma cell lines (HMCLs) can induce M-MDSC differentiation through the secretion of important mediators like CCL5 and macrophage migration inhibitory factor (MIF), and that blocking these molecules significantly reduces M-MDSC induction. We have previously demonstrated that immunomodulatory drugs (IMiDs), such as lenalidomide (LEN) and pomalidomide (POM), are effective at inhibiting M-MDSC induction by decreasing CCL5 and MIF expression (Kuwahara-Ota S, Br J Haematol 2020); however, the effects of cereblon E3 ligase modulators (CELMoDs) such as iberdomide (IBER) and mezigdomide (MEZI)—which exhibit anti-tumor activity even in LEN- and POM-resistant MM—on M-MDSC induction remain unknown. This study aims to examine the cellular and molecular effects of CELMoDs on M-MDSC induction in the presence of myeloma cells.
 Methods To evaluate how CELMoDs influence M-MDSC induction, we conducted 96-hour co-culture experiments with two HMCLs and peripheral blood mononuclear cells (PBMCs) from healthy donors. IBER, MEZI, and POM were added at the start of co-culture at concentrations known to be non-cytotoxic from MTT viability tests. We identified M-MDSC populations phenotypically and functionally, and analyzed subsequent molecular changes using RNA microarray gene expression profiling and cytokine assays.
 Results While all three agents promoted degradation of Aiolos and Ikaros in HMCLs, IBER (7.5 nM), MEZI (2.5 nM), and POM (1 μM) maintained over 70% viability in HMCLs after 96 hours of treatment. Despite this, IBER (7.5 nM), MEZI (2.5 nM), and POM (1 μM) significantly decreased M-MDSC induction from PBMCs in a dose-dependent manner. Notably, IBER and MEZI inhibited M-MDSC induction at concentrations 150–1000 times lower than those required for POM, indicating their higher potency. Transcriptomic profiling revealed that co-culture with HMCLs significantly upregulated inflammatory response genes, including TNFα/NFκB and IL6–JAK–STAT pathways, in myeloma cells. Conversely, CD33⁺ PBMCs showed downregulation of interferon-α and -γ response gene sets, consistent with the development of an immunosuppressive phenotype. Interestingly, CELMoDs and POM had opposing effects on inflammation-related gene expression in the two cell populations: they suppressed proinflammatory signals in HMCLs, as shown by decreased CCL5 expression, but simultaneously increased the expression of inflammatory and interferon-related genes in CD33⁺ PBMCs, including those involved in TNFα/NFκB signaling. These findings suggest that CELMoDs modulate immune responses in a cell-type-specific manner within the tumor microenvironment. Further analyses demonstrated that all agents suppressed MIF expression in CD33⁺ PBMCs. Consistent with this, pharmacological inhibition of MIF abrogated M-MDSC induction, confirming its mechanistic involvement. Additionally, we observed that CELMoDs and POM reduced IL-10 secretion from HMCLs, a cytokine previously implicated in M-MDSC generation. Neutralization of IL-10 with a specific antibody significantly inhibited M-MDSC induction in co-cultures with IL-10–producing HMCLs but had no effect in IL-10–non-producing HMCLs, underscoring the central role of IL-10 in this process.
 Conclusion This study demonstrates that CELMoDs and POM suppress M-MDSC induction by targeting key immunosuppressive mediators such as IL-10 and MIF. Notably, these agents exert opposing transcriptional effects in tumor and immune cells, attenuating proinflammatory signals in myeloma cells while enhancing immune activation in PBMCs. These dual effects likely contribute to remodeling the tumor microenvironment toward an immune-permissive state. Collectively, our findings provide a mechanistic rationale for using CELMoDs to target MDSCs and enhance anti-tumor immunity in MM.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86ed67fc256c70ceb145554908eb67444703e4f" target='_blank'>
              Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma
              </a>
            </td>
          <td>
            Yui Niiyama-Uchibori, Yu Inoue, Shotaro Chinen, Takahisa Nakamura, Hiroaki Nagata, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Y. Shimura, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 CD8+ T cells have the unique capacity to efficiently detect and eliminate intracellular pathogen-infected cells and tumors. One important functional feature of memory CD8+ T (Tm) cells that we and other characterized in prior works, is their ability to provide early protection during reactivation prior to clonal expansion, by enabling the rapid activation and mobilization of innate immune defenses. However, the molecular transcriptional and epigenetic mechanisms underlying CD8+ Tm cell rapid cognate antigen (Ag) dependent reactivation in vivo are poorly understood. Through single cell transcriptomic and chromatin accessibility analyses of Tm cells early post cognate Ag reactivation, we discovered that a small set of transcription factors (TF) are differentially regulated and have enriched binding sites in newly accessible promoters. We hypothesize that these TF drive the early protective effector program that mediate CD8+ Tm cell-dependent host protection. We are using high dimensional flow cytometry and multiplex assays to explore the kinetic of expression of cognate Ag-dependent TF expression, how they regulate each other and how they control distinct effector functions of the Tm cells. We are also testing the roles of these TF using in vitro and in vivo gain and loss of function approaches. We will present data offering new insights into the transcriptional regulation required for an effective CD8+ Tm cell response.



 Supported by NIH R01 AI103338



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb5ea1846a9c481b19e3f99101f2b081fd4d0b9c" target='_blank'>
              Molecular mechanisms of early memory CD8+ T cell reactivation in vaccinated hosts 4399
              </a>
            </td>
          <td>
            Richard Garcia Betancourt, Marie Boutet, G. Lauvau
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 Aging profoundly impacts the immune system, yet the underlying mechanisms driving age-related immunopathologies remain poorly understood. Previous studies have demonstrated that CD8 T cells undergo significant remodeling with age, where memory CD8 T cells largely replace the naïve cells and form two distinct subsets defined by PD1 expression. However, the data connecting these cells to physiological outcomes remained scarce. In this study, we report striking functional differences between young and aged PD1- memory CD8 T cells. We found that aged PD1- memory CD8 T cells lose antigen specificity upon activation and engage in MHC I-independent killing. Despite lacking canonical surface markers of activated or effector T cells, aged PD1- memory CD8 T cells exhibit a transcriptional profile and surface markers resembling pathogenic CXCR6+ CD8 T cells, known mediators of liver damage in the NASH model. In aged mice, these pathogenic cells accumulate systemically and drive widespread tissue damage. Mechanistically, this process is mediated by Fas-FasL interactions and regulated by IL-15 in an antigen-independent manner. This novel cellular mechanism offers a potential explanation for the extensive tissue damage observed in elderly individuals during inflammatory conditions and underscores the therapeutic potential of targeting CD8 T cells to mitigate age-associated diseases.



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7ea1e9bf0ad0a553f67bfe65bf772b9feed2510" target='_blank'>
              Non-specific cytotoxicity of aged memory CD8 T cells drives excessive tissue damage 3669
              </a>
            </td>
          <td>
            I. Shchukina, Patrick Rodrigues, Veronika Vachova, Jan Kossl, Maxim N. Artyomov
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 The development of long-term memory CD8 T cells from the initial effector pool is crucial for effective adaptive immunity. It is evolutionarily advantageous for the immune system to populate the memory compartment with CD8 T cells proven capable of eliminating tumor cells. We propose that the immune system employs a mechanism of functional “certification” whereby only effector CD8 T cells that successfully engage and kill tumor cells receive the necessary signals for memory differentiation. We present evidence that NKG2D serves as a key signaling checkpoint, certifying effector CD8 T cells with essential translational and epigenetic inputs required for robust anti-tumor memory formation. Our data show that temporary blockade of NKG2D signaling during the effector phase results in the development of dysfunctional memory CD8 T cells. Mechanistically, NKG2D engagement increases levels of phosphorylated RPS6 and downregulates the expression of DNMT3a and DNMT3b, indicating that NKG2D modulates the translational machinery and epigenetic programming of CD8 T cells. Notably, these “uncertified” memory cells failed to protect against a melanoma challenge. Our findings reveal a previously undescribed role for NKG2D in guiding effector CD8 T cells toward a functional memory fate in anti-tumor immunity, providing insights with significant implications for vaccine development and adoptive cell therapies targeting cancer.



 This study was supported by the RO1 CA188395 and the Volo Helath Family Foundation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d4b56d9d6f8c5e7860273edded80c727e0e5d13a" target='_blank'>
              NKG2D Signaling Certifies Effector CD8 T Cells for Anti-tumor Memory Formation 2320
              </a>
            </td>
          <td>
            J. Guevara-Patiño
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="


 Introduction While autologous CD19-directed CAR-T cell therapy has been highly efficacious in certain B cell malignancies, its efficacy in chronic lymphocytic leukemia (CLL) has been limited by toxicity and T cell dysfunction characteristic of CLL pathophysiology. CAR natural killer (CAR-NK) therapy holds promise as a possible alternative due to a favorable toxicity profile and off-the-shelf allogeneic sourcing potential. A potential challenge for CAR-NK therapy in CLL is the emergence of compensatory pro-survival signaling in tumor cells which may inhibit tumor cell apoptosis. Receptor tyrosine kinase-like orphan receptor (ROR1) is ubiquitously expressed on CLL cells, and signaling via its ligand Wnt5a has been associated with both ibrutinib and venetoclax resistance; however, its connection to cell therapy resistance remains underexplored. Here, we studied Wnt5a-induced ROR1 signaling as an underlying CAR-NK resistance mechanism in CLL and leveraged our findings to develop a novel dual CAR-NK construct designed to overcome apoptotic resistance in CLL.
 Methods ROR1 expression on peripheral blood-derived primary CLL cells was measured via flow cytometry. CLL cells were incubated with 200ng/mL of recombinant Wnt5a and were assessed for their apoptotic priming via BH3 profiling, a functional assay that measures the proximity of tumor cells to the apoptotic threshold and cellular dependence on specific anti-apoptotic proteins. Resistance to NK-mediated killing was evaluated by treating CLL cells with 1ug/mL Wnt5a and exposing them to either CD19-CAR-NK or untransduced primary NK cells, with Annexin V and propidium iodide (PI) staining used to assess CLL cell apoptosis. The ROR1 inhibiting monoclonal antibody (mAb) zilovertamab was used to investigate attenuation of Wnt5a/ROR1-associated survival. Tandem, 2nd generation anti-CD19/ROR1 (dual) CAR constructs were designed by joining an anti-CD19 scFv with an anti-ROR1 scFv via a (G4S)4 linker, followed by a 4-1BB costimulatory domain and a CD3Z signaling domain. CAR constructs were transduced into Jurkat and peripheral blood-derived primary NK cells via an optimized baboon lentivirus protocol. Effector cell activation and cytotoxicity against primary CLL cells, a CD19+ CLL-derived cell line MEC-1, and the ROR1+ NCCIT cell line were evaluated via flow cytometry-based readouts of NK activation marker expression and Annexin/PI staining.
 Results ROR1 expression was confirmed as present in primary CLL cells in all samples (n=33, ΔMFI [ROR1-Isotype] range: 346–2199). Stimulation of the cells with Wnt5a led to reduced apoptotic priming by 11–18% at 4h and 14–42% at 24h (BIM 0.1 µM), with greater reductions observed in high-ROR1 samples. Correspondingly, high-ROR1+ CLL samples incubated with Wnt5a exhibited up to 20% reduction in cell death compared to untreated conditions when co-cultured with either CD19 CAR-NK or untransduced primary NK cells. In venetoclax-treated CLL cells, zilovertamab reversed Wnt5a-induced resistance to NK-mediated killing, restoring cell death levels from 7.6% to 13.9% and restored apoptotic priming by increasing BIM-induced cytochrome C release from 5% to 18%.
 Dual CAR-Jurkat cells showed increased expression of CD69 in the presence of either CD19+ MEC1 or ROR1+ NCCIT cell lines, while single-directed CARs exhibited no increase in activation against nonspecific targets. Dual CAR-NK cells similarly demonstrated higher CD69 expression in primary CLL patient cells (n=6) compared to single-targeting and untransduced NK cells at 16h. Cytotoxicity assays also showed that the dual CAR-NK kills at least as well as CD19-CAR-NK, and outperformed ROR1-CAR-NK and untransduced NK cells across high- and low-ROR1 patients.
 Conclusion We demonstrated that Wnt5a-induced ROR1 signaling is a key pathway that reduces CLL cell priming for apoptosis and enhances CLL cell survival against NK cells, a process reversible ex vivo by zilovertamab. We subsequently developed a novel tandem CD19/ROR1 CAR-NK product with enhanced activation against CLL cells compared to single-directed CARs. This dual CAR-NK also has the potential to subvert single antigen escape. In vivo studies are underway using NSG mice engrafted with HG3 CLL cells engineered to express both ROR1 and constitutive Wnt5a to assess whether a novel dual CAR-NK product expressing the D10-derived anti-ROR1 scFv (derived from zilovertamab) more effectively reduces tumor burden compared to non-ROR1-inhibiting CAR constructs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e744636b917a48416c5a21d06b1eaab753958a65" target='_blank'>
              A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Salem Elias, Andrew Lu, Fuguo Liu, Xingyu Deng, Olivia Stringham, Jeremy Zhang, Nathalie Javidi-Sharifi, Lara Bencsics, Stephanie Chamberlain, R. Romee, M. Davids
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="


 Suppressive immune cells and their associated cytokines and chemokines promote vascular endothelial proliferation and malformation, hindering immune cell penetration into the tumor core. In a phase II trial combining bevacizumab with atezolizumab in metastatic NSCLC patients (with a disease control rate of 87.5%) whose disease progressed after atezolizumab monotherapy, we analyzed blood biomarker changes collected at baseline, one week post-therapy, and at disease progression. Myeloid cells, including neutrophils, PMN-MDSCs, and M-MDSCs, were significantly correlated with responses to therapy. Durable responders exhibited high CXCL5 levels (p = 0.005) in blood. Additionally, lower neutrophil-to-lymphocyte ratios (p = 0.022), PMN-MDSCs (p = 0.036), and PD1+CD8+ T cells (p > 0.001) were associated with improved overall survival. Lower levels of suppressive proteins, including TCTP (p = 0.013), IL-6 (p < 0.001), IL-18 (p = 0.03), VEGF-A (p < 0.001), TIE-2 (p = 0.06), PD-L2 (p = 0.041), and CD147 (p = 0.008), were associated with better survival outcomes, highlighting their roles in therapy resistance. In vivo, vascular malformation and immune cell exclusion were prominent, with differential immune cell distribution between the tumor core and edge depending on hypoxia and vascular abnormalities. Combination therapy reduced suppressive and exhausted immune cells. These findings underscore the role of myeloid cells and factors such as IL-6, TCTP, and VEGF-A in resistance to therapy.



 This research was supported by NRF (National Research Foundation of Korea) funded by the Korean Government (RS-2022-NR075028)



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b83f651a43406b89a53faee6059bef8047e5b3f" target='_blank'>
              Immune exclusion driven by myeloid cells contributes to resistance to checkpoint inhibitor and anti-angiogenic therapy in NSCLC 4771
              </a>
            </td>
          <td>
            J. Koh, Young Kyoung Lee, Mi Soon Kim, B. Ku, Sehhoon Park, Myung-Ju Ahn
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains a paradigm of immunotherapy resistance, characterized by minimal effector T cell infiltration and failure to respond to immune checkpoint blockade (ICB) therapies such as anti-PD-1. In contrast, autoimmune states such as experimental autoimmune encephalomyelitis (EAE)—a murine model of multiple sclerosis—elicit robust, antigen-specific T cell responses within the central nervous system. We hypothesized that proinflammatory mechanisms sustaining autoimmunity in EAE could be co-opted to overcome immune tolerance in GBM. Single-cell RNA sequencing was used to profile T cell phenotypes from EAE and syngeneic GBM (CT-2A) models. EAE was induced in tumor-bearing mice, and tumor-specific EAE variants were generated using tumor cell lysate immunization. Cytokine expression was profiled via Luminex and white matter changes were visualized with diffusion tensor imaging and T2 mapping. Functional studies included adoptive transfer of CD3+ T cells or regulatory T cells, and hydrogel-based delivery of IL-6, IL-23, and anti-TGF-β to tumor-draining lymph nodes (TDLNs). T cell bioenergetics were assessed via Seahorse metabolic profiling and flow cytometry. EAE induction in GBM-bearing mice significantly improved survival and increased intratumoral Th1 and Th17 T cell infiltration. Tumor lysate immunization reproduced these effects and sensitized tumors to anti-PD-1 therapy. IL-6, IL-23, and IL-1β were identified as shared inflammatory mediators in both EAE and tumor-immunized states. Targeted lymphoid conditioning via hydrogels loaded with recombinant IL-6, IL-23, and anti-TGF-β reprogrammed TDLNs, enhanced T cell activation and oxidative phosphorylation, and extended survival (P<0.0001). Therefore, autoimmune inflammatory circuits can be repurposed to recondition the immunosuppressive GBM TME. Lymphoid niche modulation using a combination of IL-6, IL-23, and TGF-β blockade offers a novel strategy to sensitize GBM to currently available immunotherapeutic strategies such as anti-PD-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec557fff3154e9f6980a04bed886b991ce663c85" target='_blank'>
              IMMU-13. Leveraging the immune milieu of experimental autoimmune encephalomyelitis to perpetuate an anti-tumor T cell response in glioblastoma
              </a>
            </td>
          <td>
            John Choi, Lily H Kim, John Klich, Andrew Tran, Peggy Ho, Rohit Verma, Kwang Bog Cho, Si Yeon Lee, Gordon Li, Lawrence Steinman, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Glioblastoma (GBM), the most common and malignant primary brain tumor, exhibits profound immune suppression, hindering immunotherapy efficacy. GBM-derived extracellular vesicles (EVs) play a major role through the immunosuppressive polarization of myeloid cells. Inhibition of EV-myeloid cell interactions thus represents a novel target to mitigate GBM-mediated immune suppression. However, there are multiple mechanisms of EV-target interaction, and downstream pathways of GBM-EV signaling are poorly understood. We explored two pharmacological agents targeting different mechanisms of EV uptake: Methyl-B-cyclodextrin (MBCD), which disrupts lipid rafts, and cytochalasin D, which inhibits actin polymerization. Our results showed immunosuppressive myeloid cell (CD11b+/ CD15-/ HLA-DRlow/ CD14high) populations increased upon GBM-EV treatment. Following cytochalasin D treatment, fewer immunosuppressive myeloid cells were observed (7.40%±1.01 vs. untreated 9.66%±2.86), with rescuing T cell proliferation. Conversely, MBCD treatment increased immunosuppressive myeloid cell levels (10.42%±2.38 vs. untreated 8.87%±3.97) without impacting T cell proliferation. This study demonstrates the feasibility of pharmacologically targeting EV-myeloid cell interactions to rescue tumor mediated immune suppression by inhibiting actin-dependent endocytosis with cytochalasin D. The converse results using MBCD treatment indicate differential importance of different EV uptake pathways in monocyte regulation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c83aad2ce4bc7312164a625b88f12016523ef26e" target='_blank'>
              Selective Targeting of EV Uptake Pathways in Glioblastoma to Combat Tumor-Induced Immune Suppression 4324
              </a>
            </td>
          <td>
            Minori Aoki, Mohammad Asad, Julio Inocencio, Stefan Mitrasinovic, C. Crisman, Ian Parney, Patrick Lasala, Vijay Agarwal, Emad Eskandar, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is the deadliest primary brain tumor, characterized by immunosuppression, low infiltration of lymphocytes, and lack of response to immune checkpoint blockade (ICB) therapies. In other solid tumors, the presence of functional B cells is predictive of response to ICB. However, in GBM, although B cells are antigen-experienced, they do not differentiate to functional plasma cells. B cell activation is opposed by inhibitory signaling, especially mediated through the key inhibitory receptor CD22, which must be halted for differentiation to proceed. We hypothesized that GBM-infiltrating B cells are functionally arrested via CD22 and the immunosuppressive GBM microenvironment, which is characterized by high numbers of tumor-associated myeloid cells (TAMs). Using patient GBM samples and GBM single-cell RNA sequencing data, we showed that TAMs such as microglia strongly express the CD22 ligand α2,6 sialic acid and the α2,6 sialic acid-synthesizing enzyme ST6GAL1. We created an in vitro model of TAMs by treating murine bone-marrow-derived myeloid cells (BMDMs) with supernatant from the murine glioma cell line CT2A. Tumor cell supernatant doubled the expression of α2,6 sialic acid on the TAMs compared to BMDMs, driven by increased expression of St6gal1, showing that secreted factors from tumor cells may remodel TAMs toward a more immunosuppressive state. To elucidate the direct impact of myeloid cells on B cells, we cocultured B cells with TAMs or the microglial cell line BV2. B cells cocultured with TAMs and BV2 cells showed increased phosphorylation of repressive signaling molecules downstream of CD22, including p-SHP-2 and p-SHIP1. This study suggests that myeloid cells are reprogrammed in the context of the tumor microenvironment to become more suppressive to B cells. In future work, we aim to develop a therapeutic targeting α2,6 sialic acid on TAMs in vivo to restore B cell function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c16dc7ca0407ae61b2e9c308129f9a72d793423" target='_blank'>
              TMIC-72. Glioma-associated myeloid cells promote B cell inhibition
              </a>
            </td>
          <td>
            Alina R Murphy, Si Wang, G. Vázquez-Cervantes, Hanxiao Wan, Joshua Katz, Rebecca Du, Jiawei Huo, Tzu-yi Chia, Leah K. Billingham, Suzi Delay, M. Lesniak, Peng Zhang, J. Miska, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Respiratory syncytial virus (RSV) infection causes significant morbidity in elderly adults. To determine how advanced age impacts myeloid cell (MC) antiviral responses, we developed a 3D human lung model (HLM) to recapitulate the small airway. The HLM is composed of layered primary differentiated small airway epithelial cells at air-liquid interface, fibroblasts embedded in collagen, and endothelial cells. Introduced blood MC (monocytes and dendritic cells) from 36-40yo (Adult) or 69-88yo (Elderly) donors migrated throughout the HLM. Recovered MC were assessed using flow cytometry, microscopy, and transcriptional profiling. MC acquired phenotypes and morphology of tissue-resident cells, indicating adaptation to the airway environment and differentiation into tissue-resident macrophages. However, prior to infection, sorted Elderly MCs showed reduced expression of genes promoting macrophage differentiation and function, e.g. PPARG, MARCO, INHBA, yet showed higher basal expression of pro-inflammatory genes, e.g. IL18, CDKN1A, TLR9, compared to sorted Adult MCs. After RSV challenge, HLM built with Elderly MC harbored significantly more RSV RNA, consistent with poor induction of genes in IFN signaling, viral sensing, and macrophage activation pathways. Thus, diminished expression of canonical macrophage genes, increased baseline inflammation, and reduced ability to build up antiviral IFN responses contribute to the impaired viral clearance in HLM bearing Elderly MC.



 Funded by NIH R01 EB025596



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23985d18f4cdd665e0b30abb7a4851c7e3a9795d" target='_blank'>
              Age shapes the myeloid cell antiviral response to RSV infection in a human airway tissue model 4051
              </a>
            </td>
          <td>
            S. Kovats, Mandi M. Roe, Taylor Do, Magdalena Chlebicz, Sean Turner, Laura Mejia, Antonius Oomens, H. Gappa-Fahlenkamp
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="


 Background: Acute Myeloid Leukemia (AML) is characterized by a profoundly dysregulated bone marrow microenvironment (BME) that fosters disease progression and immune escape. While inflammatory cytokines are pivotal in shaping immune responses, a comprehensive understanding of their complex interplay, prognostic significance, and mechanistic roles in AML, particularly across different FAB subtypes, remains a critical unmet need.
 Aims: This study aimed to: 1) comprehensively profile inflammatory cytokines in AML patient BME and identify those with prognostic significance; 2) delineate the cellular sources and inter-cytokine regulatory mechanisms within the AML BME using cutting-edge single-cell transcriptomics; and 3) investigate the functional impact of key inflammatory axes on immune cell function and explore their potential as novel therapeutic targets.
 Methods: We analyzed bone marrow supernatant from46 AML patients and 20 healthy controls for 20 inflammatory cytokines. Clinical correlations, including 5-year overall survival (OS), genetic risk stratification, and FAB subtype, were assessed using ROC analysis, univariate and multivariate Cox regression. For mechanistic insights, single-cell RNA sequencing (scRNA-seq) was performed on bone marrow samples from AML patients and healthy individuals. We employed an innovative CNV, tumor score, classification score methods for robust tumor cell clustering. Subsequent analysis involved mapping cytokine expression to specific cell types, performing ligand-receptor pairing, immune cell communication analysis, and signaling pathway enrichment. Inflammatory cytokine interaction networks were constructed using Cytoscape and STRING. Functional studies utilized in vitro co-culture systems with AML cell lines and primary patient cells, assessing T cell chemotaxis and cytotoxicity, followed by rescue experiments with cytokine modulation.
 Results: Our initial profiling identified 7 significantly dysregulated inflammatory cytokines in AML patient BME. Among these, 5 were significantly associated with 5-year OS, and 2, including IL-1A, emerged as independent prognostic factors for adverse OS. Cytokine expression also varied significantly across FAB subtypes, with M1 and M2 exhibiting distinct inflammatory profiles compared to M5 AML, suggesting an influence of tumor cell origin. ScRNA-seq revealed CCL3 and CCL4 were primarily expressed by healthy T cells, whose numbers and functional capacity were notably reduced in AML patients, with increased naive T cells and decreased CCL3/4 expression. Ligand-receptor and cell communication analyses confirmed reduced CCL3/4 impaired immune cell recruitment and tumor-killing. Network analysis highlighted IL-1A as a central regulator that significantly influenced CCL3/4 expression on T cells. Elevated BME IL-1A was found to suppress T cell CCL3/4 expression, directly contributing to impaired T cell chemotaxis and cytotoxicity. In vitro functional assays demonstrated IL-1A inhibition (using antagonists) restored T cell CCL3/4 expression and anti-leukemic activity. Importantly, exogenous CCL3/4 supplementation synergized with IL-1A inhibition, leading to robust recovery of T cell function and enhanced tumor suppression.
 Conclusion: Our study provides a comprehensive systems-level inflammatory cytokine atlas in AML, identifying IL-1A as a critical independent prognostic factor and a central player in AML immune evasion. We innovatively demonstrate that IL-1A orchestrates the suppression of the CCL3/4-T cell chemotaxis axis, leading to impaired T cell function and compromised anti-tumor immunity. This finding, particularly pronounced in specific FAB subtypes like M5 AML, highlights a novel mechanism by which the AML microenvironment promotes disease progression. Our preclinical data suggest that targeting IL-1A, either alone or in combination with CCL3/4 supplementation, represents a promising immunomodulatory strategy to restore T cell function and improve therapeutic outcomes in AML. These insights open new avenues for refining prognostic models and developing precision immunotherapies for AML patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a819f457cfa0e8527729fec197131b12c0dfcd4f" target='_blank'>
              Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target
              </a>
            </td>
          <td>
            Shuqing Wang, Jian Li
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in the treatment of hematological malignancies. However, the immunosuppressive tumor microenvironment of both solid and liquid tumors is a major barrier for CART efficacy. Immunosuppressive myeloid cells inhibit CART efficacy. Colony-stimulating factor 1 receptor (CSF1R) promotes macrophage proliferation, survival, and anti-inflammatory response and is upregulated on myeloid cells in many cancers, making CSF1R an appealing therapeutic target. We aimed to test the interactions between CSF1R, myeloid cells, and CART response, and to study CSF1R targeting in the context of CART cell therapy. We utilized CD19-targeted CART cell therapy (CART19) in lymphoma preclinical models and thyroid-stimulating hormone receptor (TSHR)-targeting CART cell therapy (TSHR-CART) in thyroid cancer models.
 We first measured CSF1R expression on myeloid cells in vitro. Suppressive myeloid cells, polarized from healthy donor monocytes using an anaplastic thyroid cancer (ATC) cell line, 8505c, or mantle cell lymphoma cell line, JeKo-1, significantly upregulate CSF1R (p=0.0002) compared to media control. After polarization, myeloid cells significantly inhibit TSHR-CART and CART19 antigen-specific proliferation compared to freshly isolated monocytes (p=0.012, p<0.01, respectively) indicating that suppressive myeloid cells contribute to CART failure in multiple tumor types.
 We then performed single cell RNA sequencing on peripheral blood taken at baseline from patients with mantle cell lymphoma treated with CART19. We found a significant increase of CSF1R on monocyte subsets in CART19 non-responders vs responders (padj=0.0037).
 Next, we determined the impact of CSF1R blockade on CART cell therapy in vivo. Using lymphoma models, B6 mice were engrafted with the luciferase+ CD19+ murine lymphoma cell line TBL-12 (1x106 cells i.v. 1 day after 250 mg/kg cyclophosphamide). Tumor burden was significantly reduced after 7 days of treatment with low dose CART19 (0.5x106 i.v.) + anti-mouse CSF1R antibody (16mg/kg i.p. twice weekly) vs CART19 + IgG control (p=0.0146). We then tested the impact of CSF1R blockade in mice experiencing tumor relapse. After TBL-12 engraftment, mice were treated with anti-mouse CSF1R or IgG control antibody followed two days later with high dose CART19 (1x106 i.v.) to induce remission. Mice were re-challenged with TBL-12 14 days later. Mice treated with anti-mouse CSF1R antibody showed increased tumor control and significantly higher survival (p=0.0416).
 Using thyroid cancer models, first we identified high macrophage infiltration in biopsy specimens of patients with ATC compared to normal thyroid tissue and benign thyroid tumors through immunohistochemistry (IHC) of patient samples (p<0.01, p<0.0001, respectively). To test if macrophages are associated with CART failure in ATC, NSG mice were subcutaneously engrafted with 1x106 TSHR+ THJ529 tumors, an ATC cell line derived from patient biopsy samples from the Mayo Clinic thyroid cancer biobank, followed by i.v. treatment with 1x107 TSHR-CART or untransduced T cell control (UTD). IHC staining of tumor tissue collected at experimental endpoints revealed a dose-dependent, significant infiltration of human CD3+ T cells into the tumors which inversely correlated with murine F4/80+ myeloid cell and murine YM-1+ M2 macrophage infiltration.
 This led us to hypothesize that myeloid cell targeting with CSF1R blockade can improve TSHR-CART efficacy. We utilized the same ATC model described above to test CSF1R targeting. When TSHR+ THJ529 tumors reached approximately 100 mm3, mice were randomized by tumor volume and treated with CSF1R inhibitor PLX5622 (600mg/kg) or vehicle control, followed by either UTD or TSHR-CART cells 5x106 i.v. Mice treated with TSHR-CART + PLX5622 showed significantly improved tumor control vs TSHR-CART + vehicle control (p<0.0001) or UTD + PLX5622 (p<0.0001).
 Together, our results highlight immunosuppressive myeloid cells which express CSF1R as a major cell type limiting CART efficacy in both solid and liquid tumors. We also identified a strategy to overcome myeloid-mediated suppression of CART cells by targeting CSF1R with antibody or small molecule inhibitors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e70c6725806d92da3358391536cc8d0798874cb" target='_blank'>
              Targeting CSF1R to overcome myeloid cell suppression in CART therapy
              </a>
            </td>
          <td>
            Grace DeFranco, Kun Yun, Claudia Manriquez Roman, Jennifer M Feigin, Samuel Olivier, M. Hefazi Torghabeh, C. Stewart, Brooke L. Kimball, E. Siegler, T. Huynh, J. Gleba, M. Pawlush, Andrew Zakko, Michael Redig, Skyeler Klinge, Long K Mai, Aylin Alasonyalilar Demirer, James L Miller, Erin Miller, R. Sakemura, Ismail Can, O. Sirpilla, Omar L Gutierrez Ruiz, Dominic A. Skeele, Sophia Y. Goldberg, Sara Foote, Ateka Saleh, Hong Xia, E. Ogbodo, Yushi Qiu, R. Smallridge, Abba Zubair, H. Tun, John A. Copland, S. Kenderian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="


 Background: Autologous stem cell transplantation (ASCT) remains the standard of care consolidation in eligible patients with multiple myeloma. Typically, this is followed by lenalidomide maintenance therapy until progression or intolerance. This combinatorial approach results in improved progression-free survival compared to drug-based consolidation. However, the majority of patients ultimately relapse, consistent with myeloma progression and immune escape. Increasing evidence suggests that myeloma may invoke a suppressive tumor microenvironment (TME), principally in the bone marrow (BM), which may impair endogenous T cells and/or therapeutic T cell engagers or chimeric antigen receptor T cells targeting tumor antigen. Immunosuppressive myeloid cells are known to be abundant in the TME, and we and others have previously implicated macrophages in this process.
 To examine potential cellular sources of immunosuppression in the TME, we used flow cytometry to analyze myeloid cells in the BM from patients undergoing ASCT for myeloma. BM mononuclear cells were isolated from aspirates drawn at approximately 2-6 weeks prior to ASCT (n=13), 90 days post-transplant, and at relapse or 1-year post transplant. Post-transplant samples were categorized as relapsed (n=12) or controlled for >1 year (n=8). BM from patients with progressive myeloma was characterized by a population of CD64+CD172+ macrophages that express CD169, putatively marking BM residency, and exhibiting a highly immunosuppressive phenotype evidenced by expression of CD163, CD155, PD-L1, and CSF-1R. Notably, the frequency of CD169+CD163+ macrophages (within CD64+ cells) but not the CD64+CD172+ macrophage population as a whole were expanded in patients at the time of relapse (mean frequency pre-ASCT: 3.46%, D+90: 2.96%, controlled: 4.02%, relapse: 13.83%; P<0.05 relapse vs. controlled; P<0.01 relapse vs. pre-ASCT or D+90), and correlated with multiple myeloma burden in the BM (r2 = 0.477, P=0.0103).
 Using a preclinical system of ASCT in mice bearing VK*MYC myeloma, we identified a similar macrophage subset in the BM, characterized as CD11b+Ly6GnegCD11c+CD64+ with high expression of CSF-1R, PD-L1, and F4/80. We sought to target these putatively immunosuppressive macrophages, using antibody-based CSF-1R inhibition, to determine whether we could augment lenalidomide maintenance after ASCT. We used a suboptimal T cell dose wherein endogenous anti-myeloma immunity is limited and assessed each therapy alone and in combination. We used cereblon (CRBN)-transgenic mice that are genetically modified to allow engagement of thalidomide and its derivatives (including lenalidomide), resulting in degradation of the IMiD targets, Aiolos and Ikaros. As expected, CSF-1R inhibition efficiently ablated the CX3RC1+Ly6Clo monocyte population in the blood and BM (mean frequency in lineage negative in blood: 2.9% vs. 18.1% in isotype-treated; in BM: 0.4% vs. 5.8% in isotype-treated; p<0.001 for both sites). While single agent CSF-1R inhibition or lenalidomide had no significant effect on disease progression, the combination of the two agents had a synergistic effect in attenuating myeloma relapse after ASCT. At 108 days follow-up, median overall survival for mice receiving CSF-1R inhibition and lenalidomide was not reached, while median survival was 65 days for either isotype- or lenalidomide-treated mice, and 77 days for mice receiving only CSF-1R inhibition (P<0.05). Myeloma M band progression was also significantly reduced with combination therapy (p<0.001).
 Conclusion: The ability of CSF-1R inhibition to deplete CSF-1R+ macrophages and prevent tissue fibrosis has previously been demonstrated in preclinical models of chronic graft-versus-host disease (GVHD). Subsequent clinical trials have proven axatilimab, a human anti-CSF-1R antibody, to be well tolerated and effective for the treatment of chronic GVHD, leading to FDA approval. Given lenalidomide is already a standard maintenance therapy, combination therapy with axatilimab represents a readily testable clinical strategy for augmenting progression-free survival in patients with multiple myeloma after ASCT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93ee7098bb14373b537fde66a2a31ad8ddc75d5f" target='_blank'>
              CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation
              </a>
            </td>
          <td>
            Simone A. Minnie, Rachael Adams, Kathleen S. Ensbey, Christine R. Schmidt, Melissa Comstock, Justina Lyons, Samuel R. W. Legg, Tomoko Sekiguchi, Nicole S. Nemychenkov, Julie R. Boiko, M. Koyama, Andrew Spencer, Damian Green, Geoff Hill
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 This work aims to understand how myeloid cell development and function are dysregulated in Down syndrome (DS). Introduction: Individuals with DS experience severe immune dysregulation, including altered myeloid cell function and hyperactive interferon (IFN) signaling. However, it’s unclear which phenotypes are cell-intrinsic effects of trisomy 21 (T21) or how IFN signaling impacts myeloid cell function in DS.



 Induced pluripotent stem cells (iPSCs) generated from individuals with and without DS were used to create hematopoietic stem and progenitor cells (HSPCs). These HSPCs underwent myelopoiesis, and cell subsets were characterized by flow cytometry. Myeloid functions, such as phagocytosis and NET formation, were measured after stimulation in the presence or absence of IFNs.



 T21 samples showed lower ratio of mature to progenitor immune cells during myelopoiesis and impaired production of total myeloid cells and monocytes. IPSC-derived and primary T21 monocytes showed impaired phagocytosis of S. Aureus at baseline and after IFN treatment. Meanwhile, unstimulated and PMA-stimulated T21 neutrophils showed elevated and earlier NET formation.



 T21 results in cell-intrinsic alterations in monocyte production and defects in phagocytosis of bacteria, both in the presence and absence of interferons. Elevated and earlier NET production suggest that T21 neutrophils are primed for NET formation.



 NIH grant R01AI150305, NIH grant R24OD035579, Linda Crnic Institute for Down Syndrome, Global Down Syndrome Foundation, and the Anna and John J Sie Foundation.



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/66da24ad513bbfe58177e311cbeb37debf473082" target='_blank'>
              Multimodal analysis of dysregulated myeloid cell function in Down syndrome 9171
              </a>
            </td>
          <td>
            Brian F. Niemeyer, Eleanor C. Britton, Madeline Hipp, Pamela Navarrete, A. Rachubinski, Joaquin M. Espinosa
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Background: Despite recent advancements in the treatment of chronic lymphocytic leukemia (CLL), Richter's transformation (RT) into diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge with poor outcomes (Coombs et al., 2023). While CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) has shown efficacy in de novo DLBCL, its effectiveness in RT is less well defined (Kittai et al., 2024). Factors such as prior treatment, T cell exhaustion, and distinct immune microenvironments may contribute to limited efficacy in DLBCL (Fraietta et al., 2018; Jain et al., 2023). We evaluated clinical outcomes and immune correlates of CD19 CAR-T in patients with RT at our institution.
 Methods: We retrospectively analyzed 15 patients with RT-DLBCL treated with CD19 CAR-T between 2017 and 2024. A comparator cohort of 19 patients with de novo DLBCL treated with CD19 CAR-T was also analyzed. Pre-infusion peripheral blood mononuclear cells (PBMCs) were analyzed using multiparametric flow cytometric profiling. RNA expression from tumor biopsies was analyzed using NanoString transcriptomic profiling with the IO360 panel, which includes 770 genes found in the tumor microenvironment.
 Results: Fifteen patients with RT-DLBCL were included, 47% male with a median age at infusion of 69 years (range 47-77). The median interval from CLL to RT diagnosis was 41 months (range: 7-210), and from RT diagnosis to CAR-T was 20 months (range: 2-50). CAR-T products used were tisagenlecleucel (tisa-cel, 53%), lisocabtagene maraleucel (liso-cel, 27%), and axicabtagene ciloleucel (Axi-cel, 20%). One patient had received an allogeneic CAR-T product 7 months prior to Tisa-cel. Three patients received hematopoietic stem cell transplant before CAR-T (2 autologous, 1 allogeneic). Leading up to CAR-T, 93% had received RT-directed therapy (median 4 lines) and 66% had received prior CLL therapy. Cytokine release syndrome (CRS) occurred in 67% (7% grade ≥3) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 40% (13% grade ≥3). Overall response rates (ORR) were 80% at day 30 and 47% at 3 months. The median follow-up was 9 months.
 In the comparator de novo DLBCL cohort, median age at CAR-T was 68 (25–76), with 68% male. Most (74%) had received 1–2 prior lines of therapy before CAR-T. The majority (18/19) received axi-cel, and one patient received tisa-cel. Three patients received an autologous stem cell transplant before CAR-T. CRS of any grade occurred in 79% (11% grade ≥3), and ICANS in 74% (42% grade ≥3). The ORR was 88% at day 30 and 82% at 3 months. The median follow-up period was 26 months (range: 1-67).
 Flow cytometry revealed significantly higher frequencies of exhausted T cells in RT patients compared to de novo DLBCL (p=0.0329). RT patients had significantly higher frequencies of TCF1⁺ PD1⁺ (p=0.0217) and TCF1⁺ TIGIT⁺ (p=0.0158) CD8+ T cells, indicating a predominance of dysfunctional precursor-exhausted populations in circulation prior to CAR-T infusion. Moreover, there was an increase in central memory (CM, CD45RO⁺ CCR7⁺) CD8+ T cells in RT samples compared to de novo DLBCL (p=0.0436). Notably, these CM cells exhibited a significantly more exhausted phenotype in RT patients than in de novo cases (PD-1+ p=0.0266, TIGIT+ p=0.0490). Supporting the exhaustion phenotype found by flow cytometry, Nanostring analysis confirmed a significant increase in ENTPD1 expression, a gene that encodes the ectonucleotidase CD39, in tumors from RT patients compared to de novo DLBCL (p=0.02), as well as an increase in DUSP2 expression (p<0.0001), a phosphatase associated with exhaustion on tumor-infiltrating T cells and poor outcomes (Lu 2020; Dong 2018).
 Conclusions: CD19 CAR-T therapy shows promising initial responses in RT, though durability remains limited. Compared to de novo DLBCL, RT patients exhibit higher pre-treatment T cell exhaustion and more immunosuppressive tumor gene expression profiles, which may underlie poorer CAR-T durability. Ongoing transcriptomic analyses will further elucidate tumor-intrinsic and microenvironmental mechanisms of CAR-T resistance in RT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8898e13acca4c0791f3ab6eeb2b41de76671fe10" target='_blank'>
              Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation
              </a>
            </td>
          <td>
            M. B. Hammami, C. Savid-Frontera, Sean Haney, Douglas Marachion, Sean Yoder, Mohammad Hussaini, Michael D. Jain, Frederick L Locke
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 The immunosuppressive tumor microenvironment is a major challenge in GBM. We are developing oncolytic Zika virus (ZIKV) as a treatment that targets treatment-resistant glioma stem cells and ignites CD8+ T-cell dependent anti-tumor immune response. We previously demonstrated that ZIKV infection significantly improves survival in multiple mouse models of GBM (Nair et al, JCI insight, 2021). However, myeloid driven immunosuppression remains a critical barrier. While Siglec-15 has recently been described as a myeloid immune checkpoint in other cancers (Wang et al, Nat Med, 2019), it is relatively unexplored in GBM. An antibody against Siglec-15 is in a phase II clinical trial for metastatic solid tumors (NCT04699123), but not tumors of the central nervous system. In human GBM specimens, we observed that Siglec-15 is highly expressed on myeloid (16-23%) and tumor cells (18-19%). Here, we use therapeutic and genetic approaches to target Siglec-15, as well as immunotherapy-resistant mouse models of GBM. In CT2A-bearing mice, long-term survival (90 days) increased from 40% (only ZIKV) to 60% (anti-Siglec-15+ZIKV). Adding antibody against PD-1 further improves the long-term survival (83%). In the immunotherapy-resistant SB28 model, triple therapy (anti-Siglec-15+ZIKV+anti-PD-1) led to 76% long-term survivors and greater CD8+ T-cell activation (1.7-fold). Upon re-challenge of cured mice, we detected an increase in CD8+ brain resident memory T-cells (11-fold) and CD8+ effector memory T-cells (11-fold), and 80% of mice survived. These findings with antibody against Siglec-15 were further confirmed using Siglec-15 knockout mice. Mechanistically, using bone marrow derived myeloid cells and T-cell proliferation assays, we determined that depletion of Siglec-15 improves phagocytosis of tumor cells (CT2A; 25.2% and SB28; 6.9%) and significantly improves T-cell activation (81%) and T-cell proliferation (86.8%), and these findings may explain why we observed improved outcomes. These results suggest the potential of this triple therapy in overcoming the problem of the immunosuppressive tumor microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a95001b5599103be9128f5ed56fc151095bff75" target='_blank'>
              TMIC-21. Dual blockade of Siglec-15 and PD-1, combined with oncolytic Zika virus therapy, confers protection against immune-resistant gliomas
              </a>
            </td>
          <td>
            Ashwani Kesarwani, Sonam Verma, Amber Neil Griffith, Tong Hu, Fei Shu, Amanda Andrade de Costa, Y. Li, Mridu Kanga, Brett H Herzog, D. DeNardo, Mai Dang, Jingqin Luo, Pei-Yong Shi, Xuping Xie, Jun Wang, Lieping Chen, Albert Kim, Peggy L. Kendall, Michael S Diamond, Milan G Chheda
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) remains a clinical challenge due to high relapse rates, primarily driven by therapy-resistant leukemic stem and progenitor cells (LSCs). We proposed that intrinsic inflammatory signaling events serve as a survival mechanism in leukemic cells, but that the balance between beneficial and deleterious inflammatory signaling is finely regulated and context-dependent. Indeed, we have previously shown that TNF receptor 1 (TNFR1)-dependent signaling readily kills AML in vivo by activating Receptor-interacting protein kinase 3 (RIPK3) (PMID: 27411587). Hence, we speculated that disruption of critical pro-survival signaling nodes downstream of TNFR1 can be leveraged therapeutically.
 In this study, we describe a novel cytokine-based therapeutic strategy that selectively kills LSCs while simultaneously preserving and even supporting normal hematopoiesis. Using syngeneic murine FLT3-ITD-driven AML models, we found that genetic deletion of the specific TNF superfamily cytokine lymphotoxin alpha (LTA) disrupts cell death pathways and accelerates leukemogenesis, underscoring its role as an intrinsic tumor suppressor. Importantly, therapeutic administration of lymphotoxin alpha as recombinant cytokine reactivated a suppressed RIPK3-dependent signaling cascade, leading to cell death of leukemic progenitor cells and, in parallel, to myeloid differentiation of the leukemic clone. In both syngeneic and patient-derived xenograft (PDX) models representing common oncogenic driver mutations, cytokine monotherapy induced deep and sustained remissions (>300 days), highlighting its efficacy as single agent.
 Mechanistically, the anti-leukemic activity is mediated through depletion of the pro-survival adaptor molecule TNF Receptor-Associated Factor 2 (TRAF2) in the TNFR1 complex I. Notably, this approach spares normal hematopoietic cells due to the presence of a robust pool of TRAF2. Resembling the physiological process of cytokine-mediated emergency granulopoiesis, we even observed propagation of hematopoietic progenitor populations thereby offering a distinct advantage over conventional cytotoxic treatments, which often suppress bone marrow function. These findings reveal a potentially actionable immune mechanism that could shift AML treatment paradigm by uncoupling therapeutic efficacy from toxicity on the healthy hematopoeisis, and provide a rationale for further clinical development of cytokine-based therapies in AML.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3b6686a9b7d1ec600f893083d7517e863079cdd" target='_blank'>
              Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo.
              </a>
            </td>
          <td>
            Ulrike Hoeckendorf, S. Dutta, A. Kloos, Marah Runtsch, Carina Zoetsch, Yongjie Wang, B. Perfler, Sebastian Vosberg, T. Haferlach, Konstanze Döhner, Katharina S. S. Götze, Florian Bassermann, M. Heikenwälder, Johannes Schmoellerl, Johannes Zuber, A. Wahida, Ann-Cathrin Burk, R. Zeiser, H. Sill, A. K. Jayavelu, Armin Zebisch, M. Heuser, Michael Dengler, Philipp Jost
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="major obstacle is the immunosuppressive liver microenvironment, characterized by the presence of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and a high proportion of tumor-associated macrophages (TAMs). Programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors such as nivolumab and pembrolizumab have shown limited clinical efficacy in HCC, with only a subset of patients responding to treatment. Conversely, CAR-T cell therapies targeting tumor antigens such as glypican-3 (GPC3) and alpha-fetoprotein (AFP) have shown promise but face limitations due to the difficulty of generating effective T cell responses within the immunosuppressive liver milieu (11). Organoids provide an excellent platform for investigating T cell interactions in hepatobiliary cancers. These 3D models enable the study of immune responses in an environment that closely resembles the in vivo tumor microenvironment (12). Researchers have successfully">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a1b0e2f8ddf3d5e1eaebd7db8f530b03067bdcc" target='_blank'>
              Organoid models for T cell-based immunotherapy in hepatobiliary cancers
              </a>
            </td>
          <td>
            Liwei Du, Jiaxun Dong, Shunda Du
          </td>
          <td>2025-11-25</td>
          <td>Hepatobiliary Surgery and Nutrition</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Increased activation of the NLRP3 inflammasome in immune cells, including macrophages, has been implicated in the pathogenesis of multiple chronic inflammatory diseases. Targeted depletion of macrophages has been explored as a cross-disease therapeutic strategy, but without subtype-specific markers, this strategy risks elimination of macrophages with homeostatic functions. In this study, Liu et al. identified a subpopulation of pathogenic macrophages, referred to as Toe-Macs, which are characterized by overexpression of the DNA demethylase TET3 in metabolic dysfunction–associated steatohepatitis (MASH), non–small cell lung cancer (NSCLC), and endometriosis. When induced into the disease microenvironment, Toe-Macs produced proinflammatory cytokines and chemokines. Selective elimination of Toe-Macs attenuated disease progression without any discernible side effects in mouse models of MASH and NSCLC. These findings highlight the role of Toe-Macs in the pathogenesis of chronic inflammatory diseases and provide a rationale for exploring TET3 as a therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/104b6ef43608f9bf119926e9935cb7aaf2a5e734" target='_blank'>
              TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases
              </a>
            </td>
          <td>
            Shojiro Haji, Yoshihiro Ogawa
          </td>
          <td>2025-11-03</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fe1fd70d582b73456d2a4754cfa0b98111080ee7" target='_blank'>
              pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection.
              </a>
            </td>
          <td>
            Elena Hernández-García, Miguel Galán, Sofía C Khouili, Elena Moya-Ruiz, Ana Redondo-Urzainqui, F. J. Cueto, Saraí Martínez-Cano, Manuel Rodrigo-Tapias, E. Tomasello, Santos Mañes, Marc Dalod, D. Sancho, S. Iborra
          </td>
          <td>2025-11-25</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="


 Lupus is a complex autoimmune disease that involves dysregulation of the B cell compartment. Potential mechanisms for this dysregulation include abnormalities in immune dampening pathways, such as the programmed cell death 1 receptor (PD-1). Though PD-1 functions as a negative regulator in T cells, its role in B cells is not clear. We used comprehensive flow and mass cytometry to examine the expression of PD-1 on peripheral blood B cells from lupus and healthy controls in two large patient cohorts. PD-1 was increased on antigen experienced B cells including double negative, memory, and CD11c+ age-associated B cells. Heterogeneity in patient PD-1+ B cells was uncovered, including an enriched PD-1+CD11c+CXCR3+ B cell subset which we speculate may be pathogenic due to their potential to migrate to sites of inflammation, and a diminished PD-1+PD-L1+ B cell subset which we expect is an immunosuppressive phenotype. PD-1 expression was higher in patients with elevated anti-dsDNA, high disease activity and increased with in vitro stimulation (anti-BCR and TLR9). Surprisingly, PD-1+ B cells proliferated more than PD-1- B cells, and PD-1 blockade with an anti-PD-1 antibody further increased proliferation. Our results suggest that PD-1 function in B cells is different than its inhibitory signaling role in T cells. Further, the expansion of PD-1 expressing B cells in lupus, especially in patients with high disease activity, highlights a new potential pathogenic B cell population.



 Supported by T32ES007026; Public Health Sciences Pilot Award; NIH Accelerating Medicines Partnership (RA/SLE Network)



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5935df81b4ecf4492f3d3f23ff65634bbec5dc4d" target='_blank'>
              PD-1 expressing B cells are expanded in lupus 4452
              </a>
            </td>
          <td>
            Melanie Perkins, Nida Meednu, Daria Krenitsky, Alice Horisberger, A. Griffith, Joshua Keegan, Fan Zhang, James A. Lederer, Deepak A. Rao, Lisa A. DeLouise, J. Anolik
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2024', '2025'],
    y: [2, 2],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>